Immune system and blood-brain barrier-wide biomarker analyses provide causal evidence for autoimmunity in dementia

Joni V. Lindbohm, MD, PhD;^{1,2} Nina Mars, MD, PhD;³ Pyry N. Sipilä, MD, PhD;² Prof. Archana Singh-Manoux;^{1,4} Heiko Runz, MD, PhD; ^{5,6} FinnGen; ³ Prof. Gill Livingston; ^{7,8} Prof. Sudha Seshadri; 9,10,11,12 Prof. Ramnik Xavier; 13,14 Prof. Aroon D. Hingorani; 15,16,17 Prof. Samuli Ripatti;^{2,3,18}* Prof. Mika Kivimäki^{1,2}*

¹ Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London, UK

² Clinicum, Department of Public Health, University of Helsinki, P.O. Box 41, FI-00014 Helsinki, Finland

³ Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland

⁴ Université de Paris, Inserm U1153, Epidemiology of Ageing and Neurodegenerative diseases. Paris, France

⁵ Molecular Medicine Partnership Unit (MMPU), University of Heidelberg/EMBL, Heidelberg, Germany

⁶ Translational Biology, Biogen Inc, Cambridge, MA, USA

⁷ Division of Psychiatry, University College London, London, UK

⁸ Camden and Islington NHS Foundation Trust, London, UK

⁹ Glenn Biggs Institute of Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio, TX, USA.

¹⁰ Boston University School of Public Health, Boston, MA, USA.

¹¹ New York University Grossman School of Medicine, New York, NY, USA.

¹² Boston University School of Medicine, Boston, MA, USA.

¹³ Center for Computational and Integrative Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

¹⁴ Department of Molecular Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

¹⁵ Invite trais of Councies and the search are as In it is a straightful of the search and the search and the search are the s

¹⁶ University College London, British Heart Foundation Research Accelerator, London, UK.

¹⁸Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA

* Authors contributed equally

Correspondence to Dr Joni Lindbohm, Clinicum, Department of Public Health, University of Helsinki, P.O. Box 41, FI-00014 Helsinki, Finland; E-mail address: joni.lindbohm@helsinki.fi; Telephone: +358 9 1911 Fax: +358 9 191 27 600

¹⁷ Health Data Research UK, London, UK.

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

Immune system and blood brain barrier (BBB) dysfunction are implicated in the development of Alzheimer's disease and other dementias, but their causal role remains unknown. We performed Mendelian randomization (MR) for over 43,643 immune system and BBB-related biomarkers and identified 126 potential causal risk factors for dementias. A phenome-wide analysis using MR-based polygenic risk score in FinnGen study (N=339,233) for these risk factors revealed a common genetic background for dementias and autoimmune diseases which was supported by further HLA analyses. Pathway analyses linked the 126 proteins to amyloid- β , tau and α -synuclein pathways, increased inflammatory responses, and altered self-tolerance mechanisms. In inverse-probability-weighted analyses simulating randomized controlled drug trials in observational data, anti-inflammatory and immunosuppressive medications were associated with reduced dementia risk (p<0.01 for methotrexate and TNF- α inhibitors). These converging results from different research lines suggest that autoimmunity is a modifiable component in diseases causing dementia.

4

Background

1

2 3

4

5

6

7 8

9

10

11 12

13 14

15 16

17

18

19 20

21

22

23

24 25 26

27

28

29

30 31

32

33 34

35

36

37

38

39

40

41

42

43

44

Dysregulation of peripheral and central immune systems and chronic neuroinflammation occur in diseases, such as severe infections and autoimmune diseases that relate to increased risk of dementia.¹⁻³ In central immune system, neuroinflammation can closely relate to sustained activation of microglia, the resident immune cells in the central nervous system (CNS), and lead to neurodegeneration and increased deposition of plaques and tangles.¹⁻³ When CNS encounters infections, trauma, or toxins, microglia are key in the acute immune response and in this phase are neuroprotective. When the microglia activation continues, this leads to chronic production of proinflammatory products including reactive oxygen species, nitric oxide, and cytokines.¹⁻³ This in turn may exacerbate disease-specific pathology, such as amyloid β and tau protein in Alzheimer's disease, and neurodegeneration.¹

In addition, the peripheral immune system and blood brain barrier are thought to be important in the development of dementias.^{1,4} Because of the crosstalk between the central and peripheral immune system and BBB, the causal factors linking inflammation to dementias may originate from any of these systems. Chronic peripheral inflammation, from low-grade systemic inflammation^{5,6} and infections, ⁷ can disrupt BBB so that it allows neurotoxic and pro-inflammatory plasma components and pathogens to enter CNS. 4 Dysfunctional BBB may also promote peripherally driven neuroinflammation by increasing endothelial adhesion molecules and chemokines and migration of peripheral leukocytes to CNS. 4 These processes expose CNS to prolonged neuroinflammation and subsequent neurodegeneration, although the role of centrally and peripherally driven CNS autoimmunity in dementias remains unclear. 8-11 In addition, there is limited data to confirm the causal nature of these hypothesised mechanisms.¹⁻³

Mendelian randomization (MR), using large GWAS libraries for unconfounded genetic proxies for biomarkers, and triangulation, combining multiple research methods with different sources of strengths and biases to identify convergent evidence, improve validity of causal estimates and success rate in drug development. 12,13 Although a range of studies on the immune system and BBB have been conducted, ¹⁻⁴ to the best of our knowledge, there are currently no published large-scale, immune system and BBB-wide MR analyses, confirmed by triangulation to identify novel drug targets and risk factors for dementias.

In this study, we analyse biomarkers of immune system and BBB (Figure 1) and use MR to study potential causal associations with five outcomes (Alzheimer's disease, Parkinson's diseases, frontotemporal dementia, vascular dementia, and poor cognitive performance) and triangulate the results. We identify several novel associations between inflammatory and immune checkpointrelated biomarkers and dementias. Using single nucleotide polymorphisms (SNPs) strongly associated with these biomarkers, we create MR-based polygenic risk scores (PRS) for the diseases. In phenome-wide association analyses (PheWAS) for the PRSs, we observe shared genetic risk factors with autoimmune diseases and dementias, which are supported by HLA analysis. In line with this, our pathway analyses for risk factors identified in MR show enrichment in inflammatory and self-tolerance related processes, which are in close interaction with amyloid β, tau protein, and α-synuclein. Lastly, using inverse-probability-weighted (IPW) survival analysis to simulate a

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

5

randomized controlled trial design in observational data with up to 20 years of follow-up, we identify anti-inflammatory medications which may lower the risk of dementias. In summary, we detect several novel risk factors and potential drug targets for dementia-causing diseases in a triangulation framework and propose that dementias may have an autoimmune component which is modifiable with anti-inflammatory medication. These findings are set out in **Figure 2**.

Results

Mendelian randomization and proteomics analyses

In the discovery step, we used MR to identify potential causal risk factors for dementias. The MR-base search provided 30,913 components for the immune system and 12,730 components for BBB; 254 immune system components and 132 BBB components passed the false discovery rate (FDR) of 5% (**Figure 1**). After removal of duplicates, 126 unique biomarkers were associated (p-value <0.000502) with neurodegenerative diseases in MR analyses using Wald ratio (when only 1 or 2 SNPs was available) or inverse variance-weighted method (when 3 or more SNPs were available) (**Figure 3A and B**). MR sensitivity analyses showed no strong evidence of reverse causality, and evidence of horizontal pleiotropy for only two outcomes. (**STable 1 and SFigures 1A and B**). The 126 biomarkers (FDR <5%) showed few off-target associations, mainly with type 1 diabetes and LDL-C. (**SFigure 2**).

While most biomarkers were disease-specific, 8 were associated with Alzheimer's disease, vascular dementia, and poor cognitive performance. The SNPs for the latter biomarkers were centred within 500 kilobases (kb) from *APOE* gene, one of the strongest genetic risk factors for late-onset Alzheimer's disease (**SFile 1**). To differentiate the effects of these biomarkers from *APOE*, we studied dementia outcomes and plasma proteins measured within the Whitehall II cohort (N=6,235). Out of the 8 proteins, 2 were associated with all-cause dementia in a 20-year follow-up and 1 (IFIT2) of these remained after adjustment of *APOE* status (**SFigure 3**; data on dementia subtypes were not available).

The 118 outcome-specific biomarkers did not show similar enrichment around high-risk genes for Alzheimer's disease such as *APP*, *PSEN1*, *PSEN2*, *ADAM10*, *TREM2*, *PLD3*, and *UNC5C*. Instead, they were characterized by inflammatory, chemokine, complement, and adhesion processes (C1Q, C1R, C4B, CCL1, CDHR5, GPNMB, IL1β, IL17, IL27, IL37, LTBR, PTP1B, SIGIRR), antigen presenting and immune checkpoints (HLA-DR, HLA-DQ, BAFFR, C1R, C1Q, CD11, CD19, CD20, CD33, CD40, CX3CR1, PD-1, and PDL-1), and BBB tight junction related biomarkers (TJP, AIMP1, BIN1).

Polygenic risk score and HLA analysis

To study the diseases that share common genetic background with dementias, we created MR-based polygenetic risk score (PRS) using the SNPs of the 126 biomarkers for dementias and then run a phenome-wide association analysis (PheWAS) (**Figure 4**). After linkage disequilibrium (LD) pruning and SNP matching in FinnGen (N=339,233), 92 SNPs were available for a PRS for

t is made available under a CC-BY-NC-ND 4.0 International license

Alzheimer's disease (the number of SNPs for other outcomes was insufficient, ≤25). The PRS was

strongly and positively associated with risk of all types of dementia-causing diseases (except

Parkinson's disease) and autoimmune disorders, such as rheumatic diseases, type 1 diabetes and its

complications. The PRS was also associated with increased risk of thyroiditis, coronary heart

disease, hyperlipidaemia, and the likelihood of having medications for Crohn's disease (indicating

disease severity), but reduced risk of cancers. We studied whether HLA-types that predispose to

autoimmune diseases are also associated with dementias. These analyses showed 21 directionally

consistent HLA association with dementias and at least one autoimmune disease (Figure 5A-E).

Pathway analyses

To identify pathways the 126 biomarkers are involved in, we performed analyses based on KEGG, ClueGO, and ConsensusPathDB databases. The findings provided further support for the autoimmune component in dementias. KEGG and ClueGO analyses showed that the identified biomarkers increased MHC-II-mediated antigen presentation in several processes, HLA-DR expression across all hematopoietic cell lines, neuronal adhesion molecule CNTN2, and PD-L1 in T-cell-antigen interactions that reduces self-tolerance. The biomarkers also decreased barrier protecting IL-17F, self-tolerance increasing PDCD1 in T-cell-antigen interactions, and antiviral complement factor B and IFNAR1 (**SFigures 4A-H and 5**). ConsensusPathDB analyses showed that all of the 42 plasma proteins included in the 126 biomarkers had physical interactions with or were in a biological pathway within zero to two molecule distance from amyloid precursor protein, tau protein, or α-synuclein (**SFigure 6A-R**).

Inverse probability-weighted analyses

To evaluate the autoimmune hypothesis in relation to modifiability and drug repurposing, we used inverse probability-weighted (IPW) analyses in FinnGen and studied whether commonly used anti-inflammatory and immunosuppressive medications are likely to reduce the risk of dementias (**Table 1**). We validated the IPW protocol with a positive control, by replicating the randomized controlled trial (RCT) effect between statin medication and myocardial infarction and used anti-inflammatory medications as negative control. Supporting the autoimmune hypothesis, risk of dementiacausing diseases was reduced with methotrexate and TNF-α inhibitors. Methotrexate appeared to decrease risk only in those with above-average MR-based autoimmune PRS (50% cut-off). To identify rare medications not detectable in FinnGen with sufficient power, we additionally searched the OpenTargets database. This search identified 64 drugs that target 18 of the 126 proteins, suggesting that these may have potential for repurposing to treatment of dementias (**SFile 2**).

Discussion

125 Using triangulation across Mendelian randomization, plasma proteomics, polygenic risk scores,

HLA type, pathway, and IPW analyses, we identified causal support for 126 risk factors and

- potential drug targets for dementia-causing diseases. Of these 118 were novel MR associations.
- Most of the identified risk factors and targets were outcome specific, and included inflammatory,
- self-tolerance, and/or BBB tight junction related biomarkers. A phenome-wide analysis of PRS
- from SNPs associated with the identified risk factors showed that Alzheimer's disease share genetic
- background with autoimmune diseases, such as rheumatoid arthritis and type 1 diabetes. The

autoimmune hypothesis was also supported by HLA analyses showing 21 HLA-type associations

common to dementias and autoimmune diseases. Pathway analyses linked the 126 biomarkers to

autoimmunity via antigen presentation and reduced self-tolerance and showed that all 42 plasma

135 proteins of the 126 biomarkers are closely related to α-synuclein, amyloid precursor, and tau protein

pathways that characterize Alzheimer's and Parkinson's diseases and dementia with Levy bodies.

The autoimmune hypothesis was further supported by IPW analyses mimicking randomized

controlled drug trial in observational data. They suggested anti-inflammatory medication use may

potentially reduce the risk of these illnesses.

132

133

134

136 137

138

139 140 141

142

143

144

145

146

147

148 149

150 151 152

153

154

155 156

157

158 159

160

161

162

163

164

165 166

167 168

169

170

171 172

173

174

175

Several lines of earlier and current evidence support the hypothesis that diseases causing dementia have an autoimmune component (Figure 2). Epidemiological studies have shown higher rates of cognitive impairment, Alzheimer's diseases, Parkinson's disease, vascular, and frontotemporal dementia in rheumatic disease patients. 18-22 Diabetes is a recognized risk factor for Alzheimer's disease²³ and individuals with type 1 diabetes have higher rate of cognitive decline, Alzheimer's disease, and vascular dementia. 24,25 Thyroiditis, which often has an autoimmune origin, increases risk of dementias. 10,26 In agreement with these findings, we showed that MR-based Alzheimer's disease PRS increased risk of all these autoimmune diseases. In addition, the PRS was associated with reduced risk of cancers, which is a well-described beneficial side effect of reduced selftolerance commonly harnessed in cancers medications.²⁷

Furthermore, risk factors, course of disease, and clinical picture in dementias and autoimmune diseases have several similarities. Alzheimer's and autoimmune diseases are more common in women^{9,28,29} and the diseases share inflammatory risk factors such as smoking and obesity. ^{9,23,30,31} Infections increase risk for autoimmune diseases, ³² rate of cognitive decline, ¹ and dementias even 20 years before the diagnosis, and can acutely trigger rheumatoid arthritis, type 1 diabetes and the formation of autoantibodies against CNS that lead to tissue degeneration. 8,9,11 Interestingly, many inflammation-related biomarkers in our analyses influenced pathways closely related to amyloid precursor protein, tau protein, or α-synuclein suggesting that they may contribute to proteinopathies that characterize of Alzheimer's and Parkinson's disease and dementia with Levy bodies. This process has some similarities with AA form of amyloidosis in rheumatic arthritis in which uncontrolled inflammation accumulates amyloid to a range of tissues³³ and with islet amyloidosis in diabetes that leads to tissue degeneration.³⁴ Two MR studies suggested inflammatory risk factor may not be causally linked to dementias. 35,36 However, those studies did not focus on processes that control self-tolerance and they may have used inflammatory markers that are only responses to these processes and thus prone to produce null finding or reverse causation in MR analyses.

Common cellular mechanisms between autoimmune disease and dementias

At cellular level, loss of central tolerance in central immune organs and subsequent escape of autoreactive B- and T-cells to periphery^{37,38} are thought to predispose to autoimmune diseases together with certain HLA alleles. 9,39,40 Conversion to disease may occur after complex interplay between inflammation, infections, and tissue damage, with subsequent failure of peripheral selftolerance mechanisms such as ignorance, anergy, suppression, inhibition, and antigen presentation.^{37,38} Our results link all of these mechanism to the development of dementias.

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license.

BBB normally controls tightly the access of toxins, pathogens, and peripheral molecules and cells to CNS.⁴ This keeps peripheral lymphocytes "ignorant" of CNS structures and prevents activation of autoreactive cells against CNS.³⁸ However, chronic antigen exposure and activation of innate and adaptive immune systems impair BBB by releasing pro-inflammatory cytokines, prostaglandins, and histamine leading to endothelial damage and upregulation of adhesion molecules.^{4,41} This exposes CNS to autoreactive peripheral lymphocytes that lose their ignorance.³⁸ The prolonged inflammation also leads to reduced anergy, which allows more potentially self-reactive T-lymphocytes to proliferate.³⁸

Our MR analyses support these processes. We showed that higher plasma levels of the integral part of BBB, the tight junction component (TJP1⁴²), and proteins degrading it (AIMP1⁴³ and BIN1⁴⁴), increased the risk of dementias. Moreover, pro-inflammatory C1Q, C1R, CD20, CD11, CDHR5, GPNMB, and IL1β⁴⁵⁻⁴⁹ elevated risk of dementias, whereas anti-inflammatory C4B, IL27, IL37, PTP1B, and SIGGIRR⁵⁰⁻⁵⁴ and barrier protecting IL-17F⁵⁵ reduced the risk. In suppression and inhibition, regulatory T-cells suppress, or molecules on B- and T-cells inhibit activation of lymphocytes at peripheral checkpoints.³⁸ Our MR analyses identified several checkpoint regulators including BAFFR, C1R, C1Q, CD11, CD19, CD20, CD22, CD33, CD40, CX3CR1, LTBR, PD-1, and PDL-1^{37,48,56-64} as potential causal risk factors for poor cognitive performance and dementias, uncovering the importance of checkpoint control and autoreactive lymphocytes in dementias.

HLA analyses were also consistent with the autoimmunity hypothesis. After the increase in BBB permeability, peripherally driven neuroinflammation activates central neuroinflammatory responses in astrocytes and microglia. The chronic neuroinflammation, pathogens, and tissue damage initiate antigen presentation in HLA receptors on antigen-presenting cells in CNS that can activate the autoreactive B- and T-cells and initiate self-sustaining autoimmunity against CNS structures. Supporting this we identified 21 shared HLA-types between autoimmune diseases and dementias. Similarly, MR and pathway analyses supported causal status of HLA-DR and HLA-DQ cell types in dementias.

The autoreactive cells can be activated via bystander activation, or HLA-mediated molecular mimicry and epitope spreading. 8-10,38 In bystander activation, sustained or excessive immune response can bypass normal T-cell antigen presentation to B-cells and activate autoreactive B-cell to plasma cell that produces autoantibodies. In molecular mimicry, autoreactive T- and B-cells first target foreign antigens, and then cross-react with similar self-antigens expressed by host cells. In epitope spreading, cryptic epitopes (parts of dying cells, and intrinsic or foreign DNA or RNA) normally invisible to immune system become visible after tissue damage, which activates autoreactive B- and T cells on these epitopes.

Our results also provide support for these mechanisms. In MR analyses, we observed that higher levels of naïve and memory CD20 B-cells, the main drug target for B-cell induced autoimmune diseases, 65 increases risk for Alzheimer's diseases. Similarly, higher levels of CD19, a co-receptor on B-cells that can lead to autoimmunity when hyperactivated, 66 increased Parkinson's diseases risk. We also observed that higher levels of IgG against Epstein-Barr virus' nuclear antigen, a marker of active infection that can mimic CNS structures, 67,68 elevated Alzheimer's diseases risk. In

9

addition, IFIT2 that intercepts foreign RNA and protects against central viral infections, ⁶⁹ reduced 220

the risk of all dementia causing diseases except Parkinson's diseases. Moreover, the pathway 221

222 analyses suggested that many proteins (COPS6, SOCS3, PSMB5, TOLLIP, TRIM21, PRPF40A,

- NOC4L, RPS6, IK, KRR1, and MTO1)⁷⁰⁻⁸⁰ involved in intracellular pathways from DNA, RNA,
- 224 and protein processing to antigen presentation may be linked with amyloid β , tau protein, and α -

225 synuclein.

223

226

229

230 231

232

233

234

235

238

239

240 241

245 246

247

248

249

250 251

252 253 254

255

262

227 The identified 8 proteins with SNPs located near APOE gene were associated with increased BBB 228

permeability, inflammation, neurotoxicity, and lipid transport disturbances, 42,56,69,81-84 which are all

processes linked to APOE in Alzheimer's disease. 85 Our results suggest that the 8 proteins may be

linked to the effects of APOE. Another novel result was that higher levels of CD33, one of the top

GWAS hits for Alzheimer's diseases⁸⁶ and target receptor on microglia for an ongoing trial

(NCT03822208) including mild to moderate Alzheimer's diseases patients, increased the risk of

disease even when expressed on peripheral leukocytes.

Anti-inflammatory medications and dementias

236 Our IPW analyses on use of anti-inflammatory medications, including records of filled drug 237

prescriptions in initially dementia-free individuals at baseline followed up to 20 years supported the

modifiability of dysfunctional autoimmune processes. We replicated protective associations

between TNF-α inhibitors. 87 methotrexate. 88 and Alzheimer's disease. As novel findings we showed

that methotrexate may be protective only for Alzheimer's and Parkinson's disease among those

with high MR-based PRS. These findings are plausible on a cellular level for BBB degradation and

242 neuroinflammation. TNF- α is a gatekeeper of inflammatory responses and endothelial

243 permeability. 89 Methotrexate, in turn, modulates a range of inflammatory and immune responses in

244 nearly every cell types forming the foundations for treatment of rheumatoid arthritis. 9 NSAIDs and

antihistamines appeared to decrease risk for all dementias but the validation using a negative control

outcome (coronary heart disease) suggested that the IPW model for these medications was

insufficient to replicate trial design.

Randomized controlled trials of TNF- α inhibitors in Alzheimer's disease patients have not shown benefits in 1 to 2 year follow-up. 90,91 However, in autoimmune diseases, early initiation of antiinflammatory medication is of paramount importance suggesting that the trials of medication for

people with established dementia may be too late.⁹

Strengths and limitations

Our triangulation approach has several strengths. By using a broad set of immune system and BBB

256 biomarkers we were able to study these systems comprehensively without restrictions to specific

257 predefined hypotheses. Our findings are based on MR, a promising approach to examine causality, ¹²

258 and on analyses using plasma proteomics, PRS, HLA, pathway, and IPW analyses in two

259 independent cohorts and a range of databases. Plasma protein analyses allowed us to adjust effect

260 estimates for APOE which was not possible in Mendelian randomization analyses for some

261 proteins. PRS and HLA analyses used data from the FinnGen study with a sample size of 340,000

providing sufficient statistical power for the identification of shared novel risk alleles between

263 dementias and autoimmune disease. We used ConsensusPathDB, which is one of the most perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

10

comprehensive collection of databases on molecular pathways and interactions. 92 The medication analyses used IPW survival analysis that is suggested to provide more reliable causal estimates than traditional survival analyses of observational data. 93

Our study has also several limitations. Although we explored over 40,000 biomarkers related to the immune system and BBB, we may have missed some biomarkers due to limitations in search protocol or lack of SNPs. Our plasma protein analyses were limited by lack of data on dementia subtypes. The PRS and PheWAS analyses were done with samples with European ancestry and may not apply to non-European ancestries. Due to limited number of SNPs included in PRS, we may have missed important immune system and BBB related associations in our phenome-wide analyses. Nonetheless, the Alzheimer's MR-based PRS associated strongly with all types of dementia (except Parkinson's disease) and a range of outcomes related to type 1 diabetes and rheumatic diseases suggesting that at least these findings are robust. The IPW analyses on medications may include some bias due to a limited number of covariates for simulation of randomized control trial. However, major bias is unlikely for the main findings since the analysis protocol was validated by a positive- and negative-control analyses.

Conclusions

In summary, this study provides novel insights into autoimmunity, BBB, and inflammatory dysfunctions that may contribute to the development of dementias. As the inflammatory components are potentially modifiable with anti-inflammatory medications, the present results also raise hypotheses on several novel drug targets for dementia-causing diseases which need to be validated in future experimental studies. Randomized controlled trials on early initiation of these medications for high-risk individuals are warranted while antigen-specific prevention strategies may offer new avenues in search of treatment for dementias.

Methods

Mendelian randomization

The SNPs for biomarkers and outcomes were searched from MR-base database. Humane system and BBB search terms were identified using identifiers of cell types, receptors, proteins, metabolites, and genes. The identifiers were searched from several publications 3,4,6,23,36,38,40,95,96 and from Uniprot with search terms "immune" and "blood brain barrier". Outcomes included all cohorts with following diseases: all types of Alzheimer's disease, Parkinson's disease, vascular dementia, frontotemporal dementia, dementia in general, and progression of dementia. (**SMethods**). Poor cognitive performance was chosen as an intermediate outcome. Two sample MR was used to analyse associations between biomarkers and outcomes. First analyses estimated effects with Wald ratio or inverse variance-weighted analyses. For biomarker-outcome pairs that passed FDR of 5% and shared over two common SNPs we performed sensitivity analyses with weighted

t is made available under a CC-BY-NC-ND 4.0 International license 11

median, simple mode, MR Egger, and backward Mendelian randomization¹² with TwoSampleMR

and MRInstruments R packages.

To assess off-target effects of the observed causal biomarkers, we performed a phenome-wide MR analysis for each biomarker, using GWAS summary statistics for 210 UK Biobank endpoints conducted by Neale lab and with recognized dementia risk factors.^{23,98}

Plasma protein analyses

Plasma protein measurements in Whitehall II study were available for 6,235 individuals of whom 310 developed dementia and the methods have been describe before (**SMethods**). ^{6,99,100} In brief, the plasma proteins were measured using the SomaScan version 4.0 and 4.1 assays. ^{6,101,102} The assays were validated against external reference population and protein-specific conversion coefficients were used to balance the technical differences between versions 4.0 and 4.1. Using DNA extracted from whole blood, a standard PCR assay determined *APOE* genotype using the salting out method. ^{103,104} In analyses, proteins were transformed to a normal distribution by inverse rank-based normal transformation. The analyses used plasma samples measured in 1995/1997 and the follow-up ended at onset of dementia, death, or 1st of October 2019, which ever occurred first. Cox regression models adjusted for age, sex, and *APOE* estimated associations between the proteins and dementia. ¹⁰⁵ The proportionality assumption in all Cox models was assessed with Schoenfeld residuals and with log-log plots. ¹⁰⁵ We used statistical software R (3.6.0 and 4.1.0) for these analyses.

Polygenic risk score and IPW analyses

FinnGen Data Freeze 8 contains 339,233 individuals, and is a collection of prospective epidemiological and disease-based cohorts, and hospital biobank samples and links genotypes by the unique national personal identification numbers to nationwide health registries, including the national hospital discharge (available from 1968), death (1969–), cancer (1953–) and medication reimbursement (1964–) and purchase (1995–) registries. Genotyping and imputation is described in **SMethods**.

PRS was constructed from SNPs that were associated with the 126 MR identified causal biomarkers for dementias. The SNPs were LD-pruned with clumping cut-off $R^2 = 0.01$ in 500kb window with R package TwoSampleMR. The available SNPs were searched from FinnGen genotypes and the final scores were generated with PLINK v2.00aLM3 by calculating the SNP-biomarker beta weighted sum of risk alleles for each SNP. The PRS was scaled to zero mean and unit variance, and we analysed its phenome-wide associations across 2401 disease endpoints. The association between PRS and endpoints were studied with logistic regression, adjusting for birth year, sex, and ten first principal components of ancestry.

The IPW analyses⁹³ were done in FinnGen and included participants aged over 45 without any dementia-causing disease at baseline (N = 90,512). ATC codes for anti-inflammatory medication use were obtained from linkage to national medication purchase registry (data starts from 1995) and

perpetuity. It is made available under a $\frac{\text{CC-BY-NC-ND 4.0 International license}}{12}$

in each analyses we included only new medication users to simulate trial design.¹⁰⁶ A model including a range of baseline and time-varying variables and informative censoring estimated the weights (**SMethods**). The analyses used time-varying Cox models and assumptions were assessed similar to plasma proteins. The follow-up started in 1997 and ended at onset of dementia, death, or 31st of December 2019, which ever occurred first. We used R (4.1.2) and ipw package for these analyses.

HLA analyses

The analyses were done using HLA alleles, imputed with high accuracy using a Finnish-specific reference panel, which has been previously described in detail. After filtering based on a HLA carrier frequency of ≥ 0.01 and posterior probability of ≥ 0.6 , we assessed the association between HLA alleles and dementias and autoimmune diseases using logistic regression adjusted for birth year, sex, and ten first principal components of ancestry.

Pathway analyses

KEGG pathway analysis was done with Generally Applicable Gene-set Enrichment (GAGE), ¹⁰⁸ using MR betas and p-values as input for expression ratios. GO term enrichment analyses were done with ClueGO version 2.5.8¹⁰⁹ in Cytoscape version 3.7.2¹¹⁰ (**SMethods**). The hypergeometric test used all the 76 plasma proteins or surface receptors of the 126 biomarkers as input and all immune system and BBB related proteins from Uniprot⁹⁷ as background, with correction for 5% FDR. The shortest interaction path analyses were done with ConsensusPathDB, ⁹² a web based analysis tool containing several biomedical databases.

Open Targets analyses

Medications that change the levels of the 126 biomarkers were searched from Open Targets database using Uniprot protein and Entrez gene symbols.

Ethics statement

394

399

408

423

432433

- In the Whitehall II study, research ethics approvals were renewed at each wave; the most recent
- 396 approval was obtained from the University College London Hospital Committee on the Ethics of
- 397 Human Research (reference number 85/0938). Written, informed consent from participants was
- 398 obtained at each contact.
- 400 Patients and control subjects in FinnGen provided informed consent for biobank research, based on
- 401 the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish
- 402 Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were
- 403 collected based on study-specific consents and later transferred to the Finnish biobanks after
- 404 approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare
- and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The
- 406 Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement
- number for the FinnGen study is Nr HUS/990/2017.
- The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers:
- 410 THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018,
- 411 THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and
- 412 THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers:
- 413 VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution
- 414 (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA
- 415 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020),
- 416 Findata permit numbers THL/2364/14.02/2020,
- 417 THL/4055/14.06.00/2020, THL/3433/14.06.00/2020, THL/4432/14.06/2020,
- 418 THL/5189/14.06/2020, THL/5894/14.06.00/2020, THL/6619/14.06.00/2020,
- 419 THL/209/14.06.00/2021, THL/688/14.06.00/2021, THL/1284/14.06.00/2021,
- 420 THL/1965/14.06.00/2021, THL/5546/14.02.00/2020, THL/2658/14.06.00/2021,
- 421 THL/4235/14.06.00/2021 and Statistics Finland (permit numbers: TK-53-1041-17 and
- 422 TK/143/07.03.00/2020 (earlier TK-53-90-20) TK/1735/07.03.00/2021).
- The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 8
- 425 include: THL Biobank BB2017 55, BB2017 111, BB2018 19, BB 2018 34, BB 2018 67,
- 426 BB2018 71, BB2019 7, BB2019 8, BB2019 26, BB2020 1, Finnish Red Cross Blood Service
- 427 Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154 and amendment
- 428 #1 (August 17 2020), AB20-5926 and amendment #1 (April 23 2020), Biobank Borealis of
- Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018 and amendment 22 § /2020,
- 430 Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 & 06.10.2020), Central
- Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001.

Acknowledgments and Funding Sources

- We want to acknowledge the participants and investigators of FinnGen study. The FinnGen project
- is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the
- 436 following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers
- 437 Squibb (and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp &

perpetuity. It is made available under a $\frac{\text{CC-BY-NC-ND 4.0 International license}}{14}$

- Dohme Corp, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US
- 439 Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis AG, and Boehringer
- Ingelheim. Following biobanks are acknowledged for delivering biobank samples to FinnGen:
- 441 Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank
- 442 (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland
- 443 (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-
- 444 English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-
- 445 US/Research and development/Finnish Clinical Biobank Tampere), Biobank of Eastern Finland
- 446 (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-
- 447 FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank
- 448 (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) and Terveystalo Biobank
- 449 (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). All Finnish Biobanks are
- 450 members of BBMRI.fi infrastructure (www.bbmri.fi). Finnish Biobank Cooperative -FINBB
- (https://finbb.fi/) is the coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank
- data can be accessed through the Fingenious® services (https://site.fingenious.fi/en/) managed by
- 453 FINBB.

454

466 467

468469470

476 477

- The study was supported by the Wellcome Trust (221854/Z/20/Z), the UK Medical Research
- 456 Council (S011676, K013351, R024227), the National Institute on Aging (National Institutes of
- 457 Health; R01AG056477 and RF1AG062553), the British Heart Foundation (RG/16/11/32334), the
- 458 Academy of Finland (311492), NordForsk (75021), and SomaLogic, Inc. JVL was supported by
- Academy of Finland (339568). NM was supported by the Academy of Finland (331671). PNS was
- supported by the Emil Aaltonen Foundation. MK was supported by the Wellcome Trust
- 461 (221854/Z/20/Z), UK Medical Research Council (MR/S011676, MR/R024227), US National
- 462 Institute on Aging (R01AG062553, R01AG056477), Academy of Finland (311492), Helsinki
- Institute of Life Science (H970), and the Finnish Work Environment Fund (190424). SR was
- 464 funded by Academy of Finland (285380 and 312062), Sigrid Jusélius Foundation and University of
- Helsinki HiLIFE Fellow grants 2017-2020.
 - FinnGen consortium authors are listed in FinnGen Banner Authors file.

Author Contributions

- JVL, NM, SR, and MK generated the hypothesis and designed the study. JVL wrote the first draft
- of the report, did the primary analyses, with support from NM, and performed literature searches.
- 473 All authors interpreted the data and critically commented and reviewed the report. JVL and MK had
- full access to pseudonymised data from the Whitehall II. JVL, NM, and SR had full access to
- pseudonymised data from the FinnGen study.

Competing interests

- 478 In Whitehall II study part of the proteins were measured as academic–industry partnership project
- beween UCL and SomaLogic, Inc. which provided expertise in plasma proteins and funded 2240
- SOMAscan assays. PNS reports a grant from the Emil Aaltonen foundation, during the conduct of
- 481 the study. MK reports grants from Wellcome Trust, UK Medical Research Council, US National

perpetuity. It is made available under a $\frac{\text{CC-BY-NC-ND 4.0 International license}}{15}$

Institute on Aging, Academy of Finland, Helsinki Institute of Life Science, and the Finnish Work Environment Fund, during the conduct of the study.

Data sharing

Data, protocols, and other metadata of the Whitehall II and FinnGen studies are available according to the data sharing policies of these studies. Pre-existing data access policy for Whitehall II specify that research data requests can be submitted to each steering committee; these will be promptly reviewed for confidentiality or intellectual property restrictions and will not unreasonably be refused. Detailed information on data sharing can be found here:

https://www.ucl.ac.uk/epidemiology-health-care/research/epidemiology-and-public-

health/research/whitehall-ii/data-sharing Individual-level patient or protein data may further be restricted by consent, confidentiality, or privacy laws/considerations. The FinnGen data may be accessed through Finnish Biobanks' FinBB portal (www.finbb.fi).

References

526

527528

- 529 1. Bettcher, B.M., Tansey, M.G., Dorothée, G. & Heneka, M.T. Peripheral and central immune 530 system crosstalk in Alzheimer disease - a research prospectus. *Nat Rev Neurol* **17**, 689-701 531 (2021).
- 532 2. Kinney, J.W., *et al.* Inflammation as a central mechanism in Alzheimer's disease. *Alzheimers Dement (N Y)* **4**, 575-590 (2018).
- Tan, E.K., *et al.* Parkinson disease and the immune system associations, mechanisms and therapeutics. *Nat Rev Neurol* **16**, 303-318 (2020).
- 536 4. Sweeney, M.D., Zhao, Z., Montagne, A., Nelson, A.R. & Zlokovic, B.V. Blood-Brain 537 Barrier: From Physiology to Disease and Back. *Physiological Reviews* **99**, 21-78 (2019).
- 538 5. Franceschi, C., Garagnani, P., Parini, P., Giuliani, C. & Santoro, A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. *Nat Rev Endocrinol* **14**, 576-590 (2018).
- 541 6. Lindbohm, J.V., *et al.* Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies. *Alzheimer's & dementia : the journal of the Alzheimer's Association* (2021).
- 544 7. Sipilä, P.N., *et al.* Hospital-treated infectious diseases and the risk of dementia: a large, 545 multicohort, observational study with a replication cohort. *Lancet Infect Dis* **21**, 1557-1567 546 (2021).
- 547 8. Op de Beeck, A. & Eizirik, D.L. Viral infections in type 1 diabetes mellitus--why the β cells? *Nat Rev Endocrinol* **12**, 263-273 (2016).
- 549 9. Smolen, J.S., et al. Rheumatoid arthritis. Nature Reviews Disease Primers 4, 18001 (2018).
- 550 10. Stassi, G. & De Maria, R. Autoimmune thyroid disease: new models of cell death in autoimmunity. *Nat Rev Immunol* **2**, 195-204 (2002).
- 552 11. Prüss, H. Autoantibodies in neurological disease. *Nat Rev Immunol* **21**, 798-813 (2021).
- Holmes, M.V., Richardson, T.G., Ference, B.A., Davies, N.M. & Davey Smith, G.
 Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. *Nat Rev Cardiol* 18, 435-453 (2021).
- 556 13. Munafo, M.R. & Davey Smith, G. Robust research needs many lines of evidence. *Nature* 557 553, 399-401 (2018).
- Law, M.R., Wald, N.J. & Rudnicka, A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. *Bmj* **326**, 1423 (2003).
- Bally, M., *et al.* Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. *Bmj* **357**, j1909 (2017).
- Thanigaimani, S., Phie, J., Krishna, S.M., Moxon, J. & Golledge, J. Effect of disease modifying anti-rheumatic drugs on major cardiovascular events: a meta-analysis of randomized controlled trials. *Sci Rep* **11**, 6627 (2021).
- 566 17. Ridker, P.M., *et al.* Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. 567 *New England Journal of Medicine* **380**, 752-762 (2018).
- 568 18. Broce, I., *et al.* Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. *PLoS Med* **15**, e1002487 (2018).
- 570 19. Chou, R.C., Kane, M., Ghimire, S., Gautam, S. & Gui, J. Treatment for Rheumatoid 571 Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis. *CNS Drugs* **30**, 572 1111-1120 (2016).
- Wallin, K., *et al.* Midlife rheumatoid arthritis increases the risk of cognitive impairment two decades later: a population-based study. *J Alzheimers Dis* **31**, 669-676 (2012).

- 17
- Zhou, M., Xu, R., Kaelber, D.C. & Gurney, M.E. Tumor Necrosis Factor (TNF) blocking
 agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid
 arthritis and psoriasis. *PLoS One* 15, e0229819 (2020).
- Li, X., Sundquist, J. & Sundquist, K. Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: a nationwide epidemiological study from Sweden.
 Neurodegener Dis 10, 277-284 (2012).
- 581 23. Livingston, G., *et al.* Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet (London, England)* **396**, 413-446 (2020).
- 583 24. Jacobson, A.M., *et al.* Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. *Lancet Diabetes*585 *Endocrinol* **9**, 436-445 (2021).
- 586 25. Lacy, M.E., *et al.* Long-term Glycemic Control and Dementia Risk in Type 1 Diabetes. *Diabetes Care* **41**, 2339-2345 (2018).
- 588 26. Sipilä, P.N., *et al.* Long-term risk of dementia following hospitalization due to physical diseases: A multicohort study. *Alzheimer's & dementia : the journal of the Alzheimer's Association* **16**, 1686-1695 (2020).
- 591 27. Leach, D.R., Krummel, M.F. & Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. *Science* **271**, 1734-1736 (1996).
- 593 28. Krischer, J.P., et al. The Influence of Type 1 Diabetes Genetic Susceptibility Regions, Age,
 594 Sex, and Family History on the Progression From Multiple Autoantibodies to Type 1
 595 Diabetes: A TEDDY Study Report. *Diabetes* 66, 3122-3129 (2017).
- 596 29. Gleicher, N. & Barad, D.H. Gender as risk factor for autoimmune diseases. *J Autoimmun* **28**, 597 1-6 (2007).
- 598 30. Corbin, K.D., *et al.* Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms. *Endocr Rev* **39**, 629-663 (2018).
- 600 31. Rasouli, B., *et al.* Smoking and the Risk of LADA: Results From a Swedish Population-601 Based Case-Control Study. *Diabetes Care* **39**, 794-800 (2016).
- Nielsen, P.R., Kragstrup, T.W., Deleuran, B.W. & Benros, M.E. Infections as risk factor for autoimmune diseases A nationwide study. *J Autoimmun* **74**, 176-181 (2016).
- 604 33. Perfetto, F., *et al.* Systemic amyloidosis: a challenge for the rheumatologist. *Nature Reviews Rheumatology* **6**, 417-429 (2010).
- 606 34. Rojas, J., *et al.* Pancreatic Beta Cell Death: Novel Potential Mechanisms in Diabetes 607 Therapy. *J Diabetes Res* **2018**, 9601801 (2018).
- 608 35. Fani, L., *et al.* Circulating biomarkers of immunity and inflammation, risk of Alzheimer's disease, and hippocampal volume: a Mendelian randomization study. *Translational Psychiatry* **11**, 291 (2021).
- Walker, K.A., *et al.* Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk. *Nature Aging* **1**, 473-489 (2021).
- on Boehmer, H. & Melchers, F. Checkpoints in lymphocyte development and autoimmune disease. *Nat Immunol* **11**, 14-20 (2010).
- Theofilopoulos, A.N., Kono, D.H. & Baccala, R. The multiple pathways to autoimmunity. *Nat Immunol* **18**, 716-724 (2017).
- Buzzetti, R., Zampetti, S. & Maddaloni, E. Adult-onset autoimmune diabetes: current knowledge and implications for management. *Nat Rev Endocrinol* **13**, 674-686 (2017).
- Dendrou, C.A., Petersen, J., Rossjohn, J. & Fugger, L. HLA variation and disease. *Nat Rev Immunol* 18, 325-339 (2018).
- 41. Abbott, N.J. Inflammatory mediators and modulation of blood-brain barrier permeability. *Cell Mol Neurobiol* **20**, 131-147 (2000).
- Furuse, M., *et al.* Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. *J Cell Biol* **127**, 1617-1626 (1994).

- Li, C., Ma, W., Zhao, Y. & Wang, H. Changes in the expression of endothelial
 monocyte-activating polypeptide II in the rat hippocampus following status epilepticus. *Int J Mol Med* 47, 699-707 (2021).
- Thomas, S., et al. Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell
 Barrier Function. Dig Dis Sci 61, 423-432 (2016).
- 630 45. Carmona, F.D., *et al.* Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis. *Ann Rheum Dis* **71**, 114-119 (2012).
- Dalakas, M.C., Alexopoulos, H. & Spaeth, P.J. Complement in neurological disorders and emerging complement-targeted therapeutics. *Nat Rev Neurol* **16**, 601-617 (2020).
- 634 47. Migliorini, P., Italiani, P., Pratesi, F., Puxeddu, I. & Boraschi, D. The IL-1 family cytokines and receptors in autoimmune diseases. *Autoimmun Rev* **19**, 102617 (2020).
- 636 48. Nowatzky, J., Manches, O., Khan, S.A., Godefroy, E. & Bhardwaj, N. Modulation of human Th17 cell responses through complement receptor 3 (CD11 b/CD18) ligation on monocytederived dendritic cells. *J Autoimmun* **92**, 57-66 (2018).
- 639 49. Saade, M., Araujo de Souza, G., Scavone, C. & Kinoshita, P.F. The Role of GPNMB in Inflammation. *Front Immunol* **12**, 674739 (2021).
- 641 50. Berdnikovs, S., *et al.* PTP1B deficiency exacerbates inflammation and accelerates leukocyte trafficking in vivo. *J Immunol* **188**, 874-884 (2012).
- 643 51. Kamitaki, N., *et al.* Complement genes contribute sex-biased vulnerability in diverse disorders. *Nature* **582**, 577-581 (2020).
- 645 52. Meka, R.R., Venkatesha, S.H., Dudics, S., Acharya, B. & Moudgil, K.D. IL-27-induced 646 modulation of autoimmunity and its therapeutic potential. *Autoimmun Rev* **14**, 1131-1141 647 (2015).
- Xu, W.D., Zhao, Y. & Liu, Y. Insights into IL-37, the role in autoimmune diseases.
 Autoimmun Rev 14, 1170-1175 (2015).
- 650 54. Cavalli, G. & Dinarello, C.A. Suppression of inflammation and acquired immunity by IL-651 37. *Immunol Rev* **281**, 179-190 (2018).
- 652 55. McGeachy, M.J., Cua, D.J. & Gaffen, S.L. The IL-17 Family of Cytokines in Health and Disease. *Immunity* **50**, 892-906 (2019).
- 654 56. Brink, R. Regulation of B cell self-tolerance by BAFF. Semin Immunol 18, 276-283 (2006).
- 655 57. Choi, J.W., *et al.* The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma and their relationship with PD-1 expression. *Scientific Reports* **10**, 657 14372 (2020).
- Wang, Q., *et al.* Transient BAFF Blockade Inhibits Type 1 Diabetes Development in Nonobese Diabetic Mice by Enriching Immunoregulatory B Lymphocytes Sensitive to Deletion by Anti-CD20 Cotherapy. *J Immunol* **199**, 3757-3770 (2017).
- Yamauchi, T., *et al.* T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. *Nature Communications* **12**, 1402 (2021).
- 663 60. Dörner, T., Shock, A. & Smith, K.G. CD22 and autoimmune disease. *Int Rev Immunol* **31**, 363-378 (2012).
- 665 61. Gommerman, J.L. & Summers deLuca, L. LTβR and CD40: working together in dendritic cells to optimize immune responses. *Immunol Rev* **244**, 85-98 (2011).
- 667 62. Maldini, C.R., Ellis, G.I. & Riley, J.L. CAR T cells for infection, autoimmunity and allotransplantation. *Nat Rev Immunol* **18**, 605-616 (2018).
- 669 63. Schittenhelm, L., Hilkens, C.M. & Morrison, V.L. β(2) Integrins As Regulators of Dendritic
 670 Cell, Monocyte, and Macrophage Function. *Front Immunol* 8, 1866 (2017).
- 671 64. Wang, J. & Fu, Y.X. The role of LIGHT in T cell-mediated immunity. *Immunol Res* **30**, 672 201-214 (2004).


- 19
- 673 65. Meffre, E. & O'Connor, K.C. Impaired B-cell tolerance checkpoints promote the 674 development of autoimmune diseases and pathogenic autoantibodies. *Immunol Rev* **292**, 90-675 101 (2019).
- 676 66. Hobeika, E., Nielsen, P.J. & Medgyesi, D. Signaling mechanisms regulating B-lymphocyte activation and tolerance. *J Mol Med (Berl)* **93**, 143-158 (2015).
- 678 Gate, D., *et al.* Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease. *Nature* **577**, 399-404 (2020).
- 680 68. Xiao, D., *et al.* A meta-analysis of interaction between Epstein-Barr virus and HLA-681 DRB1*1501 on risk of multiple sclerosis. *Scientific Reports* **5**, 18083 (2015).
- 682 69. Das Sarma, J., *et al.* Ifit2 deficiency restricts microglial activation and leukocyte migration following murine coronavirus (m-CoV) CNS infection. *PLoS Pathog* **16**, e1009034 (2020).
- Bech-Otschir, D., *et al.* COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. *Embo j* **20**, 1630-1639 (2001).
- 686 71. Bertram, K., *et al.* Cryo-EM Structure of a Pre-catalytic Human Spliceosome Primed for Activation. *Cell* **170**, 701-713.e711 (2017).
- Choudhary, B., Marx, O. & Norris, A.D. Spliceosomal component PRP-40 is a central regulator of microexon splicing. *Cell Rep* **36**, 109464 (2021).
- 690 73. Groettrup, M., *et al.* A role for the proteasome regulator PA28alpha in antigen presentation. *Nature* **381**, 166-168 (1996).
- Kamura, T., *et al.* VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. *Genes Dev* **18**, 3055-3065 (2004).
- Lu, K., Psakhye, I. & Jentsch, S. Autophagic clearance of polyQ proteins mediated by ubiquitin-Atg8 adaptors of the conserved CUET protein family. *Cell* **158**, 549-563 (2014).
- 596 76. Sturm, M., Cheng, J., Baßler, J., Beckmann, R. & Hurt, E. Interdependent action of KH domain proteins Krr1 and Dim2 drive the 40S platform assembly. *Nat Commun* **8**, 2213 (2017).
- Wada, K. & Kamitani, T. Autoantigen Ro52 is an E3 ubiquitin ligase. *Biochem Biophys Res Commun* 339, 415-421 (2006).
- 701 78. Yamashita, D., *et al.* hDREF regulates cell proliferation and expression of ribosomal protein genes. *Mol Cell Biol* **27**, 2003-2013 (2007).
- 703 79. Zhu, X., *et al.* Noc4L-Mediated Ribosome Biogenesis Controls Activation of Regulatory and Conventional T Cells. *Cell Rep* **27**, 1205-1220.e1204 (2019).
- 705 80. Li, X., Li, R., Lin, X. & Guan, M.X. Isolation and characterization of the putative nuclear modifier gene MTO1 involved in the pathogenesis of deafness-associated mitochondrial 12 S rRNA A1555G mutation. *J Biol Chem* **277**, 27256-27264 (2002).
- 708 81. Estefanía, E., *et al.* Human KIR2DL5 is an inhibitory receptor expressed on the surface of NK and T lymphocyte subsets. *J Immunol* **178**, 4402-4410 (2007).
- 710 82. Adly, A.A.M., Ismail, E.A., Tawfik, L.M., Ebeid, F.S.E. & Hassan, A.A.S. Endothelial 711 monocyte activating polypeptide II in children and adolescents with type 1 diabetes mellitus: 712 Relation to micro-vascular complications. *Cytokine* **76**, 156-162 (2015).
- Dolan, J., *et al.* The extracellular leucine-rich repeat superfamily; a comparative survey and analysis of evolutionary relationships and expression patterns. *BMC Genomics* **8**, 320 (2007).
- 716 84. García-Heredia, J.M. & Carnero, A. The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment. *Oncotarget* **8**, 98580-98597 (2017).
- 718 85. Yamazaki, Y., Zhao, N., Caulfield, T.R., Liu, C.C. & Bu, G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. *Nat Rev Neurol* **15**, 501-518 (2019).
- Naj, A.C., *et al.* Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nat Genet* **43**, 436-441 (2011).

- 723 87. Torres-Acosta, N., O'Keefe, J.H., O'Keefe, E.L., Isaacson, R. & Small, G. Therapeutic
 724 Potential of TNF-α Inhibition for Alzheimer's Disease Prevention. *J Alzheimers Dis* 78, 619-626 (2020).
- Judge, A., *et al.* Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. *Alzheimers Dement (N Y)* **3**, 612-621 (2017).
- 728 89. Chen, A.Y., Wolchok, J.D. & Bass, A.R. TNF in the era of immune checkpoint inhibitors: friend or foe? *Nature Reviews Rheumatology* **17**, 213-223 (2021).
- 730 90. Aisen, P.S., *et al.* Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease ProgressionA Randomized Controlled Trial. *JAMA* **289**, 2819-2826 (2003).
- 732 91. Butchart, J., *et al.* Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. *Neurology* **84**, 2161-2168 (2015).
- Herwig, R., Hardt, C., Lienhard, M. & Kamburov, A. Analyzing and interpreting genome data at the network level with ConsensusPathDB. *Nature Protocols* **11**, 1889-1907 (2016).
- 736 93. Hernán, M.A. & Robins, J.M. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. *Am J Epidemiol* **183**, 758-764 (2016).
- Hemani, G., *et al.* The MR-Base platform supports systematic causal inference across the human phenome. *Elife* **7**(2018).
- 740 95. Akiyama, H., *et al.* Inflammation and Alzheimer's disease. *Neurobiology of aging* **21**, 383-421 (2000).
- 742 96. O'Brien, J.T. & Thomas, A. Vascular dementia. *Lancet (London, England)* 386, 1698-1706
 743 (2015).
- 744 97. UniProt, C. UniProt: a worldwide hub of protein knowledge. *Nucleic acids research* **47**, 745 D506-D515 (2019).
- 746 98. http://www.nealelab.is/uk-biobank/.
- 747 99. Kivimaki, M., *et al.* Validity of Cardiovascular Disease Event Ascertainment Using Linkage to UK Hospital Records. *Epidemiology (Cambridge, Mass.)* **28**, 735-739 (2017).
- 749 100. Sommerlad, A., et al. Accuracy of general hospital dementia diagnoses in England: 750 Sensitivity, specificity, and predictors of diagnostic accuracy 2008-2016. Alzheimer's & dementia: the journal of the Alzheimer's Association 14, 933-943 (2018).
- 752 101. Gold, L., *et al.* Aptamer-based multiplexed proteomic technology for biomarker discovery. 753 *PloS one* **5**, e15004 (2010).
- 754 102. Williams, S.A., *et al.* Plasma protein patterns as comprehensive indicators of health. *Nature medicine* **25**, 1851-1857 (2019).
- 756 103. Bolla, M.K., Wood, N. & Humphries, S.E. Rapid determination of apolipoprotein E genotype using a heteroduplex generator. *Journal of lipid research* **40**, 2340-2345 (1999).
- 758 104. Miller, S.A., Dykes, D.D. & Polesky, H.F. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic acids research* **16**, 1215 (1988).
- 760 105. Cox, D.R. Regression Models and Life-Tables. *Journal of the Royal Statistical Society. Series B (Methodological)* **34**, 187-220 (1972).
- 762 106. Dickerman, B.A., García-Albéniz, X., Logan, R.W., Denaxas, S. & Hernán, M.A. Avoidable flaws in observational analyses: an application to statins and cancer. *Nat Med* **25**, 1601-1606 (2019).
- 765 107. Ritari, J., Hyvärinen, K., Clancy, J., Partanen, J. & Koskela, S. Increasing accuracy of HLA imputation by a population-specific reference panel in a FinnGen biobank cohort. *NAR*767 *Genom Bioinform* **2**, lqaa030 (2020).
- 108. Luo, W., Friedman, M.S., Shedden, K., Hankenson, K.D. & Woolf, P.J. GAGE: generally applicable gene set enrichment for pathway analysis. *BMC Bioinformatics* **10**, 161 (2009).
- 770 109. Bindea, G., *et al.* ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics* **25**, 1091-1093 (2009).

Shannon, P., et al. Cytoscape: a software environment for integrated models of biomolecular 110. interaction networks. *Genome Res* **13**, 2498-2504 (2003).

Figure 1. Flowchart of the study design. HLA, human leukocyte antigen; KEGG, Kyoto Encyclopedia of Genes and Genomes; PRS, polygenic risk score; SNP, single nucleotide polymorphism.

1) Biomarker discovery step: two-sample Mendelian randomization analyses



2) Validation step for the 126 biomarkers: triangulation analyses




Figure 2. The autoimmune hypothesis of diseases causing dementias, the supporting evidence from current analyses are listed at each mechanism. BBB, blood brain barrier; CD, cluster of differentiation; CNS, central nervoussystem; HLA, Human Leukocyte Antigen; cluster of differentiation; IPW, inverse probability weighted;

Central immune organs

Complement

Thymus Bone marrow

1) Increased production of primed mature CD8 T-cell autoreactive B-cells and CD4 and CD8 T-cells due to failed positive and negative selection in bone marrow and thymus.

Supporting evidence from:

- Mendelian randomization
- Polygenic risk scores
- **HLA** analyses
- Pathway analyses

Capillary


2) Chronic antigen stimulation and increased inflammation reduces anergy and allows more autoreactive cells to proliferate. It also degrades BBB that leads to contact between autoreactive peripheral and CNS epitopes.

Supporting evidence from:

- Mendelian randomization
- Plasma proteomics
- IPW analyses
- Pathway analyses


Bacteria and viruses

Neutrophi



Autoreactive

Lymph node



Secondary immune organs


Plasma cell

4) Antigen-presenting cells migrate to lymph nodes and activate autoreactive CD4 T-helper cells that activate autoreactive B-cells to plasma cells that secrete autoantibodies.

Supporting evidence from:

- Mendelian randomization
- HLA analyses
- Pathway analyses

Lymph node




6) Memory cells for autoantigens are formed and they react to reoccurring inflammation, tissue damage and infections. This sustains autoimmune driven neuroinflammation that causes permanent damage to CNS.

Supporting evidence from:

- Mendelian randomization
- Plasma proteomics
- IPW analyses
- Pathway analyses

Blood brain barrier




3) Inflammation, tissue damage, and infections activate autoreactive B- and T-cells via bystander activation or antigen presentation mediated molecular mimicry and cryptic epitopes. Autoreactive CD8-cells attack CNS cells. Inflammation increases amyloid production.


Supporting evidence from:

- Mendelian randomization
- Plasma proteomics
- **HLA** analyses
- Pathway analyses
- IPW analyses

Autoantibodies 5) Autoantibodies and peripheral leukocytes infiltrate CNS, activate

Supporting evidence from:





neurodegeneration and formation of amyloid β , tau protein, and α -

microglia, and sustain neuroinflammation. This leads to

Figure 3A. Wald ratio or inverse variance weighted Mendelian randomization estimates for outcome-specific biomarkers.




Figure 3B. Wald ratio or inverse variance weighted Mendelian randomization estimate for biomarkers that associated with at least three outcomes. These biomarkers localized around APOE gene. Biomarkers outcome pairs with no common SNPs available are on grey colour.




Figure 4. Phenome-wide association analyses for a Mendelian randomization-based polygenic risk score constructed only from SNPs that associated with levels of causal Alzheimer's disease biomarkers in Mendelian randomization Wald ratio or inverse variance weighted analyses. Upward pointing triangle means risk increasing and downward risk decreasing. Larger triangle indicates larger effect size.







Figure 5A-E. Association between different HLA-allele subclasses (y-axis) and dementia causing diseases, autoimmune diseases and their complications (x-axis). The HLA-types with at least one directionally consistent association with autoimmune diseases are bolded. Left side of the panel describes dementias and right side autoimmune diseases and their complications. *, false discovery rate p < 0.02; **, p < 0.01.




-0.6 -0.3 0.0 0.3 0.6









perpetuity. It is made available under a $\frac{\text{CC-BY-NC-ND 4.0 International license}}{33}$

Table 1. Associations between dementias and anti-inflammatory medications from inverse probability weighted (IPW) analyses in the FinnGen study. The positive control IPW analyses validate the analysis protocol by replicating association between statin medication and coronary heart disease. The negative control IPW analyses validate the associations between each anti-inflammatory medication and dementias by replicating the null finding between anti-inflammatory medications and coronary heart disease.

The baseline variables in IPW analyses were birth year, sex, ten principal components and time-varying variables statin, ACE-blocker, AT-blocker, renin-blocker, calcium channel blocker, any diuretic, insulin, metformin, other diabetes drug, depression medication, antipsychotic, and anticoagulant use as well as time varying any cancer, myocardial infarction, atrial fibrillation, heart failure, venous thromboembolism, ischemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage, obesity, sleep apnoea, and chronic obstructive pulmonary diseases, with informative censoring included. Because of limited number of participants, TNF- α inhibitors users in dementias include also baseline users, other analyses include only medication-free individuals at baseline. The estimates for randomized control trials are from references 14 to 17. Secondary prevention randomized control trial was used for methotrexate because no primary prevention trial was available. MR-PRS, Mendelian randomization based polygenic risk score for Alzheimer's disease; NSAID, non-steroidal anti-inflammatory drugs; TNF- α , tumor necrosis factor α ; IPW, inverse probability weighted analyses; RCT, randomized control trials.

`	4	
ጘ	4	


Medication	Disease	HR and 95% CIs	p-value
Statins			
Positive control for IPW			
protocol	Coronary heart disease IPW	0.38 (0.19 to 0.78)	0.009
	Coronary heart disease RCT	0.39 (0.29 to 0.49)	<0.001
Methotrexate	Alzheimer´s disease	0.71 (0.56 to 0.90)	0.004
Methotrexate	Alzheimer's disease MR-PRS ≥50%	0.64 (0.49 to 0.88)	0.004
	Alzheimer's disease MR-PRS <50%	0.84 (0.59 to 1.19)	0.330
	Vascular dementia	0.64 (0.39 to 1.19) 0.64 (0.30 to 1.37)	0.330
	Parkinson's disease	0.48 (0.29 to 0.81)	0.255
	Parkinson 's disease MR-PRS ≥50%	0.46 (0.29 to 0.81) 0.20 (0.05 to 0.83)	0.000
	Parkinson's disease MR-PRS < 50%	0.61 (0.08 to 4.37)	0.622
Negative control	Coronary heart disease IPW	0.97 (0.84 to 1.11)	0.622
Negative control	3	,	
	Coronary heart disease RCT	0.96 (0.79 to 1.16)	0.862
TNF-α inhibitors	Alzheimer´s disease	0.32 (0.14 to 0.76)	0.010
	Vascular dementia	0.27 (0.04 to 1.91)	0.188
	Parkinson's disease	0.26 (0.04 to 1.82)	0.173
Negative control	Coronary heart disease IPW	1.03 (0.55 to 1.95)	0.916
J	Coronary heart disease RCT	1.09 (0.77 to 1.56)	0.645
NSAIDs	Alzheimer´s disease	0.37 (0.35 to 0.40)	< 0.001
	Vascular dementia	0.25 (0.20 to 0.32)	< 0.001
	Parkinson´s disease	0.65 (0.57 to 0.75)	< 0.001
Negative control	Coronary heart disease IPW	0.38 (0.34 to 0.41)	< 0.001
	Coronary heart disease RCT	1.48 (1.00 to 2.26)	0.059
A matile into me im a c	Alahasina an'a dia aga	0 [4 (0 40 += 0 (1)	.0.001
Antihistamines	Alzheimer´s disease	0.54 (0.48 to 0.61)	< 0.001
	Vascular dementia	0.43 (0.29 to 0.64)	< 0.001
No sotion control	Parkinson's disease	0.70 (0.56 to 0.89)	0.003
Negative control	Coronary heart disease IPW	0.59 (0.51 to 0.69)	0.009
	Coronary heart disease RCT	No RCT available	
Corticosteroids	Alzheimer´s disease	0.65 (0.40 to 1.06)	0.085
Corticosterolas	Vascular dementia	1.02 (0.32 to 3.21)	0.972
	Parkinson's disease	0.50 (0.12 to 2.18)	0.358
Negative control	Coronary heart disease IPW	0.55 (0.25 to 1.23)	0.556
regative control	Coronary heart disease RCT	No RCT available	0.550
Salazines	Alzheimer´s disease	0.89 (0.71 to 1.11)	0.296
	Vascular dementia	0.82 (0.41 to 1.66)	0.583
	Parkinson´s disease	0.69 (0.42 to 1.11)	0.128
Negative control	Coronary heart disease IPW	1.06 (0.89 to 1.27)	0.490
·	Coronary heart disease RCT	No RCT available	

35


Supplementary Table 1. Significant backward Mendelian randomization results with p-value below 0.05. These hazard ratios were not stronger than observed in forward Mendelian randomization analyses in Supplementary Figure 1A and B.

Exposure	Outcome	Number of SNPs	HR (95% CIs)	p-value
Alzheimer's disease	FSC-A on plasmacystoid dendritic cell	20	0.85 (0.73 to 0.98)	0.0275
Late-onset Alzheimer's disease	Protein \$100-A13	13	0.51 (0.41 to 0.63)	< 0.001

Supplementary Figure 1A. Mendelian randomization sensitivity analyses for one standard deviation change in biomarker levels associated with late onset Alzheimer's diseases and with at least 3 SNPs available. The source of outcome and MR-base outcome identifier is described below the biomarker. Black = inverse variance weighted, grey = weighted median, blue = simple mode, red = Egger Mendelian randomization.



Supplementary Figure 1B. Mendelian randomization sensitivity analyses for one standard deviation change in biomarker levels associated with other dementias than late onset Alzheimer's diseases and with at least 3 SNPs available. The source of outcome and MR-base outcome identifier is described below the Biomarker. Black = inverse variance weighted, grey = weighted median, blue = simple mode, red = Egger Mendelian randomization.




perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

38

Supplementary Figure 2. Phenome-wide association analyses for the 126 biomarkers, effect size describes one standard deviation change in biomarker levels. All biomarker and outcomes pairs that passed false discovery rate correction of 5% are presented. Most biomarkers associated with only few outcomes and the grey boxes indicate no association after false discovery rate correction of 5% or lack of common SNPs.





Supplementary Figure 3. Plasma protein associations with dementia for one standard deviation change in protein levels from the Whitehall II cohort. The analyses included 8 proteins that had SNPs clustered around APOE and associated with at least three dementia subtypes in Mendelian randomization analyses. Analyses are first adjusted for age and sex and then additionally for APOE status.


Protein measured from plasma		HR	95% CIs	p-value
Endothelial monocyte-activating polypeptide 2 Endothelial monocyte-activating polypeptide 2 APOE adjusted	+	1.02 1.11	(0.91 to 1.14) (0.97 to 1.27)	0.750 0.140
Interferon-induced protein with tetratricopeptide repeats 2 Interferon-induced protein with tetratricopeptide repeats 2 APOE adjusted	- + -	0.79 0.84	(0.70 to 0.88) (0.73 to 0.97)	<0.001 0.010
Killer cell immunoglobulin-like receptor 2DL5A Killer cell immunoglobulin-like receptor 2DL5A	- - -	1.03 0.95	(0.90 to 1.18) (0.85 to 1.07)	0.640 0.390
Killer cell immunoglobulin-like receptor 2DL5A APOE adjusted Killer cell immunoglobulin-like receptor 2DL5A APOE adjusted	-	0.98 0.95	(0.83 to 1.17) (0.83 to 1.09)	0.860 0.480
Leucine-rich repeat neuronal protein 1:Cytoplasmic domain Leucine-rich repeat neuronal protein 1:Cytoplasmic domain APOE adjusted	-	1.38 1.01	(1.23 to 1.54) (0.83 to 1.22)	<0.001 0.930
Leucine-rich repeat neuronal protein 1:Extracellular domain Leucine-rich repeat neuronal protein 1:Extracellular domain APOE adjusted	•	1.08	(0.95 to 1.24) (0.91 to 1.28)	0.250 0.390
Tight junction protein ZO-1 Tight junction protein ZO-1 APOE adjusted	-	0.96 0.95	(0.86 to 1.08) (0.83 to 1.09)	0.520 0.460
Tumor necrosis factor receptor superfamily member 13C Tumor necrosis factor receptor superfamily member 13C APOE adjusted	•	1.00	(0.88 to 1.14) (0.87 to 1.18)	0.950 0.870
ValinetRNA ligase	+	0.99	(0.89 to 1.11)	0.930
ValinetRNA ligase APOE adjusted	05 075 15 2	0.95	(0.84 to 1.09)	0.490
	0.5 0.75 1.5 2			


40


Supplementary Figures 4 A-H. KEGG functional pathway enrichment analyses for all proteins and receptors that associated with dementias in Mendelian randomization analyses. The estimated causal betas were used in place of log fold change.


























Supplementary Figure 5. ClueGO enrichment analyses for all the 76 proteins and receptors in the biomarkers that had evidence of causal association in Mendelian randomization analyses. All proteins that associated with Uniprot search terms "immune system" and "blood brain barrier" were used as a background dataset. GO-terms in blue were enriched in cluster where most significant associations were observed for cell adhesion molecules. In the red cluster, the most significant GO-term associations were observed for hematopoietic cell lineage. Big dots describe the GO-terms and small dots the genes associated with these terms.





Supplementary Figures 6A-R. ConsensusPathDB shortest interaction path analyses for the 42 proteins that were causally associated with dementia causing diseases in Mendelian randomization analyses. Figures A-N include biomarkers for amyloid and tau and O-R for α -synuclein pathways.























Supplementary methods

1

2

3

26

27

Mendelian randomization analyses

- The SNPs for biomarkers and outcomes were searched from MR-base database. Immune system 4
- and BBB search terms were identified using identifiers of cell types, receptors, proteins, and genes. 5
- The identifiers were searched from several publications²⁻¹⁰ and from Uniprot¹¹ with search terms 6
- "immune" and "blood brain barrier". Outcomes included all cohorts with following dementia-7
- causing diseases: all types of Alzheimer's disease, Parkinson's disease, vascular dementia, 8
- 9 frontotemporal dementia, dementia in general, and progression of dementia. Poor cognitive
- performance was chosen as an intermediate outcome. Two sample Mendelian randomization was 10
- used to analyse associations between biomarkers and outcomes. 12 First analyses estimated effects 11
- with Wald ratio or inverse variance-weighted analyses. For biomarker-outcome pairs that passed 12
- FDR of 5% and shared over two common SNPs we performed sensitivity analyses with weighted 13
- median, simple mode, MR Egger, and backward Mendelian randomization¹² with TwoSampleMR 14
- 15 and MRInstruments R packages.
- 16 To assess off-target effects of the observed causal biomarkers, we performed a phenome-wide
- Mendelian randomization analyses for each biomarker, using GWAS summary statistics for 210 17
- UK Biobank endpoints conducted by Neale lab and with recognized dementia risk factors. ^{5,13} All 18
- analyses used European ancestry as reference, clumping cut-off R2 = 0.01 and a 10,000kb window. 19
- 20 LD proxies were searched with R2 = 0.6 and a proxy split size of 500. The biomarkers and outcome
- alleles were harmonized by inferring from positive strand alleles using allele frequencies for 21
- 22 palindromes. We used statistical software R (3.6.0 and 4.1.0) for these analyses. Novelty of our
- 23 Mendelian randomization findings was evaluated with Pubmed search using following search
- terms: (Mendelian randomization) AND (dementia OR Alzheim* OR Parkin* OR cognitive 24
- 25 decline) AND (Entrez gene symbol OR Uniprot protein identifier) without limitations.

Plasma proteins and Whitehall II study

- Plasma protein measurements in Whitehall II study were available for 6,235 individuals of whom 28
- 29 310 developed dementia. The participants are linked to the National Health Services (NHS)
- Hospital Episode Statistics (HES) database, and the British National mortality register using 30
- individual NHS identification numbers for linkage. 14 The NHS provides nearly complete health care 31
- coverage for all individuals legally resident in the UK. Incident dementia was defined using the 32
- 33 WHO International Classification of Diseases, version 10 (ICD-10) codes F00, F01, F03, G30, and
- 34 G31 and ICD-9 codes 290.0-290.4, 331.0-331.2, 331.82, and 331.9. We also conducted informant
- 35 interviews and checked participants' medications at each screening (in 1996-1998, 2011-2013 and
- 2016-2017) for dementia-related medication. Sensitivity and specificity of dementia assessment 36
- 37 based on HES data is 0.78 and 0.92.15
- The plasma proteins were measured using the SomaScan version 4.0 and 4.1 assays. 4,16,17 The 38
- 39 assays were validated against external reference population and protein-specific conversion
- coefficients were used to balance the technical differences between versions 4.0 and 4.1. The 40

- analyses used plasma samples measured in 1995/1997 and stored in 0.25 mL aliquots at -80°C. 41
- Earlier studies describe performance of the SomaScan assay and the modified aptamer binding in 42
- detail. 4,16,17 In brief, the assay uses a mix of thousands of slow off-rate modified aptamers 43
- 44 (SOMAmers) that bind to proteins in participants' plasma samples where the specificity is ensured
- with two-step process analogous to a conventional immunoassay. The specificity of the aptamer 45
- reagents is good and has been tested in several ways. 4,18,19 Median intra- and inter-assay coefficients 46
- of variation for SomaScan version 4 are ~5% and assay sensitivity is comparable to that of typical 47
- 48 immunoassays, with a median lower limit of detection in the femtomolar range.
- 50 In the Whitehall II study, standard self-administered questionnaires provided data on age and sex.
- 51 Using DNA extracted from whole blood, a standard PCR assay determined APOE genotype using
- the salting out method. ^{20,21} Two blinded independent observers read the genotype and any 52
- discrepancies were resolved by repeating the PCR analysis. 53
- 54 In analyses, proteins were transformed to a normal distribution by inverse rank-based normal
- transformation. The follow-up ended at onset of dementia, death, or 1st of October 2019, which ever 55
- occurred first. Age, sex, and APOE adjusted Cox regression models estimated associations between 56
- the proteins and dementia.²² The proportionality assumption in all Cox models was assessed with 57
- Schoenfeld residuals and with log-log plots.²² We used statistical software R (3.6.0 and 4.1.0) for 58
- 59 these analyses.

49

60

61

72

Polygenic risk score and IPW analyses

- 62 FinnGen Data Freeze 8 contains 339,233 individuals, and represents approximately 7% of Finnish
- adult population. FinnGen is a collection of prospective epidemiological and disease-based cohorts, 63
- 64 and hospital biobank samples and links genotypes by the unique national personal identification
- numbers to nationwide health registries, including the national hospital discharge (available from 65
- 66 1968), death (1969–), cancer (1953–) and medication reimbursement (1964–) and purchase (1995–)
- registries. The registry-based follow-up ended on Dec 31, 2019. Alzheimer's disease was defined 67
- with ICD-10 codes under F00 and G30, ICD-9 codes under 3310, ICD-8 code under 29010, and 68
- 69 medication purchase code N06D. Vascular dementia was defined with ICD-10 codes under F01 and
- ICD-9 codes under 4378. Parkinson's disease was defined with ICD-10 codes under G20, ICD-9 70
- codes under 3320A, ICD-8 code under 34200, and reimbursements code 110. 71
- 73 FinnGen samples were genotyped with Illumina and Affymetrix arrays (Illumina Inc., San Diego,
- 74 and Thermo Fisher Scientific, Santa Clara, CA, USA), and genotype calls were made with the
- 75 GenCall or zCall (for Illumina) and the AxiomGT1 algorithm for Affymetrix data. Individuals with
- 76 ambiguous gender, high genotype missingness (>5%), excess heterozygosity (+-4SD) and non-
- 77 Finnish ancestry were excluded, as well as all variants with high missingness (>2%), low Hardy–
- 78 Weinberg equilibrium p-value (<1e-6) and minor allele count (MAC < 3). Array data pre-phasing
- 79 was carried out with Eagle $2.3.5^{23}$ with the number of conditioning haplotypes set to 20,000.
- 80 Genotype imputation was done using the population-specific SISu v3 imputation reference with

81 3,775 high-coverage (25-30x) whole-genome sequences in Finns, described in detail at

https://doi.org/10.17504/protocols.io.xbgfijw. 82

84 The PRS were constructed from SNPs that were associated with the Mendelian randomization

- causal 126 biomarkers for dementias. The SNPs were LD-pruned with clumping cut-off R2 = 0.01
- 86 in 500kb window with R package TwoSampleMR. The available SNPs were searched from
- FinnGen genotypes and the final scores were generated with PLINK v2.00aLM3 by calculating the 87
- SNP-biomarker beta weighted sum of risk alleles for each SNP. The PRS was scaled to zero mean 88
- 89 and unit variance, and we analysed its phenome-wide associations across 2401 disease endpoints.
- 90 The association between PRS and endpoints were studied with logistic regression, adjusting for
- 91 birth year, sex, and ten first principal components of ancestry.
- 93 We used IPW analyses to emulate randomized control trials on the effect of preventive anti-
- inflammatory medication on risk of dementias in FinnGen.²⁴ These analyses included participants 94
- aged over 45 without any dementia-causing disease at baseline (N = 90,512) ATC codes for anti-95
- inflammatory medication use were searched from medication purchase registry that starts from 96
- 97 1995. To simulate trial design and to avoid immortal time bias, each analyses included only new
- 98 medication users. In IPW analyses, we assumed that when medication is initiated, it is continued
- 99 until end of follow-up to simulate intention to treat analyses and thus to provide conservative
- 100 estimates. The baseline variables in IPW analyses were birth year, sex, ten principal components of
- ancestry and time-varying variables statin, ACE-blocker, AT-blocker, renin-blocker, calcium 101
- 102 channel blocker, any diuretic, insulin, metformin, other diabetes drug, depression medication,
- 103 antipsychotic, and anticoagulant use as well as time varying any cancer, myocardial infarction,
- atrial fibrillation, heart failure, venous thromboembolism, ischemic stroke, intracerebral 104
- 105 haemorrhage, subarachnoid haemorrhage, obesity, sleep apnoea, and chronic obstructive pulmonary
- 106 diseases, with informative censoring included. The positive control analyses on statin medication
- used these same variables but did not include statin as time-varying covariate. We used R (4.1.2) for 107
- 108 these analyses.

109

110

116

117

83

85

92

HLA analyses

- The analyses were done using imputed HLA alleles, imputed with high accuracy using a Finnish-111
- specific reference panel, which has been previously described in detail.²⁵ After filtering based on a 112
- HLA carrier frequency of ≥ 0.01 and posterior probability of ≥ 0.6 , we assessed the association 113
- 114 between HLA alleles and dementias and autoimmune diseases using logistic regression, adjusting
- for birth year, sex, and ten first principal components of ancestry. 115

Pathway analyses

- KEGG pathway analysis was used for studying the effect of the biomarkers on validated pathways 118
- with Generally Applicable Gene-set Enrichment (GAGE), 26 using Mendelian randomization Wald 119

ratios or inverse variance weight betas and p-values as input for expression ratios. GO term enrichment analyses were done with ClueGO version 2.5.8²⁷ in Cytoscape version 3.7.2.²⁸ The hypergeometric test used all the 76 plasma proteins or surface receptors of the 126 biomarkers as input and all immune system and BBB related proteins from Uniprot¹¹ as background, with correction for 5% FDR. The shortest interaction path analyses were done with ConsensusPathDB,²⁹ a web based analysis tool containing a range of biomedical databases. ConsensusPathDB was used to decipher the potential common pathways between the biomarkers and amyloid β, tau protein, and α-synuclein. **Open Targets analyses** Medications that change the levels of the 126 biomarkers were searched from Open Targets database using Uniprot protein and Entrez gene symbols.

perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary references

153

154

- 155 1. Hemani, G., *et al.* The MR-Base platform supports systematic causal inference across the human phenome. *Elife* **7**(2018).
- 157 2. Akiyama, H., *et al.* Inflammation and Alzheimer's disease. *Neurobiology of aging* **21**, 383- 421 (2000).
- Dendrou, C.A., Petersen, J., Rossjohn, J. & Fugger, L. HLA variation and disease. *Nat Rev Immunol* **18**, 325-339 (2018).
- Lindbohm, J.V., et al. Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies. Alzheimer's & dementia: the journal of the Alzheimer's Association (2021).
- Livingston, G., *et al.* Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet (London, England)* **396**, 413-446 (2020).
- 166 6. O'Brien, J.T. & Thomas, A. Vascular dementia. *Lancet (London, England)* 386, 1698-1706
 167 (2015).
- Sweeney, M.D., Zhao, Z., Montagne, A., Nelson, A.R. & Zlokovic, B.V. Blood-Brain
 Barrier: From Physiology to Disease and Back. *Physiological Reviews* 99, 21-78 (2019).
- Tan, E.K., *et al.* Parkinson disease and the immune system associations, mechanisms and therapeutics. *Nat Rev Neurol* **16**, 303-318 (2020).
- 172 9. Theofilopoulos, A.N., Kono, D.H. & Baccala, R. The multiple pathways to autoimmunity.

 173 *Nat Immunol* **18**, 716-724 (2017).
- 174 10. Walker, K.A., *et al.* Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk. *Nature Aging* **1**, 473-489 (2021).
- 176 11. UniProt, C. UniProt: a worldwide hub of protein knowledge. *Nucleic acids research* **47**, D506-D515 (2019).
- 178 12. Holmes, M.V., Richardson, T.G., Ference, B.A., Davies, N.M. & Davey Smith, G.
- Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. *Nat Rev Cardiol* **18**, 435-453 (2021).
- 181 13. http://www.nealelab.is/uk-biobank/.
- 182 14. Kivimaki, M., *et al.* Validity of Cardiovascular Disease Event Ascertainment Using Linkage to UK Hospital Records. *Epidemiology (Cambridge, Mass.)* **28**, 735-739 (2017).
- 184 15. Sommerlad, A., et al. Accuracy of general hospital dementia diagnoses in England:
- Sensitivity, specificity, and predictors of diagnostic accuracy 2008-2016. *Alzheimer's & dementia: the journal of the Alzheimer's Association* **14**, 933-943 (2018).
- 187 16. Gold, L., *et al.* Aptamer-based multiplexed proteomic technology for biomarker discovery. *PloS one* **5**, e15004 (2010).
- 189 17. Williams, S.A., *et al.* Plasma protein patterns as comprehensive indicators of health. *Nature medicine* **25**, 1851-1857 (2019).
- 191 18. Emilsson, V., *et al.* Co-regulatory networks of human serum proteins link genetics to disease. *Science (New York, N.Y.)* **361**, 769-773 (2018).
- 19. Tin, A., *et al.* Reproducibility and Variability of Protein Analytes Measured Using a
 Multiplexed Modified Aptamer Assay. *The journal of applied laboratory medicine* **4**, 30-39
 (2019).
- Bolla, M.K., Wood, N. & Humphries, S.E. Rapid determination of apolipoprotein E
 genotype using a heteroduplex generator. *Journal of lipid research* 40, 2340-2345 (1999).
- 198 21. Miller, S.A., Dykes, D.D. & Polesky, H.F. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic acids research* **16**, 1215 (1988).
- 200 22. Cox, D.R. Regression Models and Life-Tables. *Journal of the Royal Statistical Society. Series B (Methodological)* 34, 187-220 (1972).

perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

- 202 23. Loh, P.R., *et al.* Reference-based phasing using the Haplotype Reference Consortium panel. *Nat Genet* **48**, 1443-1448 (2016).
- 204 24. Hernán, M.A. & Robins, J.M. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. *Am J Epidemiol* **183**, 758-764 (2016).
- 25. Ritari, J., Hyvärinen, K., Clancy, J., Partanen, J. & Koskela, S. Increasing accuracy of HLA imputation by a population-specific reference panel in a FinnGen biobank cohort. *NAR Genom Bioinform* 2, Iqaa030 (2020).
- 209 26. Luo, W., Friedman, M.S., Shedden, K., Hankenson, K.D. & Woolf, P.J. GAGE: generally applicable gene set enrichment for pathway analysis. *BMC Bioinformatics* **10**, 161 (2009).
- 27. Bindea, G., *et al.* ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics* **25**, 1091-1093 (2009).

217

- 213 28. Shannon, P., *et al.* Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* **13**, 2498-2504 (2003).
- 215 29. Herwig, R., Hardt, C., Lienhard, M. & Kamburov, A. Analyzing and interpreting genome data at the network level with ConsensusPathDB. *Nature Protocols* **11**, 1889-1907 (2016).

Supplementary file 1. Distance from *APOE* gene

SNP	Beta exposure	Exposure	Outcome	Chromosome	Position	Distance from start of APOE	Distance from end of APOE
rs12461065	0.1574	ValinetRNA ligase id:prot-a-3191	Alzheimer's disease (more excluded) id:finn-a-AD_EXMORE	19	45 102 050	- 306 961	- 310 600
rs395908	0.3382	P. EMAP-2 id:prot-c-2714_78_2	Alzheimer's disease id:ieu-b-2	19	45 380 961	- 28 050	- 31 689
rs429358	0.3499	Killer cell immunoglobulin-like receptor 2DL5A id:prot-a-1643	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 411 941	2 930	- 709
rs429358	1.1769	Leucine-rich repeat neuronal protein 1 id:prot-a-1792	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 411 941	2 930	- 709
rs429358	0.3527	PDZK1-interacting protein 1 id:prot-a-2242	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 411 941	2 930	- 709
rs429358	0.2148	3 Tight junction protein ZO-1 id:prot-a-2983	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 411 941	2 930	- 709
rs438811	-1.2435	5 Protein S100-A13 id:prot-a-2616	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 418 790	9 779	6 140
rs5167	0.2454	BAFF Receptor id:prot-c-5383_14_3	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 448 465	39 454	35 815
rs5167	0.3319	P Endothelial monocyte-activating polypeptide 2 id:prot-a-65	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 448 465	39 454	35 815
rs5167	0.277	Melanoma-associated antigen 3 id:prot-a-1828	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 448 465	39 454	35 815
rs5167	0.2145	Transmembrane protein 59-like id:prot-a-3014	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 448 465	39 454	35 815
rs5167	0.8678	3 ValinetRNA ligase id:prot-a-3191	Alzheimer's disease (more excluded) id:finn-a-AD_EXMORE	19	44 980 181	- 428 830	- 432 469
rs59325138	0.1436	Interferon-induced protein with tetratricopeptide repeats 2 id:pr	o Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 416 291	7 280	3 641
rs7412	-0.4743	B Cadherin-related family member 5 id:prot-a-490	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 412 079	3 068	- 571
rs7412	0.7212	Programme CD200 receptor 2 id:prot-a-424	Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 412 079	3 068	- 571
rs7412	-0.3721	Disintegrin and metalloproteinase domain-containing protein 11 $\mid \mid$	ic Alzheimer's disease (late onset) id:ebi-a-GCST002245	19	45 412 079	3 068	- 571
rs7412	-0.5043	Pregnancy-specific beta-1-glycoprotein 5 id:prot-a-2404	Alzheimer disease (more excluded) id:finn-a-G6_ALZHEIMER_	_E. 19	44 921 921	- 487 090	- 490 729

Supplementary File 2. Drugs available in the Open Targets database that act on the biomarkers that associated with dementias and are hypothized to reduce the risk. In total 64 different drugs were identified.

Drug_ID	Drug_name	Туре	Mechanism_of_action	Action_type	Disease_ID	Disease_name_originally_used_for Phase	Status	Source
CHEMBL2107842	ALBINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003047	hepatitis C virus infection	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00097435%22
CHEMBL2107842	ALBINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004220	chronic hepatitis C virus infection	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00759200%22,https://clinicaltrials.gov/sea
CHEMBL2107842	ALBINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004239	chronic hepatitis B virus infection	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00964665%22
CHEMBL2108252	APOLIZUMAB	Antibody	Human leukocyte antigen DR beta chain inhibitor	Inhibitor	EFO_0000095	chronic lymphocytic leukemia	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00022971%22
CHEMBL2108252	APOLIZUMAB	Antibody	Human leukocyte antigen DR beta chain inhibitor	Inhibitor	EFO_0000403	diffuse large B-cell lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00022971%22
CHEMBL2108252	APOLIZUMAB	Antibody	Human leukocyte antigen DR beta chain inhibitor	Inhibitor	EFO_0000574	lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00004101%22
CHEMBL2108252	APOLIZUMAB	Antibody	Human leukocyte antigen DR beta chain inhibitor	Inhibitor	EFO_1001469	Mantle cell lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00022971%22
CHEMBL2108252	APOLIZUMAB	Antibody	Human leukocyte antigen DR beta chain inhibitor	Inhibitor	MONDO_0018906	follicular lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00022971%22
CHEMBL4297888	APX-005M	Unknown	Tumor necrosis factor receptor superfamily member 5 agonist	Agonist	EFO_1000657	rectum cancer	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04130854%22
CHEMBL4297888	APX-005M	Unknown	Tumor necrosis factor receptor superfamily member 5 agonist	Agonist	EFO_1001968	soft tissue sarcoma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03719430%22
CHEMBL4297888	APX-005M	Unknown	Tumor necrosis factor receptor superfamily member 5 agonist	Agonist	MONDO_0007576	esophageal cancer	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03165994%22
CHEMBL4297888	APX-005M	Unknown	Tumor necrosis factor receptor superfamily member 5 agonist	Agonist	EFO_0000756	melanoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02706353%22
CHEMBL4297888	APX-005M	Unknown	Tumor necrosis factor receptor superfamily member 5 agonist	: Agonist	EFO_0002617	metastatic melanoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT03597282%22
CHEMBL4297888	APX-005M	Unknown	Tumor necrosis factor receptor superfamily member 5 agonist	: Agonist	EFO_1000044	pancreatic adenocarcinoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03214250%22
CHEMBL2109266	AVE-9633	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	MONDO_0004643	myeloid leukemia	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00543972%22
CHEMBL3989989	AXICABTAGENE CILOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000616	neoplasm	3	http://www.whocc.no/atc_ddd_index/?code=L01XX70
CHEMBL3989989	AXICABTAGENE CILOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0011057	neurotoxicity	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04150913%22
CHEMBL3989989	AXICABTAGENE CILOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_1001469	Mantle cell lymphoma	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02601313%22
CHEMBL3989989	AXICABTAGENE CILOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000096	neoplasm of mature B-cells	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT04314843%22,https://clinicaltrials.gov/sea
CHEMBL3989989	AXICABTAGENE CILOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000403	diffuse large B-cell lymphoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02926833%22
CHEMBL3989989	AXICABTAGENE CILOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000574	lymphoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04608487%22
CHEMBL3989989	AXICABTAGENE CILOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	MONDO_0018906	follicular lymphoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02348216%22
CHEMBL3989989	AXICABTAGENE CILOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	MONDO_0044889	high grade B-cell lymphoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02348216%22
CHEMBL4594618	BREXUCABTAGENE AUTOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_1001469	Mantle cell lymphoma	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02601313%22
CHEMBL4594618	BREXUCABTAGENE AUTOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000095	chronic lymphocytic leukemia	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03624036%22
CHEMBL4594618	BREXUCABTAGENE AUTOLEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000220	acute lymphoblastic leukemia	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02614066%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0000540	immune system disease	4	http://www.whocc.no/atc_ddd_index/?code=L04AC08
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	Orphanet_208650	Cryopyrin-associated periodic syndron	4	http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d271f3b-e4f9-4d80-8dcf-
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0003106	pneumonia	3 Completed	https://clinicaltrials.gov/search?id=%22NCT04362813%22

CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0003914	atherosclerosis	3 Completed	https://clinicaltrials.gov/search?id=%22NCT01327846%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_1001999	systemic juvenile idiopathic arthritis	3 Terminated	https://clinicaltrials.gov/search?id=%22NCT00886769%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	Orphanet_1451	CINCA syndrome	3 Terminated	https://clinicaltrials.gov/search?id=%22NCT00770601%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	DOID_13406	pulmonary sarcoidosis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02888080%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0000275	atrial fibrillation	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT01805960%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0000756	melanoma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03484923%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0001071	lung carcinoma	2 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04789681%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0001359	type I diabetes mellitus	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00947427%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0001360	type II diabetes mellitus	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT00900146%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0002506	osteoarthritis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01160822%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0003780	Behcet's syndrome	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02756650%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0004214	Abdominal Aortic Aneurysm	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT02007252%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0004246	mucocutaneous lymph node syndrome	2 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT02980263%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0004265	peripheral arterial disease	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT01731990%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0004274	gout	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00819585%22,https://clinicaltrials.gov/sea
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0005531	urticaria	2 Unknown status	https://clinicaltrials.gov/search?id=%22NCT01635127%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0007135	adult-onset Still's disease	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT02204293%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0008518	polymyalgia rheumatica	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT01364389%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_1000906	dry eye syndrome	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01250171%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_1001165	Schnitzler syndrome	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01390350%22,https://clinicaltrials.gov/sea
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_1001345	Hepatitis, Alcoholic	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03775109%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	HP_0000999	Pyoderma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01302795%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	MONDO_0100096	COVID-19	2 Completed	https://clinicaltrials.gov/search?id=%22NCT04365153%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	Orphanet_232	Sickle cell anemia	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02961218%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	Orphanet_309025	Mevalonate kinase deficiency	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01303380%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	Orphanet_342	Familial Mediterranean fever	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01148797%22,https://clinicaltrials.gov/sea
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0000198	myelodysplastic syndrome	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04810611%22,https://clinicaltrials.gov/sea
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0000341	chronic obstructive pulmonary disease	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00581945%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_000685	rheumatoid arthritis	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00505089%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0001365	age-related macular degeneration	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00503022%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0002517	pancreatic ductal adenocarcinoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04581343%22
CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0002609	juvenile idiopathic arthritis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00426218%22

CHEMBL12	201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0003060	non-small cell lung carcinoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03064854%22
CHEMBL12	201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0009322	proliferative diabetic retinopathy	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT01589029%22
CHEMBL12	201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	HP_0001945	Fever	1 Unknown status	https://clinicaltrials.gov/search?id=%22NCT02775994%22
CHEMBL12	201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	MONDO_0007254	breast cancer	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03742349%22
CHEMBL12	201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0000681	renal cell carcinoma	0 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04028245%22
CHEMBL21	09286	COLTUXIMAB RAVTANSINE	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000220	acute lymphoblastic leukemia	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT01440179%22
CHEMBL21	09286	COLTUXIMAB RAVTANSINE	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000403	diffuse large B-cell lymphoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01472887%22,https://clinicaltrials.gov/sea
CHEMBL21	09286	COLTUXIMAB RAVTANSINE	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0005952	non-Hodgkins lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00796731%22,https://clinicaltrials.gov/sea
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0003073	asymptomatic myeloma	3 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03937635%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000203	monoclonal gammopathy	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03236428%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000209	T-cell acute lymphoblastic leukemia	2 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04972942%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000220	acute lymphoblastic leukemia	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03384654%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000222	acute myeloid leukemia	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02807558%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000249	Alzheimer's disease	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04070378%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000574	lymphoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02927925%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000616	neoplasm	2 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT03207542%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0002690	systemic lupus erythematosus	2 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04810754%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0005761	lupus nephritis	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04868838%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0006738	plasmacytoma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04166565%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0007160	autoimmune thrombocytopenic purpu	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04703621%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0009441	Waldenstrom macroglobulinemia	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03679624%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_1001115	POEMS syndrome	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04396496%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_1001469	Mantle cell lymphoma	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT02413489%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_1001875	amyloidosis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02816476%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_1001951	colorectal carcinoma	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02060188%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	MONDO_0008315	prostate cancer	2 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT03035357%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	MONDO_0018906	follicular lymphoma	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT02413489%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_000095	chronic lymphocytic leukemia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03447808%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000183	Hodgkins lymphoma	1 Suspended	https://clinicaltrials.gov/search?id=%22NCT03432741%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000198	myelodysplastic syndrome	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03537599%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000304	breast adenocarcinoma	1 Suspended	https://clinicaltrials.gov/search?id=%22NCT03432741%22
CHEMBL17	43007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000311	cancer	1 Completed	https://clinicaltrials.gov/search?id=%22NCT03098550%22

CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO 0000330	childhood acute myeloid leukemia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03537599%22
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000519	glioblastoma multiforme	1 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04922723%22
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000673	prostate adenocarcinoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03177460%22
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0001378	multiple myeloma	1 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT03701321%22,https://clinicaltrials.gov/sea
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0003060	non-small cell lung carcinoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT03023423%22
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0004599	acute graft vs. host disease	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04204980%22
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0005952	non-Hodgkins lymphoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT01592370%22
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0006475	plasma cell leukemia	1 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT03591744%22
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_1001051	mycosis fungoides	1 Suspended	https://clinicaltrials.gov/search?id=%22NCT03432741%22
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	MONDO_0019465	nodal marginal zone B-cell lymphoma	1 Suspended	https://clinicaltrials.gov/search?id=%22NCT03432741%22
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	Orphanet_85443	AL amyloidosis	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03283917%22
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000349	clear cell renal carcinoma	0 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03473730%22
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000403	diffuse large B-cell lymphoma	0 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04139304%22
CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0006544	bladder transitional cell carcinoma	0 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03473730%22
CHEMBL3545371	DENINTUZUMAB MAFODOTIN	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000220	acute lymphoblastic leukemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01786135%22
CHEMBL3545371	DENINTUZUMAB MAFODOTIN	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000309	Burkitts lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01786135%22
CHEMBL3545371	DENINTUZUMAB MAFODOTIN	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000403	diffuse large B-cell lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01786135%22
CHEMBL3545371	DENINTUZUMAB MAFODOTIN	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_1001469	Mantle cell lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01786135%22
CHEMBL3545371	DENINTUZUMAB MAFODOTIN	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	MONDO_0018906	follicular lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01786135%22
CHEMBL4594579	FELZARTAMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0003086	kidney disease	2 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04893096%22
CHEMBL4594579	FELZARTAMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	MONDO_0002462	glomerulonephritis	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04733040%22
CHEMBL4594579	FELZARTAMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0001378	multiple myeloma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01421186%22
CHEMBL4594579	FELZARTAMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0004254	membranous glomerulonephritis	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04145440%22
CHEMBL3990038	FLOTETUZUMAB	Antibody	T cell surface glycoprotein CD3 binding agent	Binding agent	EFO_0000222	acute myeloid leukemia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02152956%22,https://clinicaltrials.gov/sea
CHEMBL1743020	FORALUMAB	Antibody	T cell surface glycoprotein CD3 inhibitor	Inhibitor	EFO_0000384	Crohn's disease	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00630643%22
CHEMBL1743020	FORALUMAB	Antibody	T cell surface glycoprotein CD3 inhibitor	Inhibitor	EFO_0004599	acute graft vs. host disease	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00805909%22
CHEMBL2108342	GEMTUZUMAB	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_0000222	acute myeloid leukemia	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00136084%22
CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_0000616	neoplasm	4	http://www.whocc.no/atc_ddd_index/?code=L01XC05
CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_0000220	acute lymphoblastic leukemia	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT00798213%22
CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_0000224	acute promyelocytic leukemia	2 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT01548911%22
CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_000095	chronic lymphocytic leukemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00038831%22
CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_0000198	myelodysplastic syndrome	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT01020539%22

CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_0000565	leukemia	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00577694%22
CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_1000309	Juvenile Myelomonocytic Leukemia	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00669890%22
CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	MONDO_0019457	therapy related acute myeloid leukem	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04915612%22
CHEMBL1201506	GEMTUZUMAB OZOGAMICIN	Antibody	Myeloid cell surface antigen CD33 binding agent	Binding agent	EFO_0000222	acute myeloid leukemia	0 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03568994%22
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	n EFO_1001231	uveitis	3 Terminated	https://clinicaltrials.gov/search?id=%22NCT02258854%22,https://clinicaltrials.gov/sea
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	n EFO_0000685	rheumatoid arthritis	2 Suspended	https://clinicaltrials.gov/search?id=%22NCT00777816%22
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	n EFO_0001359	type I diabetes mellitus	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00998699%22,https://clinicaltrials.gov/sea
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	n EFO_0002506	osteoarthritis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01882491%22,https://clinicaltrials.gov/sea
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	n EFO_0003894	acne	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01498874%22
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	n EFO_0009672	inner ear disease	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01950312%22
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	n HP_0000999	Pyoderma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01882504%22
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	n EFO_0001360	type II diabetes mellitus	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00513214%22,https://clinicaltrials.gov/sea
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	n EFO_0003780	Behcet's syndrome	1 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT01211977%22
CHEMBL1743026	GEVOKIZUMAB	Antibody	Interleukin-1 beta negative allosteric modulator	Negative allosteric m	n MONDO_0001718	scleritis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01835132%22
CHEMBL2108707	GLEMBATUMUMAB	Antibody	Transmembrane glycoprotein NMB binding agent	Binding agent	EFO_0000756	melanoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00412828%22
CHEMBL2108707	GLEMBATUMUMAB	Antibody	Transmembrane glycoprotein NMB binding agent	Binding agent	MONDO_0007254	breast cancer	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00704158%22
CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody	Transmembrane glycoprotein NMB binding agent	Binding agent	EFO_000637	osteosarcoma	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02487979%22
CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody	Transmembrane glycoprotein NMB binding agent	Binding agent	EFO_0000756	melanoma	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT02302339%22
CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody	Transmembrane glycoprotein NMB binding agent	Binding agent	EFO_1000616	Uveal Melanoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02363283%22
CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody	Transmembrane glycoprotein NMB binding agent	Binding agent	EFO_0000708	squamous cell lung carcinoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT02713828%22
CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody	Transmembrane glycoprotein NMB binding agent	Binding agent	MONDO_0007254	breast cancer	0 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT03473691%22
CHEMBL2109509	HCBE-11	Antibody	Tumor necrosis factor receptor superfamily member 3 agonist	Agonist	EFO_0000616	neoplasm	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00105170%22
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000096	neoplasm of mature B-cells	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00138086%22,https://clinicaltrials.gov/sea
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0013730	graft versus host disease	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT00577278%22
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000095	chronic lymphocytic leukemia	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00012298%22
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000183	Hodgkins lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00036855%22
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000191	MALT lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00012298%22
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000309	Burkitts lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00064246%22
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000403	diffuse large B-cell lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00036855%22
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000565	leukemia	•	https://clinicaltrials.gov/search?id=%22NCT00048737%22
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000574	lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00372905%22
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0001378	multiple myeloma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00477815%22

CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005952	non-Hodgkins lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00089284%22
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0009441	Waldenstrom macroglobulinemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00438880%22,https://clinicaltrials.gov/sea
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1000550	Splenic Marginal Zone Lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00012298%22
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001365	Lymphoma, AIDS-Related	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00036855%22
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001469	Mantle cell lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00438880%22
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0000873	lymphoblastic lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00036855%22
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0018906	follicular lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00438880%22
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0019088	post-transplant lymphoproliferative d	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00036855%22
CHEMBL1201606	IBRITUMOMAB TIUXETAN	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0019465	nodal marginal zone B-cell lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00438880%22
CHEMBL2109330	IC14	Antibody	Monocyte differentiation antigen CD14 inhibitor	Inhibitor	EFO_0005547	dengue disease	2 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT03875560%22
CHEMBL2109330	IC14	Antibody	Monocyte differentiation antigen CD14 inhibitor	Inhibitor	EFO_1000637	acute respiratory distress syndrome	2 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT03017547%22
CHEMBL2109330	IC14	Antibody	Monocyte differentiation antigen CD14 inhibitor	Inhibitor	MONDO_0100096	COVID-19	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04488081%22
CHEMBL2109330	IC14	Antibody	Monocyte differentiation antigen CD14 inhibitor	Inhibitor	MONDO_0100130	adult acute respiratory distress syndro	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT00233207%22
CHEMBL2109330	IC14	Antibody	Monocyte differentiation antigen CD14 inhibitor	Inhibitor	EFO_0000253	amyotrophic lateral sclerosis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT03487263%22
CHEMBL2109389	IMGATUZUMAB	Antibody	Low affinity immunoglobulin gamma Fc region receptor III-A	cr Cross-linking agent	EFO_1001951	colorectal carcinoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01326000%22
CHEMBL2109389	IMGATUZUMAB	Antibody	Low affinity immunoglobulin gamma Fc region receptor III-A	cr Cross-linking agent	EFO_0000616	neoplasm	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00721266%22
CHEMBL2109389	IMGATUZUMAB	Antibody	Low affinity immunoglobulin gamma Fc region receptor III-A	cr Cross-linking agent	EFO_0003060	non-small cell lung carcinoma	1 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT01702714%22
CHEMBL2109389	IMGATUZUMAB	Antibody	Low affinity immunoglobulin gamma Fc region receptor III-A	cr Cross-linking agent	EFO_0006859	head and neck malignant neoplasia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01046266%22
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000540	immune system disease	4	http://www.whocc.no/atc_ddd_index/?code=L04AA47
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0004991	Myasthenia gravis	3 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04524273%22
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	MONDO_0017287	lgG4-related disease	3 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04540497%22
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000095	chronic lymphocytic leukemia	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01466153%22
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000403	diffuse large B-cell lymphoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01453205%22
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0004256	neuromyelitis optica	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02200770%22
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0007332	Japanese encephalitis	2 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04372615%22
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000311	cancer	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00983619%22,https://clinicaltrials.gov/sea
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000574	lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02271945%22
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0001642	lymphoid neoplasm	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01957579%22
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0003885	multiple sclerosis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01585766%22
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_1001993	scleroderma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00946699%22
CHEMBL2109334	INEBILIZUMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0001378	multiple myeloma	0 Completed	https://clinicaltrials.gov/search?id=%22NCT01861340%22
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000220	acute lymphoblastic leukemia	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00483132%22
			· -			•	•	

CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000756	melanoma	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00204529%22
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003047	hepatitis C virus infection	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00381953%22
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003780	Behcet's syndrome	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00167583%22
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1001156	retinal vasculitis	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00167583%22
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002367	kidney cancer	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00416429%22
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000311	cancer	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT02159482%22
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000574	lymphoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01404936%22
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0001378	multiple myeloma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00323505%22
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0002617	metastatic melanoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00308607%22
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004220	chronic hepatitis C virus infection	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02340962%22,https://clinicaltrials.gov/sea
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1000956	hairy cell leukemia	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00001567%22
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_000676	psoriasis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02763969%22
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_000681	renal cell carcinoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01513187%22
CHEMBL2108508	INTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000764	HIV infection	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00000967%22,https://clinicaltrials.gov/sea
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000558	Kaposi's sarcoma	4	http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103132Orig1s5199lbl.pdf
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000574	lymphoma	4 Terminated	https://clinicaltrials.gov/search?id=%22NCT00854581%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0007147	anogenital venereal wart	4	http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103132Orig1s5199lbl.pdf
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0007306	herpangina	4 Completed	https://clinicaltrials.gov/search?id=%22NCT03266601%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1000956	hairy cell leukemia	4	http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103132Orig1s5199lbl.pdf
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1001051	mycosis fungoides	4 Unknown status	https://clinicaltrials.gov/search?id=%22NCT02323659%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0018906	follicular lymphoma	4	http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103132Orig1s5199lbl.pdf
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000764	HIV infection	3 Terminated	https://clinicaltrials.gov/search?id=%22NCT00125814%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0001378	multiple myeloma	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00002556%22,https://clinicaltrials.gov/sea
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0001422	cirrhosis of liver	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00273247%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0009708	metastasis	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00221702%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0024503	digestive system neuroendocrine neo	3 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT01860742%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000339	chronic myelogenous leukemia	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02001818%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000349	clear cell renal carcinoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00101114%22,https://clinicaltrials.gov/sea
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_000673	prostate adenocarcinoma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03899987%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_000681	renal cell carcinoma	2 Unknown status	https://clinicaltrials.gov/search?id=%22NCT01274273%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0001668	human papilloma virus infection	2 Unknown status	https://clinicaltrials.gov/search?id=%22NCT02801383%22,https://clinicaltrials.gov/sea
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0002618	pancreatic carcinoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00059826%22

CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004239	chronic hepatitis B virus infection	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00275938%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0000544	mucosal melanoma	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03178123%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002367	kidney cancer	2 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT00293527%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002691	livercancer	2 Unknown status	https://clinicaltrials.gov/search?id=%22NCT00471484%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0008315	prostate cancer	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT00176527%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0019471	adult T-cell leukemia/lymphoma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02737046%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000182	hepatocellular carcinoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00234182%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000311	cancer	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00311558%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000389	cutaneous melanoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00398450%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000616	neoplasm	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00908869%22,https://clinicaltrials.gov/sea
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000756	melanoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT01409174%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003047	hepatitis C virus infection	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01217359%22,https://clinicaltrials.gov/sea
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003869	breast neoplasm	1 Completed	https://clinicaltrials.gov/search?id=%22NCT03066947%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004197	hepatitis B virus infection	1 Completed	https://clinicaltrials.gov/search?id=%22NCT03294798%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004220	chronic hepatitis C virus infection	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01194037%22,https://clinicaltrials.gov/sea
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0004658	breast carcinoma in situ	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04081389%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0008170	ovarian cancer	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01639885%22,https://clinicaltrials.gov/sea
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0044881	hematopoietic and lymphoid cell neor	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04379518%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000565	leukemia	0 Completed	https://clinicaltrials.gov/search?id=%22NCT02331706%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0007254	breast cancer	0 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03599453%22
CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0100096	COVID-19	0 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04293887%22
CHEMBL2109047	INTERFERON ALFA-N3	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000694	severe acute respiratory syndrome	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00215826%22
CHEMBL2109047	INTERFERON ALFA-N3	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_000764	HIV infection	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00002078%22
CHEMBL1201557	INTERFERON ALFACON-1	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003047	hepatitis C virus infection	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00239252%22
CHEMBL1201557	INTERFERON ALFACON-1	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004220	chronic hepatitis C virus infection	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00162734%22,https://clinicaltrials.gov/sea
CHEMBL1201557	INTERFERON ALFACON-1	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0007328	influenza	1 Unknown status	https://clinicaltrials.gov/search?id=%22NCT01227798%22
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003106	pneumonia	4 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02735707%22
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0007328	influenza	4 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02735707%22
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003047	hepatitis C virus infection	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00249860%22
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0100130	adult acute respiratory distress syndro	3 Terminated	https://clinicaltrials.gov/search?id=%22NCT02622724%22
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000249	Alzheimer's disease	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01075763%22
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000270	asthma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01126177%22,https://clinicaltrials.gov/sea

CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000341	chronic obstructive pulmonary disease	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03570359%22
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000384	Crohn's disease	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT00304252%22
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000729	ulcerative colitis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00048347%22,https://clinicaltrials.gov/sea
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1000868	chronic inflammatory demyelinating p	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00099489%22
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1001373	Multiple Organ Failure	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT03119701%22
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0100096	COVID-19	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT04385095%22
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000712	stroke	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00097318%22
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003929	relapsing-remitting multiple sclerosis	1 Unknown status	https://clinicaltrials.gov/search?id=%22NCT02364986%22
CHEMBL1201562	INTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003885	multiple sclerosis	0 Completed	https://clinicaltrials.gov/search?id=%22NCT00618527%22
CHEMBL1201563	INTERFERON BETA-1B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000764	HIV infection	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00002238%22
CHEMBL1201563	INTERFERON BETA-1B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000318	cardiomyopathy	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00185250%22
CHEMBL1201563	INTERFERON BETA-1B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003929	relapsing-remitting multiple sclerosis	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03133403%22
CHEMBL1201563	INTERFERON BETA-1B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0100096	COVID-19	2 Completed	https://clinicaltrials.gov/search?id=%22NCT04343768%22,https://clinicaltrials.gov/sea
CHEMBL1201563	INTERFERON BETA-1B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0100116	Middle East respiratory syndrome	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02845843%22
CHEMBL1201563	INTERFERON BETA-1B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003885	multiple sclerosis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02474134%22
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000203	monoclonal gammopathy	2 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04614558%22
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000220	acute lymphoblastic leukemia	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03860844%22
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000222	acute myeloid leukemia	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03860844%22
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0003073	asymptomatic myeloma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02960555%22
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0005592	T-cell leukemia	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT02999633%22
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	MONDO_0044917	T-lymphoblastic lymphoma	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT02999633%22
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000540	immune system disease	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04294459%22
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000574	lymphoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03769181%22
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0000616	neoplasm	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03637764%22
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0001378	multiple myeloma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02514668%22,https://clinicaltrials.gov/sea
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_0001642	lymphoid neoplasm	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT01084252%22
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_1001264	Anemia, Hemolytic, Autoimmune	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04661033%22
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	EFO_1001951	colorectal carcinoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03555149%22
CHEMBL3545131	ISATUXIMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor	Inhibitor	Orphanet_85443	AL amyloidosis	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04754945%22
CHEMBL2109348	LFB-R603	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000095	chronic lymphocytic leukemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01098188%22
CHEMBL2109150	LINTUZUMAB	Antibody	Myeloid cell surface antigen CD33 other	Other	MONDO_0001475	neutropenia	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00002800%22
CHEMBL2109150	LINTUZUMAB	Antibody	Myeloid cell surface antigen CD33 other	Other	EFO_0000198	myelodysplastic syndrome	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00502112%22,https://clinicaltrials.gov/sea

CHEMBL2109150	LINTUZUMAB	Antibody	Myeloid cell surface antigen CD33 other	Other	EFO_0000222	acute myeloid leukemia	1 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT03932318%22
CHEMBL2109150	LINTUZUMAB	Antibody	Myeloid cell surface antigen CD33 other	Other	EFO_000565	leukemia	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT01756677%22
CHEMBL2109150	LINTUZUMAB	Antibody	Myeloid cell surface antigen CD33 other	Other	EFO_0001378	multiple myeloma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02998047%22
CHEMBL2109150	LINTUZUMAB	Antibody	Myeloid cell surface antigen CD33 other	Other	EFO_1001779	chronic myelomonocytic leukemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00283114%22
CHEMBL4297236	LISOCABTAGENE MARALEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0005952	non-Hodgkins lymphoma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03484702%22,https://clinicaltrials.gov/sea
CHEMBL4297236	LISOCABTAGENE MARALEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000095	chronic lymphocytic leukemia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03331198%22
CHEMBL4297236	LISOCABTAGENE MARALEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000220	acute lymphoblastic leukemia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03743246%22
CHEMBL4297236	LISOCABTAGENE MARALEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000403	diffuse large B-cell lymphoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02631044%22,https://clinicaltrials.gov/sea
CHEMBL4297236	LISOCABTAGENE MARALEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_1001469	Mantle cell lymphoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02631044%22
CHEMBL4297236	LISOCABTAGENE MARALEUCEL	Gene	B-lymphocyte antigen CD19 binding agent	Binding agent	MONDO_0018906	follicular lymphoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02631044%22,https://clinicaltrials.gov/sea
CHEMBL4297778	LONCASTUXIMAB TESIRINE	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_1001938	B-cell non-Hodgkins lymphoma	4	http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf
CHEMBL4297778	LONCASTUXIMAB TESIRINE	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	MONDO_0018906	follicular lymphoma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04699461%22
CHEMBL4297778	LONCASTUXIMAB TESIRINE	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000096	neoplasm of mature B-cells	1 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04970901%22
CHEMBL4297778	LONCASTUXIMAB TESIRINE	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000220	acute lymphoblastic leukemia	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT02669264%22
CHEMBL4297778	LONCASTUXIMAB TESIRINE	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000403	diffuse large B-cell lymphoma	1 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04974996%22
CHEMBL4594518	LUTIKIZUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_1000789	osteoarthritis, hand	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02384538%22
CHEMBL4594518	LUTIKIZUMAB	Antibody	Interleukin-1 beta inhibitor	Inhibitor	EFO_0002506	osteoarthritis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01668511%22
CHEMBL2109447	LYM-1	Antibody	HLA class II histocompatibility antigen, DRB1-10 beta chain oth	n Other	EFO_0000574	lymphoma	1 Unknown status	https://clinicaltrials.gov/search?id=%22NCT00009776%22,https://clinicaltrials.gov/sea
CHEMBL2109267	M195	Antibody	Myeloid cell surface antigen CD33 other	Other	EFO_0000198	myelodysplastic syndrome	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00014495%22,https://clinicaltrials.gov/sea
CHEMBL2109267	M195	Antibody	Myeloid cell surface antigen CD33 other	Other	EFO_000565	leukemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00014495%22,https://clinicaltrials.gov/sea
CHEMBL2109267	M195	Antibody	Myeloid cell surface antigen CD33 other	Other	EFO_0004251	myeloproliferative disorder	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00014495%22,https://clinicaltrials.gov/sea
CHEMBL2109337	MDX-1342	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000095	chronic lymphocytic leukemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00593944%22
CHEMBL2109337	MDX-1342	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000685	rheumatoid arthritis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00639834%22
CHEMBL2109391	MDX-447	Antibody	High affinity immunoglobulin gamma Fc receptor I cross-linkii	n Cross-linking agent	EFO_1000158	Central Nervous System Neoplasm	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00005813%22
CHEMBL4297833	MEZAGITAMAB	Antibody	Lymphocyte differentiation antigen CD38 binding agent	Binding agent	EFO_0004991	Myasthenia gravis	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04159805%22
CHEMBL4297833	MEZAGITAMAB	Antibody	Lymphocyte differentiation antigen CD38 binding agent	Binding agent	EFO_0007160	autoimmune thrombocytopenic purpu	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04278924%22
CHEMBL4297833	MEZAGITAMAB	Antibody	Lymphocyte differentiation antigen CD38 binding agent	Binding agent	EFO_0001378	multiple myeloma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04776018%22
CHEMBL4297833	MEZAGITAMAB	Antibody	Lymphocyte differentiation antigen CD38 binding agent	Binding agent	EFO_0002690	systemic lupus erythematosus	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03724916%22
CHEMBL4297833	MEZAGITAMAB	Antibody	Lymphocyte differentiation antigen CD38 binding agent	Binding agent	EFO_0005140	autoimmune disease	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02219256%22
CHEMBL4297789	MT-3724	Unknown	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005952	non-Hodgkins lymphoma	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT03645395%22
CHEMBL4297789	MT-3724	Unknown	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000095	chronic lymphocytic leukemia	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02361346%22
CHEMBL4297789	MT-3724	Unknown	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000403	diffuse large B-cell lymphoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02361346%22

CHEMBL4297789	MT-3724	Unknown	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004289	lymphoid leukemia	1 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT02556346%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	3 . 3 . 0	Binding agent	EFO_0002690	systemic lupus erythematosus	3 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04963296%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	3 1 3 0 0 0	Binding agent	EFO_0003086	kidney disease	3 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04629248%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000220	acute lymphoblastic leukemia	2 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04920968%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003060	non-small cell lung carcinoma	2 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04880863%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005761	lupus nephritis	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02550652%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0009441	Waldenstrom macroglobulinemia	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02962401%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1000956	hairy cell leukemia	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03410875%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0013730	graft versus host disease	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02867384%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0019088	post-transplant lymphoproliferative d	2 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT03086395%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000095	chronic lymphocytic leukemia	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT02336048%22,https://clinicaltrials.gov/sea
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000096	neoplasm of mature B-cells	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT04313608%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000183	Hodgkins lymphoma	1 Suspended	https://clinicaltrials.gov/search?id=%22NCT03432741%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000304	breast adenocarcinoma	1 Suspended	https://clinicaltrials.gov/search?id=%22NCT03432741%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000309	Burkitts lymphoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03223610%22,https://clinicaltrials.gov/sea
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000311	cancer	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02457598%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000403	diffuse large B-cell lymphoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03223610%22,https://clinicaltrials.gov/sea
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000565	leukemia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03759184%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000574	lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02729896%22,https://clinicaltrials.gov/sea
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000616	neoplasm	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02324257%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003884	chronic kidney disease	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02586051%22
CHEMBL1743048	OBINUTUZUMAB	Antibody		Binding agent	EFO_0005952	non-Hodgkins lymphoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04434196%22,https://clinicaltrials.gov/sea
CHEMBL1743048	OBINUTUZUMAB	Antibody	3 1 3 0 0 0	Binding agent	EFO_1001051	mycosis fungoides	1 Suspended	https://clinicaltrials.gov/search?id=%22NCT03432741%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001469	Mantle cell lymphoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02558816%22
CHEMBL1743048	OBINUTUZUMAB	Antibody		Binding agent	EFO_1001480	metastatic colorectal cancer	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04826003%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	3 1 3 0 0 0	Binding agent	EFO_1001951	colorectal carcinoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03866239%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	3 1 3 0 0 0	Binding agent	MONDO_0001023	prolymphocytic leukemia	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02296918%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	3 . 3 . 0	Binding agent	MONDO_0002083	Richter syndrome	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03113695%22
CHEMBL1743048	OBINUTUZUMAB	Antibody	3 1 3 0 0 0	Binding agent	MONDO_0018906	follicular lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02631577%22,https://clinicaltrials.gov/sea
CHEMBL1743048	OBINUTUZUMAB	Antibody	3 1 3 0 0 0	Binding agent	MONDO_0019465	nodal marginal zone B-cell lymphoma	1 Suspended	https://clinicaltrials.gov/search?id=%22NCT03432741%22
CHEMBL2109665	OCARATUZUMAB	Antibody	3 1 3 3 3 3 3	Binding agent	EFO_0000311	cancer	1 Unknown status	https://clinicaltrials.gov/search?id=%22NCT01858181%22
CHEMBL2108041	OCRELIZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000540	immune system disease	4	http://www.whocc.no/atc_ddd_index/?code=L04AA36

CHEMBL2108041	OCRELIZUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0008522	secondary progressive multiple sclero:	4 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04925557%22
CHEMBL2108041	OCRELIZUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0002690	systemic lupus erythematosus	3 Terminated	https://clinicaltrials.gov/search?id=%22NCT00539838%22
CHEMBL2108041	OCRELIZUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003840	chronic progressive multiple sclerosis	3 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT01194570%22
CHEMBL2108041	OCRELIZUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0008520	primary progressive multiple sclerosis	3 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03691077%22
CHEMBL2108041	OCRELIZUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003929	relapsing-remitting multiple sclerosis	2 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04971005%22
CHEMBL2108041	OCRELIZUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0007332	Japanese encephalitis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT03835728%22
CHEMBL2108041	OCRELIZUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000685	rheumatoid arthritis	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT02720120%22
CHEMBL2108041	OCRELIZUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003885	multiple sclerosis	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03972306%22
CHEMBL2108041	OCRELIZUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005952	non-Hodgkins lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02723071%22
CHEMBL4298084	ODRONEXTAMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000096	neoplasm of mature B-cells	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03888105%22
CHEMBL4298084	ODRONEXTAMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000095	chronic lymphocytic leukemia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02290951%22
CHEMBL4298084	ODRONEXTAMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000574	lymphoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02651662%22
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000616	neoplasm	4	http://www.whocc.no/atc_ddd_index/?code=L01XC10
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004719	pemphigus vulgaris	3 Terminated	https://clinicaltrials.gov/search?id=%22NCT01920477%22
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1000749	pemphigus	3 Terminated	https://clinicaltrials.gov/search?id=%22NCT02613910%22
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000183	Hodgkins lymphoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01195766%22
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000220	acute lymphoblastic leukemia	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT03488225%22
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000309	Burkitts lymphoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01363128%22
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000403	diffuse large B-cell lymphoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01481272%22,https://clinicaltrials.gov/sea
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000574	lymphoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01613300%22,https://clinicaltrials.gov/sea
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000756	melanoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01376713%22
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000765	AIDS	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02199184%22
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003885	multiple sclerosis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT03560739%22,https://clinicaltrials.gov/sea
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004255	nephrotic syndrome	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02394119%22
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004289	lymphoid leukemia	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01762202%22
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0009441	Waldenstrom macroglobulinemia	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT01536067%22
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0000870	childhood acute lymphoblastic leuken	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01363128%22
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0000873	lymphoblastic lymphoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01363128%22
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0003541	adult acute lymphoblastic leukemia	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01363128%22
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000095	chronic lymphocytic leukemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00742144%22,https://clinicaltrials.gov/sea
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000311	cancer	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01691807%22
CHEMBL1201836	OFATUMUMAB	Antibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000565	leukemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01110031%22

CHEMBL1201836	OFATUMUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000685	rheumatoid arthritis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00686868%22
CHEMBL1201836	OFATUMUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005952	non-Hodgkins lymphoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT01458366%22
CHEMBL1201836	OFATUMUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001469	Mantle cell lymphoma	1 Unknown status	https://clinicaltrials.gov/search?id=%22NCT01221103%22
CHEMBL1201836	OFATUMUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0001023	prolymphocytic leukemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01515176%22
CHEMBL1201836	OFATUMUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0002083	Richter syndrome	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01217749%22
CHEMBL1201836	OFATUMUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0013730	graft versus host disease	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT01680965%22
CHEMBL1201836	OFATUMUMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0018906	follicular lymphoma	1 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT00092274%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004272	anemia (phenotype)	4 Completed	https://clinicaltrials.gov/search?id=%22NCT00560274%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0008496	chronic hepatitis	4 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03013556%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000756	melanoma	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00204529%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0001422	cirrhosis of liver	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00006164%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0002430	primary myelofibrosis	3 Unknown status	https://clinicaltrials.gov/search?id=%22NCT01387763%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	HP_0012115	Hepatitis	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00147784%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002050	depressive disorder	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00136318%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000182	hepatocellular carcinoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02576964%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000339	chronic myelogenous leukemia	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01294618%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000544	infection	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00665353%22,https://clinicaltrials.gov/sea
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000565	leukemia	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT01392170%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0001378	multiple myeloma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00323505%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1000026	diffuse intrinsic pontine glioma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00036569%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1000251	Fallopian Tube Carcinoma	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT01773889%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	HP_0001873	Thrombocytopenia	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01355289%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002087	peritoneum cancer	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT01773889%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0007254	breast cancer	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT00227656%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0008170	ovarian cancer	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT01773889%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0021063	malignant colon neoplasm	2 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04798612%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0024880	metastatic malignant neoplasm	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT00227656%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000095	chronic lymphocytic leukemia	1 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT00962715%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000222	acute myeloid leukemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02328755%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000311	cancer	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02174172%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000479	essential thrombocythemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02407080%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000616	neoplasm	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00253474%22

CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_000764	HIV infection	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02471430%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0002429	polycythemia vera	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02407080%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003047	hepatitis C virus infection	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00277758%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004197	hepatitis B virus infection	1 Completed	https://clinicaltrials.gov/search?id=%22NCT03294798%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004220	chronic hepatitis C virus infection	1 Unknown status	https://clinicaltrials.gov/search?id=%22NCT02057887%22,https://clinicaltrials.gov/sea
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004239	chronic hepatitis B virus infection	1 Unknown status	https://clinicaltrials.gov/search?id=%22NCT01589952%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0007304	hepatitis D virus infection	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02637999%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0009260	non-melanoma skin carcinoma	1 Unknown status	https://clinicaltrials.gov/search?id=%22NCT00423397%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002367	kidney cancer	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00003542%22
CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0044903	myelofibrosis	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02742324%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000479	essential thrombocythemia	3 Unknown status	https://clinicaltrials.gov/search?id=%22NCT01387763%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000637	osteosarcoma	3 Unknown status	https://clinicaltrials.gov/search?id=%22NCT00134030%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0001378	multiple myeloma	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00732641%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0001422	cirrhosis of liver	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00378599%22,https://clinicaltrials.gov/sea
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0002430	primary myelofibrosis	3 Unknown status	https://clinicaltrials.gov/search?id=%22NCT01387763%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0009708	metastasis	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00221702%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1001469	Mantle cell lymphoma	3 Unknown status	https://clinicaltrials.gov/search?id=%22NCT00209209%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	HP_0012115	Hepatitis	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00039871%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000326	central nervous system cancer	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00047879%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000389	cutaneous melanoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00049530%22,https://clinicaltrials.gov/sea
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000565	leukemia	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00548847%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000574	lymphoma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04246359%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000658	plexiform neurofibroma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00396019%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000707	squamous cell carcinoma	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02218164%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0001642	lymphoid neoplasm	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02634294%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004197	hepatitis B virus infection	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT04189276%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004239	chronic hepatitis B virus infection	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02332473%22,https://clinicaltrials.gov/sea
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004243	carcinoid tumor	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00055809%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0005221	cholangiocarcinoma	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT02982720%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0006859	head and neck malignant neoplasia	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00276523%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0007304	hepatitis D virus infection	2 Unknown status	https://clinicaltrials.gov/search?id=%22NCT03105310%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0009259	skin carcinoma	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02218164%22
				-			•	

CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1000209	Craniopharyngioma	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT01964300%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_1000403	Ocular Melanoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00027742%22,https://clinicaltrials.gov/sea
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002974	cervical cancer	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT00138151%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0016691	pilocytic astrocytoma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02343224%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0018079	thymic epithelial neoplasm	2 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04517539%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0019471	adult T-cell leukemia/lymphoma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02737046%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0100096	COVID-19	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT04480138%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	Orphanet_636	Neurofibromatosis type 1	2 Unknown status	https://clinicaltrials.gov/search?id=%22NCT00846430%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000180	HIV-1 infection	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03588715%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000182	hepatocellular carcinoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04943679%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000311	cancer	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00311558%22,https://clinicaltrials.gov/sea
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000339	chronic myelogenous leukemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00303290%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000616	neoplasm	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00014261%22,https://clinicaltrials.gov/sea
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_000681	renal cell carcinoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00522249%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000756	melanoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01496807%22,https://clinicaltrials.gov/sea
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000764	HIV infection	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00006325%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000765	AIDS	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03588715%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0002429	polycythemia vera	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01193699%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0002617	metastatic melanoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02379195%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003047	hepatitis C virus infection	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT01701063%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0004220	chronic hepatitis C virus infection	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00120835%22,https://clinicaltrials.gov/sea
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	HP_0000083	Renal insufficiency	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01432535%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002087	peritoneum cancer	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00085384%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002158	fallopian tube cancer	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00085384%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0002367	kidney cancer	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00589550%22
CHEMBL1201561	PEGINTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0008170	ovarian cancer	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00085384%22
CHEMBL2108677	PEGINTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0000694	severe acute respiratory syndrome	3 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04727424%22
CHEMBL2108677	PEGINTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003929	relapsing-remitting multiple sclerosis	3 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT01337427%22
CHEMBL2108677	PEGINTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	MONDO_0100096	COVID-19	3 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04727424%22
CHEMBL2108677	PEGINTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	EFO_0003885	multiple sclerosis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02269930%22
CHEMBL2108677	PEGINTERFERON BETA-1A	Protein	Interferon alpha/beta receptor agonist	Agonist	HP_0000083	Renal insufficiency	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01119781%22
CHEMBL2108712	PLOVAMER ACETATE	Small mol	ec HLA class II histocompatibility antigen, DRB1-15 beta chain mo	oc Modulator	EFO_0003929	relapsing-remitting multiple sclerosis	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT01963611%22

CHEMBL1201830	RILONACEPT	Protein	Interleukin-1 beta inhibitor	Inhibitor	EFO_0000540	immune system disease	4	http://www.whocc.no/atc_ddd_index/?code=L04AC04
CHEMBL1201830	RILONACEPT	Protein	Interleukin-1 beta inhibitor	Inhibitor	EFO_0003884	chronic kidney disease	4 Completed	https://clinicaltrials.gov/search?id=%22NCT01663103%22
CHEMBL1201830	RILONACEPT	Protein	Interleukin-1 beta inhibitor	Inhibitor	Orphanet_208650	Cryopyrin-associated periodic syndron	4	http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=282f4099-e848-432a-bac1-
CHEMBL1201830	RILONACEPT	Protein	Interleukin-1 beta inhibitor	Inhibitor	Orphanet_47045	Familial cold urticaria	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00288704%22
CHEMBL1201830	RILONACEPT	Protein	Interleukin-1 beta inhibitor	Inhibitor	Orphanet_575	Muckle-Wells syndrome	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00288704%22
CHEMBL1201830	RILONACEPT	Protein	Interleukin-1 beta inhibitor	Inhibitor	EFO_0002609	juvenile idiopathic arthritis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00534495%22
CHEMBL1201830	RILONACEPT	Protein	Interleukin-1 beta inhibitor	Inhibitor	EFO_0004274	gout	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00610363%22
CHEMBL1201830	RILONACEPT	Protein	Interleukin-1 beta inhibitor	Inhibitor	EFO_0007427	pericarditis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT03980522%22
CHEMBL1201830	RILONACEPT	Protein	Interleukin-1 beta inhibitor	Inhibitor	EFO_1001345	Hepatitis, Alcoholic	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01903798%22
CHEMBL1201830	RILONACEPT	Protein	Interleukin-1 beta inhibitor	Inhibitor	EFO_1001881	cold urticaria	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02171416%22
CHEMBL1201830	RILONACEPT	Protein	Interleukin-1 beta inhibitor	Inhibitor	Orphanet_210115	Sterile multifocal osteomyelitis with p	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01801449%22
CHEMBL1201830	RILONACEPT	Protein	Interleukin-1 beta inhibitor	Inhibitor	Orphanet_342	Familial Mediterranean fever	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00582907%22
CHEMBL1201830	RILONACEPT	Protein	Interleukin-1 beta inhibitor	Inhibitor	EFO_0000404	diffuse scleroderma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01538719%22
CHEMBL1201830	RILONACEPT	Protein	Interleukin-1 beta inhibitor	Inhibitor	EFO_0001359	type I diabetes mellitus	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00962026%22
CHEMBL1201830	RILONACEPT	Protein	Interleukin-1 beta inhibitor	Inhibitor	EFO_1001999	systemic juvenile idiopathic arthritis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01803321%22
CHEMBL1201830	RILONACEPT	Protein	Interleukin-1 beta inhibitor	Inhibitor	EFO_0004238	hearing loss	0 Unknown status	https://clinicaltrials.gov/search?id=%22NCT02828033%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000474	epilepsy	4 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04542629%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004194	IGA glomerulonephritis	4 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04525729%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	HP_0000083	Renal insufficiency	4 Terminated	https://clinicaltrials.gov/search?id=%22NCT01312064%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003929	relapsing-remitting multiple sclerosis	3 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04578639%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004719	pemphigus vulgaris	3 Completed	https://clinicaltrials.gov/search?id=%22NCT02383589%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004826	anti-neutrophil antibody associated va	3 Completed	https://clinicaltrials.gov/search?id=%22NCT01697267%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0009562	polyneuropathy	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00259974%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	HP_0000093	Proteinuria	3 Terminated	https://clinicaltrials.gov/search?id=%22NCT01164098%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0000432	lymphoplasmacytic lymphoma	3 Completed	https://clinicaltrials.gov/search?id=%22NCT00801281%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000255	angioimmunoblastic T-cell lymphoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00169156%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000389	cutaneous melanoma	2 Unknown status	https://clinicaltrials.gov/search?id=%22NCT02142335%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000540	immune system disease	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03651518%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000557	juvenile dermatomyositis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00106184%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000717	systemic scleroderma	2 Unknown status	https://clinicaltrials.gov/search?id=%22NCT00379431%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000729	ulcerative colitis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00261118%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000765	AIDS	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02199184%22

CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000772	pneumococcal infection	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03069703%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0002612	human herpesvirus 8 infection	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT01419561%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0002689	antiphospholipid syndrome	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00537290%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003032	anaplastic large cell lymphoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01686165%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003100	peripheral neuropathy	2 Unknown status	https://clinicaltrials.gov/search?id=%22NCT00006072%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003144	heart failure	2 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT03332888%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003780	Behcet's syndrome	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00664599%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003840	chronic progressive multiple sclerosis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02545959%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003860	pancreatic neoplasm	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00001805%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003869	breast neoplasm	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00001805%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003897	stomach neoplasm	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00001805%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003898	ankylosing spondylitis	2 Unknown status	https://clinicaltrials.gov/search?id=%22NCT00432653%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004244	interstitial lung disease	2 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT02789397%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004254	membranous glomerulonephritis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01180036%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004255	nephrotic syndrome	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04783675%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004288	colonic neoplasm	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00001805%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004540	chronic fatigue syndrome	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00848692%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004599	acute graft vs. host disease	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00771875%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005761	lupus nephritis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02260934%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0007208	Churg-Strauss syndrome	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT00424749%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0007332	Japanese encephalitis	2 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT03274375%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0007359	mast-cell leukemia	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00186628%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0009538	chronic inflammatory demyelinating p	2 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04480450%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0010580	blastic plasmacytoid dendritic cell neo	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04216524%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1000318	Langerhans Cell Histiocytosis	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03096782%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1000749	pemphigus	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04400994%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1000783	diabetic neuropathy	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00050245%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1000784	microscopic polyangiitis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00104299%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1000868	chronic inflammatory demyelinating p	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03864185%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001050	multiple system atrophy	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04004819%22
CHEMBL1201576	RITUXIMAB	<u> </u>	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001264	Anemia, Hemolytic, Autoimmune	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00749112%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001946	childhood B acute lymphoblastic leuke	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT00058461%22

CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	HP_0012664	Reduced ejection fraction	2 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT03332888%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0000870	childhood acute lymphoblastic leuken	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00057811%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0001549	hemolytic-uremic syndrome	2 Unknown status	https://clinicaltrials.gov/search?id=%22NCT00531089%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0003541	adult acute lymphoblastic leukemia	2 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT02538926%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0004695	liver lymphoma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04115631%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0009348	classic Hodgkin lymphoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00654732%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0018170	idiopathic nephrotic syndrome	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01268033%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0019139	acquired hemophilia	2 Unknown status	https://clinicaltrials.gov/search?id=%22NCT03700229%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0020743	mixed phenotype acute leukemia	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02135874%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0021117	lung neoplasm	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00001805%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0044917	T-lymphoblastic lymphoma	2 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT02538926%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	Orphanet_232	Sickle cell anemia	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT01279616%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	Orphanet_238510	Lymphoproliferative syndrome	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT00869323%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	Orphanet_797	Sarcoidosis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00855205%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	Orphanet_98878	Hemophilia A	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00331006%22
CHEMBL1201576	RITUXIMAB	Antibody		Binding agent	EFO_0000096	neoplasm of mature B-cells	1 Suspended	https://clinicaltrials.gov/search?id=%22NCT04607772%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000183	Hodgkins lymphoma	1 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT02408042%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000191	MALT lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00012298%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000198	myelodysplastic syndrome	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02960646%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000209	T-cell acute lymphoblastic leukemia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03808610%22
CHEMBL1201576	RITUXIMAB	Antibody		Binding agent	EFO_0000220	acute lymphoblastic leukemia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT01371630%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000222	acute myeloid leukemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02779283%22
CHEMBL1201576	RITUXIMAB	Antibody	, , , , , , , , , , , , , , , , , , , ,	Binding agent	EFO_0000304	breast adenocarcinoma	1 Suspended	https://clinicaltrials.gov/search?id=%22NCT03432741%22
CHEMBL1201576	RITUXIMAB	Antibody	3 1 3 0 0 0	Binding agent	EFO_0000309	Burkitts lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01397825%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	, , , , , , , , , , , , , , , , , , , ,	Binding agent	EFO_0000311	cancer	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT00788684%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	3 1 3 0 0 0	Binding agent	EFO_0000339	chronic myelogenous leukemia	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT01619761%22
CHEMBL1201576	RITUXIMAB	Antibody	, , , , , , , , , , , , , , , , , , , ,	Binding agent	EFO_0000384	Crohn's disease	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT00692939%22
CHEMBL1201576	RITUXIMAB	Antibody	3 1 3 0 0 0	Binding agent	EFO_0000565	leukemia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02356159%22
CHEMBL1201576	RITUXIMAB	Antibody		Binding agent	EFO_0000616	neoplasm	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03783403%22
CHEMBL1201576	RITUXIMAB	Antibody	3 1 3 0 0 0	Binding agent	EFO_000685	rheumatoid arthritis	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT03061838%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody		Binding agent	EFO_000692	schizophrenia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03983018%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000699	Sjogren syndrome	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00101829%22,https://clinicaltrials.gov/sea

CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000707	squamous cell carcinoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT04361409%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000768	idiopathic pulmonary fibrosis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01266317%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0001359	type I diabetes mellitus	1 Unknown status	https://clinicaltrials.gov/search?id=%22NCT00798785%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0001378	multiple myeloma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00176475%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0001423	encephalomyelitis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00259805%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0001642	lymphoid neoplasm	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT01596127%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0002508	Parkinson's disease	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04127578%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0002617	metastatic melanoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT01032122%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0002690	systemic lupus erythematosus	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00036491%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003778	psoriatic arthritis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00509678%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003884	chronic kidney disease	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01178216%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003885	multiple sclerosis	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT01212094%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004145	myopathy	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00278564%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004236	focal segmental glomerulosclerosis	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03763643%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004256	neuromyelitis optica	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00787722%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004289	lymphoid leukemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00366418%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004991	Myasthenia gravis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00619671%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005140	autoimmune disease	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01086631%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005297	Granulomatosis with Polyangiitis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00072592%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005531	urticaria	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00216762%22
CHEMBL1201576	RITUXIMAB	Antibody		Binding agent	EFO_0005952	non-Hodgkins lymphoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04673617%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0007160	autoimmune thrombocytopenic purpu	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01713738%22
CHEMBL1201576	RITUXIMAB	Antibody		Binding agent	EFO_0007187	bullous pemphigoid	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00286325%22
CHEMBL1201576	RITUXIMAB	Antibody		Binding agent	EFO_0007498	Stiff-Person syndrome	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT02282514%22
CHEMBL1201576	RITUXIMAB	Antibody		Binding agent	EFO_0008520	primary progressive multiple sclerosis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02253264%22
CHEMBL1201576	RITUXIMAB	Antibody		Binding agent	EFO_0008522	secondary progressive multiple sclero:	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02253264%22
CHEMBL1201576	RITUXIMAB	Antibody		Binding agent	EFO_0008610	ocular cicatricial pemphigoid	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00584935%22
CHEMBL1201576	RITUXIMAB	Antibody		Binding agent	EFO_0009606	macular degeneration	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02332941%22
CHEMBL1201576	rituximab	Antibody	3 1 3 3 3 3	Binding agent	EFO_1000131	Blast Phase Chronic Myelogenous Leul	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02960646%22
CHEMBL1201576	RITUXIMAB	Antibody		Binding agent	EFO_1000550	Splenic Marginal Zone Lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00438880%22
CHEMBL1201576	RITUXIMAB	Antibody	3 1 3 3 3 3	Binding agent	EFO_1000956	hairy cell leukemia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03805932%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001051	mycosis fungoides	1 Suspended	https://clinicaltrials.gov/search?id=%22NCT03432741%22

CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001365	Lymphoma, AIDS-Related	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00036855%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001383	Opsoclonus-Myoclonus Syndrome	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00244361%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001466	Graves ophthalmopathy	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00150111%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001486	primary biliary cirrhosis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00364819%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001779	chronic myelomonocytic leukemia	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02960646%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1002048	kidney failure	1 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04540380%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	HP_0001871	Abnormality of blood and blood-formi	1 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04243434%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	HP_0001915	Aplastic anemia	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02960646%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0000873	lymphoblastic lymphoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02960646%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0001023	prolymphocytic leukemia	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02296918%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0001437	pulmonary alveolar proteinosis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01842386%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0001718	scleritis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00415506%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0002083	Richter syndrome	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00472849%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0002334	hematopoietic and lymphoid system n	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04022239%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0002462	glomerulonephritis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00275613%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0004095	B-cell neoplasm	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02911142%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0013730	graft versus host disease	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03689894%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0015564	Castleman disease	1 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT02228512%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0015760	T-cell non-Hodgkin lymphoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT01701986%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0018896	thrombotic thrombocytopenic purpura	1 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT00251277%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0019088	post-transplant lymphoproliferative d	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00036855%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0019457	therapy related acute myeloid leukem	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT01619761%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0019465	nodal marginal zone B-cell lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00012298%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0024880	metastatic malignant neoplasm	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT01596127%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0044881	hematopoietic and lymphoid cell neor	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02367196%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0044887	central nervous system non-hodgkin ly	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02315326%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0044889	high grade B-cell lymphoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03742258%22,https://clinicaltrials.gov/sea
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	Orphanet_1334	Chronic mucocutaneous candidosis	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01842386%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	Orphanet_282	Frontotemporal dementia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04408625%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	Orphanet_309144	Gangliosidosis	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03952637%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	Orphanet_365	Glycogen storage disease due to acid r	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02240407%22
CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	Orphanet_84	Fanconi anemia	1 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04784052%22

CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000095	chronic lymphocytic leukemia	0 Completed	https://clinicaltrials.gov/search?id=%22NCT00017381%22
CHEMBL1201576	RITUXIMAB	Antibody		Binding agent	EFO_0000403	diffuse large B-cell lymphoma	0 Completed	https://clinicaltrials.gov/search?id=%22NCT00017381%22
CHEMBL1201576	RITUXIMAB	Antibody	3 1 3 0	Binding agent	EFO_0000574	lymphoma	0 Terminated	https://clinicaltrials.gov/search?id=%22NCT00515138%22
CHEMBL1201576	RITUXIMAB	Antibody	, , , , , , , , , , , , , , , , , , , ,	Binding agent	EFO_0000621	neuroblastoma	O Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT00790413%22
CHEMBL1201576	RITUXIMAB	Antibody	3 1 3 0	Binding agent	EFO_0003086	kidney disease	0 Completed	https://clinicaltrials.gov/search?id=%22NCT00405340%22
CHEMBL1201576	RITUXIMAB	Antibody		Binding agent	EFO_0009441	Waldenstrom macroglobulinemia	0 Completed	https://clinicaltrials.gov/search?id=%22NCT00017381%22
CHEMBL1201576	RITUXIMAB	Antibody	3 1 3 0	Binding agent	EFO_1000157	Central Nervous System Lymphoma	0 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03684980%22
CHEMBL1201576	RITUXIMAB	Antibody		Binding agent	EFO_1000630	marginal zone B-cell lymphoma	0 Completed	https://clinicaltrials.gov/search?id=%22NCT00017381%22
CHEMBL1201576	RITUXIMAB	Antibody	3 1 3 0	Binding agent	EFO_1001469	Mantle cell lymphoma	O Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03295240%22
CHEMBL1201576	RITUXIMAB	Antibody		Binding agent	MONDO_0008315	prostate cancer	0 Unknown status	https://clinicaltrials.gov/search?id=%22NCT01804712%22
CHEMBL1201576	RITUXIMAB	Antibody	3 1 3 0	Binding agent	MONDO_0018906	follicular lymphoma	0 Completed	https://clinicaltrials.gov/search?id=%22NCT00017381%22
CHEMBL4297819	ROPEGINTERFERON ALFA-2B	Unknown	, , , , , , , , , , , , , , , , , , , ,	Positive modulator	EFO_0000479	essential thrombocythemia	3 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04285086%22
CHEMBL4297819	ROPEGINTERFERON ALFA-2B	Unknown	· · · ·	Positive modulator	EFO_0002429	polycythemia vera	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT04182100%22,https://clinicaltrials.gov/sea
CHEMBL4297819	ROPEGINTERFERON ALFA-2B	Unknown	· · · ·	Positive modulator	EFO_0000182	hepatocellular carcinoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04233840%22
CHEMBL4297819	ROPEGINTERFERON ALFA-2B	Unknown	' '	Positive modulator	EFO 0000339	chronic myelogenous leukemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01933906%22
CHEMBL4297819	ROPEGINTERFERON ALFA-2B	Unknown	, , ,	Positive modulator	EFO_0004220	chronic hepatitis C virus infection	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04774107%22
CHEMBL4297819	ROPEGINTERFERON ALFA-2B	Unknown	· · · ·	Positive modulator	EFO_0004239	chronic hepatitis B virus infection	1 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04638439%22
CHEMBL4297819	ROPEGINTERFERON ALFA-2B	Unknown	·	Positive modulator	EFO_0007304	hepatitis D virus infection	1 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04638439%22
CHEMBL2109477	SELICRELUMAB	Antibody	Tumor necrosis factor receptor superfamily member 5 agonist		EFO_000096	neoplasm of mature B-cells	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT03892525%22
CHEMBL2109477	SELICRELUMAB	Antibody	Tumor necrosis factor receptor superfamily member 5 agonist	•	EFO_0000756	melanoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01103635%22,https://clinicaltrials.gov/sea
CHEMBL2109477	SELICRELUMAB	Antibody	Tumor necrosis factor receptor superfamily member 5 agonist	•	EFO_0003860	pancreatic neoplasm	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00711191%22
CHEMBL2109477	SELICRELUMAB	Antibody	Tumor necrosis factor receptor superfamily member 5 agonist	O .	EFO_1000044	pancreatic adenocarcinoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01456585%22
CHEMBL2109477	SELICRELUMAB	Antibody	Tumor necrosis factor receptor superfamily member 5 agonist	O .	EFO_1001951	colorectal carcinoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03555149%22
CHEMBL2109477	SELICRELUMAB	Antibody	Tumor necrosis factor receptor superfamily member 5 agonist	9	MONDO 0007254	breast cancer	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03424005%22
CHEMBL2109477	SELICRELUMAB	Antibody	Tumor necrosis factor receptor superfamily member 5 agonist	9	EFO_0000616	neoplasm	0 Completed	https://clinicaltrials.gov/search?id=%22NCT02157831%22
CHEMBL4298047	TAFASITAMAB	Antibody	, , ,	Binding agent	EFO_000616	neoplasm	4	http://www.whocc.no/atc_ddd_index/?code=L01XC35
CHEMBL4298047	TAFASITAMAB	Antibody	3 1 3 0	Binding agent	MONDO_0018906	follicular lymphoma	3 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04680052%22
CHEMBL4298047	TAFASITAMAB	Antibody	3 1 3 0	Binding agent	EFO_0000220	acute lymphoblastic leukemia	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT01685021%22
CHEMBL4298047	TAFASITAMAB	Antibody		Binding agent	EFO_0005952	non-Hodgkins lymphoma	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT01685008%22
CHEMBL4298047	TAFASITAMAB	Antibody	3 1 3 0	Binding agent	MONDO_0001023	prolymphocytic leukemia	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02005289%22
CHEMBL4298047	TAFASITAMAB	Antibody		Binding agent	EFO_0000095	chronic lymphocytic leukemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01161511%22
CHEMBL4298047	TAFASITAMAB	Antibody	3 1 3 0	Binding agent	EFO_0000096	neoplasm of mature B-cells	1 Suspended	https://clinicaltrials.gov/search?id=%22NCT04607772%22
3			- · J · · · p · · · · · J · · · · · · · ·					

CHEMBL4298047	TAFASITAMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000403	diffuse large B-cell lymphoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT04134936%22
CHEMBL4298047	TAFASITAMAB	Antibody	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000574	lymphoma	1 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04882163%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000616	neoplasm	4	http://www.whocc.no/atc_ddd_index/?code=L01XX71
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000096	neoplasm of mature B-cells	2 Unknown status	https://clinicaltrials.gov/search?id=%22NCT03391726%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0004289	lymphoid leukemia	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02435849%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0005952	non-Hodgkins lymphoma	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03610724%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_1001469	Mantle cell lymphoma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04234061%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	MONDO_0000873	lymphoblastic lymphoma	2 Unknown status	https://clinicaltrials.gov/search?id=%22NCT03321123%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	MONDO_0018906	follicular lymphoma	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03568461%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000094	B-cell acute lymphoblastic leukemia	1 Unknown status	https://clinicaltrials.gov/search?id=%22NCT02924753%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_000095	chronic lymphocytic leukemia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03853616%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000220	acute lymphoblastic leukemia	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT01551043%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000222	acute myeloid leukemia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03896854%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000565	leukemia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03614858%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0001378	multiple myeloma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02135406%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_1000157	Central Nervous System Lymphoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04134117%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000183	Hodgkins lymphoma	0 Terminated	https://clinicaltrials.gov/search?id=%22NCT02624258%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000403	diffuse large B-cell lymphoma	0 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04890236%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0000574	lymphoma	0 Completed	https://clinicaltrials.gov/search?id=%22NCT02476734%22
CHEMBL3301574	TISAGENLECLEUCEL	Cell	B-lymphocyte antigen CD19 binding agent	Binding agent	EFO_0002618	pancreatic carcinoma	0 Unknown status	https://clinicaltrials.gov/search?id=%22NCT03497819%22
CHEMBL1201604	TOSITUMOMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000095	chronic lymphocytic leukemia	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00476047%22
CHEMBL1201604	TOSITUMOMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000574	lymphoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00107380%22,https://clinicaltrials.gov/sea
CHEMBL1201604	TOSITUMOMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001469	Mantle cell lymphoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00992992%22
CHEMBL1201604	TOSITUMOMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000096	neoplasm of mature B-cells	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00434629%22
CHEMBL1201604	TOSITUMOMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005952	non-Hodgkins lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00434629%22,https://clinicaltrials.gov/sea
CHEMBL1201604	TOSITUMOMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0018906	follicular lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00315731%22
CHEMBL3833304	TOSITUMOMAB 131I	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000574	lymphoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00006695%22,https://clinicaltrials.gov/sea
CHEMBL3833304	TOSITUMOMAB 131I	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0001378	multiple myeloma	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT00135200%22
CHEMBL3833304	TOSITUMOMAB 131I	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003032	anaplastic large cell lymphoma	2 Completed	https://clinicaltrials.gov/search?id=%22NCT00073918%22
CHEMBL3833304	TOSITUMOMAB 131I	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000095	chronic lymphocytic leukemia	1 Unknown status	https://clinicaltrials.gov/search?id=%22NCT00022880%22
CHEMBL3833304	TOSITUMOMAB 131I	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000096	neoplasm of mature B-cells	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00434629%22
CHEMBL3833304	TOSITUMOMAB 131I	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000183	Hodgkins lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00484874%22

CLIEN 4DL 2022204	TOCITUMON AND 1011	A ! !	D. L	Discalled a second	FFO 0000000	Dividitate Lucione and a second	1.0	https://slinis-ltwisls.no./ssensk9isl.0/20NGT001100710/20
CHEMBL3833304	TOSITUMOMAB 1311	Antibody		Binding agent	EFO_0000309	Burkitts lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00110071%22
CHEMBL3833304	TOSITUMOMAB 1311	Antibody		Binding agent	EFO_0000403	diffuse large B-cell lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00110071%22
CHEMBL3833304	TOSITUMOMAB 131I	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005952	non-Hodgkins lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00434629%22,https://clinicaltrials.gov/sea
CHEMBL3833304	TOSITUMOMAB 131I	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0009441	Waldenstrom macroglobulinemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00110071%22
CHEMBL3833304	TOSITUMOMAB 131I	Antibody	3 1 3 0	Binding agent	EFO_1000550	Splenic Marginal Zone Lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00110071%22
CHEMBL3833304	TOSITUMOMAB 131I	Antibody		Binding agent	EFO_1001469	Mantle cell lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00110071%22
CHEMBL3833304	TOSITUMOMAB 131I	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0000873	lymphoblastic lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00110071%22
CHEMBL3833304	TOSITUMOMAB 131I	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0018906	follicular lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00110071%22,https://clinicaltrials.gov/sea
CHEMBL3833304	TOSITUMOMAB 131I	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0019465	nodal marginal zone B-cell lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00110071%22
CHEMBL1743083	TREGALIZUMAB	Antibody	T-cell surface antigen CD4 agonist	Agonist	EFO_000685	rheumatoid arthritis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01481493%22
CHEMBL1743083	TREGALIZUMAB	Antibody	T-cell surface antigen CD4 agonist	Agonist	EFO_1001494	psoriasis vulgaris	2 Completed	https://clinicaltrials.gov/search?id=%22NCT01072383%22
CHEMBL1743083	TREGALIZUMAB	Antibody	T-cell surface antigen CD4 agonist	Agonist	MONDO_0004784	allergic asthma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04673591%22
CHEMBL4297845	TRU-015	Unknown	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000685	rheumatoid arthritis	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT00634933%22
CHEMBL4297845	TRU-015	Unknown	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000574	lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00521638%22
CHEMBL4297845	TRU-015	Unknown	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0002690	systemic lupus erythematosus	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00479622%22
CHEMBL2108354	UBLITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000403	diffuse large B-cell lymphoma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT02793583%22
CHEMBL2108354	UBLITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003885	multiple sclerosis	2 Completed	https://clinicaltrials.gov/search?id=%22NCT02738775%22
CHEMBL2108354	UBLITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003929	relapsing-remitting multiple sclerosis	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03381170%22
CHEMBL2108354	UBLITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0018906	follicular lymphoma	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03828448%22,https://clinicaltrials.gov/sea
CHEMBL2108354	UBLITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000095	chronic lymphocytic leukemia	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03671590%22,https://clinicaltrials.gov/sea
CHEMBL2108354	UBLITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000096	neoplasm of mature B-cells	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03804996%22
CHEMBL2108354	UBLITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0004256	neuromyelitis optica	1 Completed	https://clinicaltrials.gov/search?id=%22NCT02276963%22
CHEMBL2108354	UBLITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0009441	Waldenstrom macroglobulinemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01744912%22
CHEMBL2108354	UBLITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001469	Mantle cell lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT01744912%22
CHEMBL3137347	VARLILUMAB	Antibody	CD27 antigen agonist	Agonist	EFO_0000519	glioblastoma multiforme	2 Recruiting	https://clinicaltrials.gov/search?id=%22NCT03688178%22
CHEMBL3137347	VARLILUMAB	Antibody	CD27 antigen agonist	Agonist	EFO_1001961	intrahepatic cholangiocarcinoma	2 Not yet recruiting	https://clinicaltrials.gov/search?id=%22NCT04941287%22
CHEMBL3137347	VARLILUMAB	Antibody	CD27 antigen agonist	Agonist	EFO_0000272	astrocytoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02924038%22
CHEMBL3137347	VARLILUMAB	Antibody	CD27 antigen agonist	Agonist	EFO_0000574	lymphoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT03307746%22
CHEMBL3137347	VARLILUMAB	Antibody	CD27 antigen agonist	Agonist	EFO_000630	oligoastrocytoma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02924038%22
CHEMBL3137347	VARLILUMAB	Antibody	CD27 antigen agonist	Agonist	EFO_0000632	oligodendroglioma	1 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT02924038%22
CHEMBL3137347	VARLILUMAB	Antibody	CD27 antigen agonist	Agonist	EFO_0000681	renal cell carcinoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT02386111%22
CHEMBL3137347	VARLILUMAB	Antibody	CD27 antigen agonist	Agonist	EFO_0000756	melanoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT02413827%22
		_						

CHEMBL3137347	VARLILUMAB Anti	tibody CD27 antigen agonist	Agonist	EFO_0003060	non-small cell lung carcinoma	1 Recruiting	https://clinicaltrials.gov/search?id=%22NCT04081688%22
CHEMBL3137347	VARLILUMAB Anti	tibody CD27 antigen agonist	Agonist	EFO_0003863	urogenital neoplasm	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT02386111%22
CHEMBL1743088	VELTUZUMAB Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000685	rheumatoid arthritis	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT01390545%22
CHEMBL1743088	VELTUZUMAB Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000095	chronic lymphocytic leukemia	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00546793%22
CHEMBL1743088	VELTUZUMAB Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000220	acute lymphoblastic leukemia	1 Unknown status	https://clinicaltrials.gov/search?id=%22NCT01279707%22
CHEMBL1743088	VELTUZUMAB Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000403	diffuse large B-cell lymphoma	1 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT01101581%22
CHEMBL1743088	VELTUZUMAB Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000574	lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00989586%22
CHEMBL1743088	VELTUZUMAB Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005952	non-Hodgkins lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00596804%22,https://clinicaltrials.gov/sea
CHEMBL1743088	VELTUZUMAB Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0007160	autoimmune thrombocytopenic purpu	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00547066%22
CHEMBL1743088	VELTUZUMAB Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0000432	lymphoplasmacytic lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00546793%22
CHEMBL1743088	VELTUZUMAB Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0018906	follicular lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT01147393%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000565	leukemia	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT00577278%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0003032	anaplastic large cell lymphoma	2 Withdrawn	https://clinicaltrials.gov/search?id=%22NCT00310128%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0013730	graft versus host disease	2 Active, not recruiting	https://clinicaltrials.gov/search?id=%22NCT00577278%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0044887	central nervous system non-hodgkin ly	2 Terminated	https://clinicaltrials.gov/search?id=%22NCT01973062%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000096	neoplasm of mature B-cells	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00761384%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000183	Hodgkins lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00036855%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000191	MALT lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00012298%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000309	Burkitts lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00064246%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000574	lymphoma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00058292%22,https://clinicaltrials.gov/sea
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0001378	multiple myeloma	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00477815%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0005952	non-Hodgkins lymphoma	1 Unknown status	https://clinicaltrials.gov/search?id=%22NCT00807196%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1000550	Splenic Marginal Zone Lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00012298%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001365	Lymphoma, AIDS-Related	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00036855%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0000873	lymphoblastic lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00036855%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0019088	post-transplant lymphoproliferative d	1 Completed	https://clinicaltrials.gov/search?id=%22NCT00064246%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	MONDO_0019465	nodal marginal zone B-cell lymphoma	1 Terminated	https://clinicaltrials.gov/search?id=%22NCT00012298%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_000095	chronic lymphocytic leukemia	0 Completed	https://clinicaltrials.gov/search?id=%22NCT00017381%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0000403	diffuse large B-cell lymphoma	0 Completed	https://clinicaltrials.gov/search?id=%22NCT00017381%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_0009441	Waldenstrom macroglobulinemia	0 Completed	https://clinicaltrials.gov/search?id=%22NCT00017381%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1000630	marginal zone B-cell lymphoma	0 Completed	https://clinicaltrials.gov/search?id=%22NCT00017381%22
CHEMBL2108667	YTTRIUM Y 90 IBRITUMOMAB TIUXETA Anti	tibody B-lymphocyte antigen CD20 binding agent	Binding agent	EFO_1001469	Mantle cell lymphoma	0 Completed	https://clinicaltrials.gov/search?id=%22NCT00017381%22

CHEMBL2108667 YTTRIUM Y 90 IBRITUMOMAB TIUXETA Antibody B-lymphocyte antigen CD20 binding agent MONDO_0018906 follicular lymphoma 0 Completed https://clinicaltrials.gov/search?id=%22NCT00017381%22

FinnGen **Full Name Affiliation** E-mail Aarno Palotie aarno.palotie@helsinki.fi Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Mark Daly Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, mark.daly@helsinki.fi Bridget Riley-Gills Abbvie, Chicago, IL. United States bridget.rileygillis@abbvie.com Howard Jacob Abbvie, Chicago, IL, United States howard.jacob@abbvie.com Dirk Paul Astra Zeneca, Cambridge, United Kingdom dirk.paul@astrazeneca.com Athena Matakidou Astra Zeneca, Cambridge, United Kingdom athena.x.matakidou@gsk.com Adam Platt Astra Zeneca, Cambridge, United Kingdom adam.platt@astrazeneca.com Heiko Runz Biogen, Cambridge, MA, United States heiko.runz@biogen.com Sally John Biogen, Cambridge, MA, United States sally.john@biogen.com George Okafo Boehringer Ingelheim, Ingelheim am Rhein, Germany george.okafo@boehringer-ingelheim.com Nathan Lawless Boehringer Ingelheim, Ingelheim am Rhein, Germany nathan.lawless@boehringer-ingelheim.com Robert Plenge Bristol Myers Squibb, New York, NY, United States robert.plenge@bms.com joseph.maranville@bms.com Joseph Maranville Bristol Myers Squibb, New York, NY, United States mccarthy.mark@gene.com Mark McCarthy Genentech, San Francisco, CA, United States Julie Hunkapiller Genentech, San Francisco, CA, United States hunkapiller.iulie@gene.com Margaret G. Ehm meg.g.ehm@gsk.com GlaxoSmithKline, Collegeville, PA, United States GlaxoSmithKline, Espoo, Finland Kirsi Auro kirsi.m.auro@gsk.com simonne.longerich@merck.com Simonne Longerich Merck, Kenilworth, NJ. United States Caroline Fox Merck, Kenilworth, NJ. United States caroline.fox@merck.com Anders Mälarstig Pfizer, New York, NY, United States anders.malarstig@pfizer.com Katherine Klinger Translational Sciences, Sanofi R&D, Framingham, MA, USA katherine.klinger@sanofi.com Deepak Raipal Translational Sciences, Sanofi R&D, Framingham, MA, USA deepak.raipal@sanofi.com Eric Green Maze Therapeutics. San Francisco. CA. United States egreen@mazetx.com Robert Graham Maze Therapeutics. San Francisco. CA. United States rgraham@mazetx.com Robert Yang Janssen Biotech, Beerse, Belgium ryang31@its.jnj.com Chris O'Donnell Novartis Institutes for BioMedical Research, Cambridge, MA, United States chris.odonnell@novartis.com Tomi P. Mäkelä HiLIFE, University of Helsinki, Finland, Finland tomi.makela@helsinki.fi Jaakko Kaprio Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland jaakko,kaprio@helsinki,fi Petri Virolainen Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland petri.virolainen@tvks.fi

Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland

Antti Hakanen

Role 2 **Steering Committee Steering Committee** Pharmaceutical companies University of Helsinki & Biobanks University of Helsinki & Biobanks University of Helsinki & Biobanks University of Helsinki & Biobanks

Role 1

Steering Committee

antti.hakanen@tvks.fi

Terhi Kilpi	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	terhi.kilpi@thl.fi	Steering Committee	University of Helsinki & Biobanks
Markus Perola		markus.perola@thl.fi	Steering Committee	University of Helsinki & Biobanks
Jukka Partanen	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki,	•	Steering Committee	University of Helsinki & Biobanks
	Finland	James parianon e tompanonam		• · · · · · · · · · · · · · · · · · · ·
Anne Pitkäranta		anne.pitkaranta@hus.fi	Steering Committee	University of Helsinki & Biobanks
Juhani Junttila	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland	•	Steering Committee	University of Helsinki & Biobanks
Raisa Serpi	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District,	raisa.serpi@ppshp.fi	Steering Committee	University of Helsinki & Biobanks
	Oulu, Finland			
Tarja Laitinen	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,	tarja.laitinen@pshp.fi	Steering Committee	University of Helsinki & Biobanks
	Tampere, Finland			
Veli-Matti Kosma	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,	veli-matti.kosma@uef.fi	Steering Committee	University of Helsinki & Biobanks
	Kuopio, Finland			
Jari Laukkanen	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,	jari.laukkanen@ksshp.fi	Steering Committee	University of Helsinki & Biobanks
	Jyväskylä, Finland			
Marco Hautalahti	· ·	marco.hautalahti@finbb.fi	Steering Committee	University of Helsinki & Biobanks
Outi Tuovila	Business Finland, Helsinki, Finland	outi.tuovila@businessfinland.fi	Steering Committee	Other Experts/ Non-Voting Member
Raimo Pakkanen	Business Finland, Helsinki, Finland	raimo.pakkanen@businessfinland.fi	Steering Committee	Other Experts/ Non-Voting Membe
Jeffrey Waring	Abbvie, Chicago, IL, United States	jeff.waring@abbvie.com	Scientific Committee	Pharmaceutical companies
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States	bridget.rileygillis@abbvie.com	Scientific Committee	Pharmaceutical companies
Fedik Rahimov	Abbvie, Chicago, IL, United States	fedik.rahimov@abbvie.com	Scientific Committee	Pharmaceutical companies
oanna Tachmazidou	Astra Zeneca, Cambridge, United Kingdom	ioanna.tachmazidou@astrazeneca.com	Scientific Committee	Pharmaceutical companies
Chia-Yen Chen	Biogen, Cambridge, MA, United States	chiayen.chen@biogen.com	Scientific Committee	Pharmaceutical companies
Heiko Runz	Biogen, Cambridge, MA, United States	heiko.runz@biogen.com	Scientific Committee	Pharmaceutical companies
Zhihao Ding	Boehringer Ingelheim, Ingelheim am Rhein, Germany	zhihao.ding@boehringer-ingelheim.com	Scientific Committee	Pharmaceutical companies
Marc Jung	Boehringer Ingelheim, Ingelheim am Rhein, Germany	marc_oliver.jung@boehringer-ingelheim.com	Scientific Committee	Pharmaceutical companies
Shameek Biswas	Bristol Myers Squibb, New York, NY, United States	Shameek.Biswas@bms.com	Scientific Committee	Pharmaceutical companies
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com	Scientific Committee	Pharmaceutical companies
Julie Hunkapiller	Genentech, San Francisco, CA, United States	hunkapiller.julie@gene.com	Scientific Committee	Pharmaceutical companies
Margaret G. Ehm		meg.g.ehm@gsk.com	Scientific Committee	Pharmaceutical companies
David Pulford	GlaxoSmithKline, Stevenage, United Kingdom	david.x.pulford@gsk.com	Scientific Committee	Pharmaceutical companies
Neha Raghavan		neha.raghavan@merck.com	Scientific Committee	Pharmaceutical companies
Adriana Huertas-Vazquez		adriana.huertas.vazquez@merck.com	Scientific Committee	Pharmaceutical companies
Jae-Hoon Sul	Merck, Kenilworth, NJ, United States	jae.hoon.sul@merck.com	Scientific Committee	Pharmaceutical companies
Anders Mälarstig		anders.malarstig@pfizer.com	Scientific Committee	Pharmaceutical companies

Xinli Hu	Pfizer, New York, NY, United States	xinli.hu@pfizer.com	Scientific Committee	Pharmaceutical companies
Katherine Klinger	Translational Sciences, Sanofi R&D, Framingham, MA, USA	katherine.klinger@sanofi.com	Scientific Committee	Pharmaceutical companies
Robert Graham	Maze Therapeutics, San Francisco, CA, United States	rgraham@mazetx.com	Scientific Committee	Pharmaceutical companies
Eric Green	Maze Therapeutics, San Francisco, CA, United States	egreen@mazetx.com	Scientific Committee	Pharmaceutical companies
Sahar Mozaffari	Maze Therapeutics, San Francisco, CA, United States	smozaffari@mazetx.com	Scientific Committee	Pharmaceutical companies
Dawn Waterworth	Janssen Research & Development, LLC, Spring House, PA, United States	dwaterwo@its.jnj.com	Scientific Committee	Pharmaceutical companies
Nicole Renaud	Novartis Institutes for BioMedical Research, Cambridge, MA, United States	nicole.renaud@novartis.com	Scientific Committee	Pharmaceutical companies
Ma'en Obeidat	Novartis Institutes for BioMedical Research, Cambridge, MA, United States	maen.obeidat@novartis.com	Scientific Committee	Pharmaceutical companies
Samuli Ripatti	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	samuli.ripatti@helsinki.fi	Scientific Committee	University of Helsinki & Biobanks
Johanna Schleutker	Auria Biobank / Univ. of Turku / Hospital District of Southwest Finland, Turku, Finland	johanna.schleutker@utu.fi	Scientific Committee	University of Helsinki & Biobanks
Markus Perola	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	markus.perola@thl.fi	Scientific Committee	University of Helsinki & Biobanks
Mikko Arvas	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland	mikko.arvas@veripalvelu.fi	Scientific Committee	University of Helsinki & Biobanks
Olli Carpén	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	olli.carpen@helsinki.fi	Scientific Committee	University of Helsinki & Biobanks
Reetta Hinttala	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District,	reetta.hinttala@oulu.fi	Scientific Committee	University of Helsinki & Biobanks
Johannes Kettunen	Oulu, Finland Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District,	ichannes kattunen@aulu fi	Scientific Committee	University of Helsinki & Biobanks
Johannes Rettunen	Oulu, Finland	Johannes.Retturien@outu.ii	Scientific Committee	Oniversity of Heisinki & Biobanks
Arto Mannermaa	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, Kuopio, Finland	arto.mannermaa@uef.fi	Scientific Committee	University of Helsinki & Biobanks
Katriina Aalto-Setälä	Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland	katriina.aalto-setala@tuni.fi	Scientific Committee	University of Helsinki & Biobanks
Mika Kähönen	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland	mika.kahonen@uta.fi	Scientific Committee	University of Helsinki & Biobanks
Jari Laukkanen	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District, Jyväskylä, Finland	jari.laukkanen@ksshp.fi	Scientific Committee	University of Helsinki & Biobanks
Johanna Mäkelä	FINBB - Finnish biobank cooperative	johanna.makela@finbb.fi	Scientific Committee	University of Helsinki & Biobanks
Reetta Kälviäinen	Northern Savo Hospital District, Kuopio, Finland	reetta.kalviainen@kuh.fi	Clinical Groups	Neurology Group
Valtteri Julkunen	Northern Savo Hospital District, Kuopio, Finland	valtteri.julkunen@kuh.fi	Clinical Groups	Neurology Group
Hilkka Soininen	Northern Savo Hospital District, Kuopio, Finland	hilkka.soininen@uef.fi	Clinical Groups	Neurology Group
Anne Remes	Northern Ostrobothnia Hospital District, Oulu, Finland	anne.remes@oulu.fi	Clinical Groups	Neurology Group
Mikko Hiltunen	University of Eastern Finland, Kuopio, Finland	mikko.hiltunen@uef.fi	Clinical Groups	Neurology Group
Jukka Peltola	Pirkanmaa Hospital District, Tampere, Finland	jukka.peltola@pshp.fi	Clinical Groups	Neurology Group
Minna Raivio	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	minna.raivio@geri.fi	Clinical Groups	Neurology Group
Pentti Tienari	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	pentti.tienari@hus.fi	Clinical Groups	Neurology Group
Juha Rinne	Hospital District of Southwest Finland, Turku, Finland	juha.rinne@tyks.fi	Clinical Groups	Neurology Group

Roosa Kallionpää Hospital District of Southwest Finland, Turku, Finland Juulia Partanen Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Ali Abbasi Abbvie, Chicago, IL, United States Adam Ziemann Abbvie, Chicago, IL, United States Nizar Smaoui Abbvie, Chicago, IL, United States Abbvie, Chicago, IL, United States Anne Lehtonen Susan Eaton Biogen, Cambridge, MA, United States Heiko Runz Biogen, Cambridge, MA, United States Sanni Lahdenperä Biogen, Cambridge, MA, United States Shameek Biswas Bristol Myers Squibb, New York, NY, United States Julie Hunkapiller Genentech, San Francisco, CA, United States Natalie Bowers Genentech, San Francisco, CA, United States Edmond Teng Genentech, San Francisco, CA, United States Rion Pendergrass Genentech, San Francisco, CA, United States Fanli Xu GlaxoSmithKline, Brentford, United Kingdom David Pulford GlaxoSmithKline, Stevenage, United Kingdom Kirsi Auro GlaxoSmithKline, Espoo, Finland Laura Addis GlaxoSmithKline, Brentford, United Kingdom John Eicher GlaxoSmithKline, Brentford, United Kingdom Qinaain S Li Janssen Research & Development, LLC, Titusville, NJ 08560, United States Karen He Janssen Research & Development, LLC, Spring House, PA, United States Ekaterina Khramtsova Janssen Research & Development, LLC, Spring House, PA, United States Neha Raghavan Merck, Kenilworth, NJ, United States Martti Färkkilä Hospital District of Helsinki and Uusimaa, Helsinki, Finland Jukka Koskela Hospital District of Helsinki and Uusimaa, Helsinki, Finland Sampsa Pikkarainen Hospital District of Helsinki and Uusimaa, Helsinki, Finland Pirkanmaa Hospital District, Tampere, Finland Airi Jussila Katri Kaukinen Pirkanmaa Hospital District, Tampere, Finland Timo Blomster Northern Ostrobothnia Hospital District, Oulu, Finland Mikko Kiviniemi Northern Savo Hospital District, Kuopio, Finland Markku Voutilainen Hospital District of Southwest Finland, Turku, Finland Institute for Molecular Medicine, Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Mark Daly Finland: Broad Institute of MIT and Harvard: Massachusetts General Hospital Abbvie, Chicago, IL, United States Ali Abbasi Jeffrey Waring Abbvie, Chicago, IL, United States

roosa.kallionpaa@tvks.fi Clinical Groups iuulia.partanen@helsinki.fi Clinical Groups ali.abbasi@abbvie.com Clinical Groups adam.ziemann@abbvie.com **Clinical Groups** nizar.smaoui@abbvie.com **Clinical Groups** anne.lehtonen@abbvie.com Clinical Groups susan.eaton@biogen.com **Clinical Groups** heiko.runz@biogen.com **Clinical Groups** sanni.lahdenpera@biogen.com **Clinical Groups** shameek.biswas@bms.com Clinical Groups hunkapiller.julie@gene.com **Clinical Groups** bowersn1@gene.com **Clinical Groups** teng.edmond@gene.com **Clinical Groups** penders2@gene.com **Clinical Groups** chun-fang.2.xu@gsk.com **Clinical Groups** david.x.pulford@gsk.com **Clinical Groups** kirsi.m.auro@gsk.com **Clinical Groups** laura.x.addis@gsk.com **Clinical Groups** john.d.eicher@gsk.com **Clinical Groups** QLi2@its.jnj.com **Clinical Groups** khe2@its.jnj.com **Clinical Groups** ekhramts@its.jnj.com Clinical Groups neha.raghavan@merck.com **Clinical Groups** martti.farkkila@hus.fi **Clinical Groups** iukka.koskela@helsinki.fi **Clinical Groups** sampsa.pikkarainen@hus.fi Clinical Groups airi.iussila@pshp.fi **Clinical Groups** katri.kaukinen@tuni.fi **Clinical Groups** timo.blomster@ppshp.fi Clinical Groups mikko.kiviniemi@kuh.fi **Clinical Groups** markku.voutilainen@tvks.fi **Clinical Groups** mark.daly@helsinki.fi **Clinical Groups** ali.abbasi@abbvie.com **Clinical Groups** jeff.waring@abbvie.com **Clinical Groups**

Neurology Group Neurology Group Gastroenterology Group Gastroenterology Group **Gastroenterology Group**

Nizar Smaoui nizar.smaoui@abbvie.com Abbvie, Chicago, IL, United States Clinical Groups Gastroenterology Group Abbvie, Chicago, IL, United States Fedik Rahimov fedik.rahimov@abbvie.com Clinical Groups Gastroenterology Group **Gastroenterology Group** Anne Lehtonen Abbvie, Chicago, IL, United States anne.lehtonen@abbvie.com Clinical Groups Tim Lu Genentech, San Francisco, CA, United States lut8@gene.com **Clinical Groups** Gastroenterology Group Natalie Bowers Genentech, San Francisco, CA, United States bowersn1@gene.com **Clinical Groups** Gastroenterology Group Rion Pendergrass Genentech, San Francisco, CA, United States penders2@gene.com Clinical Groups Gastroenterology Group Linda McCarthy GlaxoSmithKline, Brentford, United Kingdom linda.c.mccarthy@gsk.com **Clinical Groups Gastroenterology Group** Amy Hart Janssen Research & Development, LLC, Spring House, PA, United States ahart13@its.jnj.com **Clinical Groups Gastroenterology Group** Meiiian Guan Janssen Research & Development, LLC, Spring House, PA, United States mguan4@its.jnj.com **Clinical Groups Gastroenterology Group** Jason Miller Merck, Kenilworth, NJ, United States iason.miller4@merck.com **Clinical Groups Gastroenterology Group Gastroenterology Group** Kirsi Kalpala Pfizer, New York, NY, United States kirsi.kalpala@pfizer.com **Clinical Groups** melissa.r.miller@pfizer.com Melissa Miller Pfizer, New York, NY, United States **Clinical Groups Gastroenterology Group** Xinli Hu Pfizer, New York, NY, United States xinli.hu@pfizer.com **Clinical Groups Gastroenterology Group** Kari Eklund kari.eklund@hus.fi Hospital District of Helsinki and Uusimaa, Helsinki, Finland **Clinical Groups** Rheumatology Group Antti Palomäki Hospital District of Southwest Finland, Turku, Finland aipalo@utu.fi **Clinical Groups** Rheumatology Group Pia Isomäki Pirkanmaa Hospital District, Tampere, Finland pia.isomaki@pshp.fi **Clinical Groups** Rheumatology Group Laura Pirilä laura.pirila@fimnet.fi,laura.pirila@tyks.fi Hospital District of Southwest Finland, Turku, Finland **Clinical Groups** Rheumatology Group Oili Kaipiainen-Seppänen Northern Savo Hospital District, Kuopio, Finland oili.kaipiainen-seppanen@kuh.fi **Clinical Groups** Rheumatology Group iohanna.huhtakangas@kuh.fi Northern Ostrobothnia Hospital District, Oulu, Finland Johanna Huhtakangas **Clinical Groups** Rheumatology Group Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland nina, mars@helsinki, fi Nina Mars **Clinical Groups** Rheumatology Group Ali Abbasi ali.abbasi@abbvie.com Abbvie, Chicago, IL, United States **Clinical Groups** Rheumatology Group Jeffrey Waring Abbvie, Chicago, IL, United States jeff.waring@abbvie.com Clinical Groups Rheumatology Group Fedik Rahimov Abbvie, Chicago, IL, United States fedik.rahimov@abbvie.com **Clinical Groups** Rheumatology Group Abbvie, Chicago, IL, United States Apinya Lertratanakul apinya.lertratanakul@abbvie.com **Clinical Groups** Rheumatology Group Nizar Smaoui Abbvie, Chicago, IL, United States nizar.smaoui@abbvie.com **Clinical Groups** Rheumatology Group Anne Lehtonen Abbvie, Chicago, IL, United States anne.lehtonen@abbvie.com Clinical Groups Rheumatology Group David Close Astra Zeneca, Cambridge, United Kingdom david.close@astrazeneca.com **Clinical Groups** Rheumatology Group Marla Hochfeld Bristol Myers Squibb, New York, NY, United States mhochfeld@celgene.com **Clinical Groups** Rheumatology Group Natalie Bowers Genentech, San Francisco, CA, United States bowersn1@gene.com Clinical Groups Rheumatology Group Rion Pendergrass Genentech, San Francisco, CA, United States penders2@gene.com **Clinical Groups** Rheumatology Group Jorge Esparza Gordillo jorge.x.esparza-gordillo@gsk.com **Clinical Groups** GlaxoSmithKline, Brentford, United Kingdom Rheumatology Group Kirsi Auro GlaxoSmithKline, Espoo, Finland kirsi.m.auro@gsk.com **Clinical Groups** Rheumatology Group Dawn Waterworth Janssen Research & Development, LLC, Spring House, PA, United States dwaterwo@its.jnj.com **Clinical Groups** Rheumatology Group Fabiana Farias Merck, Kenilworth, NJ, United States fabiana.farias@merck.com **Clinical Groups** Rheumatology Group Kirsi Kalpala Pfizer, New York, NY, United States kirsi.kalpala@pfizer.com **Clinical Groups** Rheumatology Group

Nan Bing nan.bing@pfizer.com Pfizer, New York, NY, United States Clinical Groups Rheumatology Group Xinli Hu Pfizer, New York, NY, United States **Rheumatology Group** xinli.hu@pfizer.com Clinical Groups Taria Laitinen **Pulmonology Group** Pirkanmaa Hospital District, Tampere, Finland taria.laitinen@pshp.fi Clinical Groups Margit Pelkonen Northern Savo Hospital District, Kuopio, Finland margit.pelkonen@kuh.fi Clinical Groups Pulmonology Group Paula Kauppi Hospital District of Helsinki and Uusimaa, Helsinki, Finland paula.kauppi@hus.fi **Clinical Groups** Pulmonology Group Hannu Kankaanranta University of Gothenburg, Gothenburg, Sweden/ Seinäioki Central Hospital, Seinäioki, Finland/ hannu.kankaanranta@tuni.fi Clinical Groups **Pulmonology Group** Tampere University, Tampere, Finland terttu.harju@oulu.fi **Clinical Groups** Terttu Harju Northern Ostrobothnia Hospital District, Oulu, Finland **Pulmonology Group** Riitta Lahesmaa rilahes@utu.fi Hospital District of Southwest Finland, Turku, Finland **Clinical Groups Pulmonology Group** Nizar Smaoui Abbvie, Chicago, IL, United States nizar.smaoui@abbvie.com Clinical Groups **Pulmonology Group** Alex Mackay Astra Zeneca, Cambridge, United Kingdom alex.mackay@astrazeneca.com **Clinical Groups Pulmonology Group** Glenda Lassi Astra Zeneca, Cambridge, United Kingdom glenda.lassi@astrazeneca.com **Clinical Groups Pulmonology Group** Susan Eaton Biogen, Cambridge, MA, United States susan.eaton@biogen.com **Clinical Groups Pulmonology Group** Hubert Chen Genentech, San Francisco, CA, United States chenh37@gene.com **Clinical Groups Pulmonology Group** Rion Pendergrass Genentech, San Francisco, CA, United States penders2@gene.com **Clinical Groups Pulmonology Group** Natalie Bowers Genentech, San Francisco, CA, United States bowersn1@gene.com **Clinical Groups Pulmonology Group** Joanna Betts joanna.c.betts@gsk.com **Clinical Groups** GlaxoSmithKline. Brentford. United Kingdom **Pulmonology Group** Kirsi Auro kirsi.m.auro@gsk.com GlaxoSmithKline, Espoo, Finland **Clinical Groups Pulmonology Group** Raiashree Mishra rajashree.x.mishra@gsk.com GlaxoSmithKline, Brentford, United Kingdom **Clinical Groups Pulmonology Group** Maid Mouded Novartis, Basel, Switzerland majd.mouded@novartis.com **Clinical Groups Pulmonology Group** Debby Ngo Novartis, Basel, Switzerland debby.ngo@novartis.com **Clinical Groups Pulmonology Group** Teemu Niiranen Finnish Institute for Health and Welfare (THL), Helsinki, Finland teemu.niiranen@thl.fi **Clinical Groups** Cardiometabolic Diseases Group Felix Vaura Finnish Institute for Health and Welfare (THL), Helsinki, Finland fechva@utu.fi **Clinical Groups** Cardiometabolic Diseases Group Veikko Salomaa veikko.salomaa@thl.fi Finnish Institute for Health and Welfare (THL), Helsinki, Finland **Clinical Groups** Cardiometabolic Diseases Group Kaj Metsärinne Hospital District of Southwest Finland, Turku, Finland kaj.metsarinne@tyks.fi **Clinical Groups** Cardiometabolic Diseases Group Jenni Aittokallio Hospital District of Southwest Finland, Turku, Finland iemato@utu.fi Cardiometabolic Diseases Group Clinical Groups Mika Kähönen Pirkanmaa Hospital District, Tampere, Finland mika.kahonen@uta.fi **Clinical Groups** Cardiometabolic Diseases Group Jussi Hernesniemi **Clinical Groups** Pirkanmaa Hospital District, Tampere, Finland iussi.hernesniemi@tuni.fi Cardiometabolic Diseases Group Daniel Gordin daniel.gordin@hus.fi Hospital District of Helsinki and Uusimaa, Helsinki, Finland Clinical Groups Cardiometabolic Diseases Group Juha Sinisalo Hospital District of Helsinki and Uusimaa, Helsinki, Finland iuha.sinisalo@hus.fi **Clinical Groups** Cardiometabolic Diseases Group Maria-Riitta Taskinen maria-riitta.taskinen@helsinki.fi **Clinical Groups** Cardiometabolic Diseases Group Hospital District of Helsinki and Uusimaa, Helsinki, Finland Tiinamaiia Tuomi tiinamaija.tuomi@hus.fi Hospital District of Helsinki and Uusimaa, Helsinki, Finland **Clinical Groups** Cardiometabolic Diseases Group Timo Hiltunen Hospital District of Helsinki and Uusimaa, Helsinki, Finland timo.hiltunen@hus.fi **Clinical Groups** Cardiometabolic Diseases Group Jari Laukkanen Central Finland Health Care District, Jyväskylä, Finland iari.laukkanen@ksshp.fi Cardiometabolic Diseases Group **Clinical Groups**

Amanda Elliott	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, USA and Massachusetts General Hospital, Boston,	aelliott@broadinstitute.org	Clinical Groups	Cardiometabolic Diseases Group
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mary reeve@helsinki fi	Clinical Groups	Cardiometabolic Diseases Group
Sanni Ruotsalainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland		Clinical Groups	Cardiometabolic Diseases Group
Benjamin Challis	Astra Zeneca, Cambridge, United Kingdom	benjamin.challis@astrazeneca.com	Clinical Groups	Cardiometabolic Diseases Group
Dirk Paul	Astra Zeneca, Cambridge, United Kingdom	dirk.paul@astrazeneca.com	Clinical Groups	Cardiometabolic Diseases Group
Julie Hunkapiller	Genentech, San Francisco, CA, United States	hunkapiller.julie@gene.com	Clinical Groups	Cardiometabolic Diseases Group
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com	Clinical Groups	Cardiometabolic Diseases Group
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com	Clinical Groups	Cardiometabolic Diseases Group
Audrey Chu	GlaxoSmithKline, Brentford, United Kingdom	audrey.y.chu@gsk.com	Clinical Groups	Cardiometabolic Diseases Group
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com	Clinical Groups	Cardiometabolic Diseases Group
Dermot Reilly	Janssen Research & Development, LLC, Boston, MA, United States	dreill11@its.jnj.com	Clinical Groups	Cardiometabolic Diseases Group
Mike Mendelson	Novartis, Boston, MA, United States	mike.mendelson@novartis.com	Clinical Groups	Cardiometabolic Diseases Group
Jaakko Parkkinen	Pfizer, New York, NY, United States	jaakko.parkkinen@pfizer.com	Clinical Groups	Cardiometabolic Diseases Group
Melissa Miller	Pfizer, New York, NY, United States	melissa.r.miller@pfizer.com	Clinical Groups	Cardiometabolic Diseases Group
Tuomo Meretoja	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	tuomo.meretoja@hus.fi	Clinical Groups	Oncology Group
Heikki Joensuu	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	heikki.joensuu@hus.fi	Clinical Groups	Oncology Group
Olli Carpén	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	olli.carpen@helsinki.fi	Clinical Groups	Oncology Group
Johanna Mattson	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	johanna.mattson@hus.fi	Clinical Groups	Oncology Group
Eveliina Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	eveliina.e.salminen@hus.fi	Clinical Groups	Oncology Group
Annika Auranen	Pirkanmaa Hospital District, Tampere, Finland	anaura@utu.fi	Clinical Groups	Oncology Group
Peeter Karihtala	Northern Ostrobothnia Hospital District, Oulu, Finland	peeter.karihtala@oulu.fi	Clinical Groups	Oncology Group
Päivi Auvinen	Northern Savo Hospital District, Kuopio, Finland	paivi.auvinen@kuh.fi	Clinical Groups	Oncology Group
Klaus Elenius	Hospital District of Southwest Finland, Turku, Finland	klaus.elenius@utu.fi	Clinical Groups	Oncology Group
Johanna Schleutker	Hospital District of Southwest Finland, Turku, Finland	johanna.schleutker@utu.fi	Clinical Groups	Oncology Group
Esa Pitkänen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	sa.pitkanen@helsinki.fi	Clinical Groups	Oncology Group
Nina Mars	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	nina.mars@helsinki.fi	Clinical Groups	Oncology Group
Mark Daly	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki,	mark.daly@helsinki.fi	Clinical Groups	Oncology Group
•	Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital	·	•	
Relja Popovic	Abbvie, Chicago, IL, United States	relja.popovic@abbvie.com	Clinical Groups	Oncology Group
Jeffrey Waring	Abbvie, Chicago, IL, United States	jeff.waring@abbvie.com	Clinical Groups	Oncology Group
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States	bridget.rileygillis@abbvie.com	Clinical Groups	Oncology Group
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtonen@abbvie.com	Clinical Groups	Oncology Group
Jennifer Schutzman	Genentech, San Francisco, CA, United States	schutzman.jennifer@gene.com	Clinical Groups	Oncology Group
Julie Hunkapiller	Genentech, San Francisco, CA, United States	hunkapiller.julie@gene.com	Clinical Groups	Oncology Group
		·		-

Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com	Clinical Groups	Oncology Group
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com	Clinical Groups	Oncology Group
Diptee Kulkarni	GlaxoSmithKline, Brentford, United Kingdom	diptee.a.kulkarni@gsk.com	Clinical Groups	Oncology Group
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com	Clinical Groups	Oncology Group
Alessandro Porello	Janssen Research & Development, LLC, Spring House, PA, United States	APorrell@ITS.JNJ.com	Clinical Groups	Oncology Group
Andrey Loboda	Merck, Kenilworth, NJ, United States	andrey_loboda@merck.com	Clinical Groups	Oncology Group
Heli Lehtonen	Pfizer, New York, NY, United States	heli.lehtonen@pfizer.com	Clinical Groups	Oncology Group
Stefan McDonough	Pfizer, New York, NY, United States	stefan.McDonough@pfizer.com	Clinical Groups	Oncology Group
Sauli Vuoti	Janssen-Cilag Oy, Espoo, Finland	swoti@its.jnj.com	Clinical Groups	Oncology Group
Kai Kaarniranta	Northern Savo Hospital District, Kuopio, Finland	kai.kaarniranta@uef.fi	Clinical Groups	Opthalmology G
Joni A Turunen	Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Eye Genetics Group, Folkhälsan Research Center, Helsinki, Finland	joni.turunen@helsinki.fi	Clinical Groups	Opthalmology G
Terhi Ollila	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	terhi.ollila@hus.fi	Clinical Groups	Opthalmology G
Hannu Uusitalo	Pirkanmaa Hospital District, Tampere, Finland	hannu.uusitalo@tuni.fi	Clinical Groups	Opthalmology G
Juha Karjalainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d juha.karjalainen@helsinki.fi	Clinical Groups	Opthalmology G
Esa Pitkänen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finlan	d esa.pitkanen@helsinki.fi	Clinical Groups	Opthalmology G
Mengzhen Liu	Abbvie, Chicago, IL, United States	mengzhen.liu@abbvie.com	Clinical Groups	Opthalmology G
Heiko Runz	Biogen, Cambridge, MA, United States	heiko.runz@biogen.com	Clinical Groups	Opthalmology G
Stephanie Loomis	Biogen, Cambridge, MA, United States	stephanie.loomis@biogen.com	Clinical Groups	Opthalmology G
Erich Strauss	Genentech, San Francisco, CA, United States	strauss.erich@gene.com	Clinical Groups	Opthalmology G
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com	Clinical Groups	Opthalmology G
Hao Chen	Genentech, San Francisco, CA, United States	haoc@gene.com	Clinical Groups	Opthalmology G
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com	Clinical Groups	Opthalmology G
Kaisa Tasanen	Northern Ostrobothnia Hospital District, Oulu, Finland	kaisa.tasanen-maatta@oulu.fi	Clinical Groups	Dermatology Gr
Laura Huilaja	Northern Ostrobothnia Hospital District, Oulu, Finland	laura.huilaja@oulu.fi	Clinical Groups	Dermatology Gr
Katariina Hannula-Jouppi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	katariina.hannula-jouppi@hus.fi	Clinical Groups	Dermatology Gr
Teea Salmi	Pirkanmaa Hospital District, Tampere, Finland	teea.salmi@pshp.fi	Clinical Groups	Dermatology Gr
Sirkku Peltonen	Hospital District of Southwest Finland, Turku, Finland	sipelto@utu.fi	Clinical Groups	Dermatology Gr
Leena Koulu	Hospital District of Southwest Finland, Turku, Finland	leena.koulu@tyks.fi	Clinical Groups	Dermatology Gr
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui@abbvie.com	Clinical Groups	Dermatology Gr
Fedik Rahimov	Abbvie, Chicago, IL, United States	fedik.rahimov@abbvie.com	Clinical Groups	Dermatology Gr
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtonen@abbvie.com	Clinical Groups	Dermatology Gr
David Choy	Genentech, San Francisco, CA, United States	choy.david@gene.com	Clinical Groups	Dermatology Gr
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com	Clinical Groups	Dermatology Gr
Dawn Waterworth	Janssen Research & Development, LLC, Spring House, PA, United States	dwaterwo@its.jnj.com	Clinical Groups	Dermatology Gro

Kirsi Kalpala	Pfizer, New York, NY, United States	kirsi.kalpala@pfizer.com
Ying Wu	Pfizer, New York, NY, United States	ying.wu3@pfizer.com
Pirkko Pussinen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	pirkko.pussinen@helsinki.fi
Aino Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	aino.m.salminen@helsinki.fi
Tuula Salo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	tuula.salo@helsinki.fi
David Rice	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	david.rice@helsinki.fi
Pekka Nieminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	pekka.nieminen@helsinki.fi
Ulla Palotie	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	ulla.palotie@helsinki.fi
Maria Siponen	Northern Savo Hospital District, Kuopio, Finland	maria.siponen@uef.fi
Liisa Suominen	Northern Savo Hospital District, Kuopio, Finland	liisa.suominen@uef.fi
Päivi Mäntylä	Northern Savo Hospital District, Kuopio, Finland	paivi.mantyla@uef.fi
Ulvi Gursoy	Hospital District of Southwest Finland, Turku, Finland	ulvi.gursoy@utu.fi
Vuokko Anttonen	Northern Ostrobothnia Hospital District, Oulu, Finland	vuokko.anttonen@oulu.fi
Kirsi Sipilä	Research Unit of Oral Health Sciences Faculty of Medicine, University of Oulu, Oulu, Finland;	kirsi.sipila@oulu.fi
	Medical Research Center, Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland	
Rion Pendergrass	Genentech, San Francisco, CA, United States	pendergrass.sarah@gene.com
Hannele Laivuori	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	d hannele.laivuori@helsinki.fi
Venla Kurra	Pirkanmaa Hospital District, Tampere, Finland	venla.kurra@tuni.fi
Laura Kotaniemi-Talonen	Pirkanmaa Hospital District, Tampere, Finland	laura.kotaniemi-talonen@tuni.fi
Oskari Heikinheimo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	oskari.heikinheimo@helsinki.fi
llkka Kalliala	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	ilkka.kalliala@hus.fi
Lauri Aaltonen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	lauri.aaltonen@helsinki.fi
Varpu Jokimaa	Hospital District of Southwest Finland, Turku, Finland	varpu.jokimaa@utu.fi
Johannes Kettunen	Northern Ostrobothnia Hospital District, Oulu, Finland	Johannes.Kettunen@oulu.fi
Marja Vääräsmäki	Northern Ostrobothnia Hospital District, Oulu, Finland	marja.vaarasmaki@oulu.fi
Outi Uimari	Northern Ostrobothnia Hospital District, Oulu, Finland	outi.uimari@oulu.fi
Laure Morin-Papunen	Northern Ostrobothnia Hospital District, Oulu, Finland	lmp@cc.oulu.fi
Maarit Niinimäki	Northern Ostrobothnia Hospital District, Oulu, Finland	maarit.niinimaki@oulu.fi
Terhi Piltonen	Northern Ostrobothnia Hospital District, Oulu, Finland	terhi.piltonen@oulu.fi
Katja Kivinen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finlan	•
Elisabeth Widen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finlan	
Taru Tukiainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finlan	
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finlan	•
Mark Daly	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki,	mark.daly@helsinki.fi
	Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital	

Clinical Groups Dermatology Group Clinical Groups Dermatology Group Clinical Groups Odontology Group

Clinical Groups Clinical Groups

Odontology Group

Women's Health and Reproduction Group Women's Health and Reproduction Group Women's Health and Reproduction Group

Niko Välimäki	University of Helsinki, Helsinki, Finland	niko.valimaki@helsinki.fi	Clinical Groups	Women's Health and Reproduction Group
Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland	eija.k.laakkonen@jyu.fi	Clinical Groups	Women's Health and Reproduction Group
Jaakko Tyrmi	University of Oulu, Oulu, Finland / University of Tampere, Tampere, Finland	jaakko.tyrmi@oulu.fi	Clinical Groups	Women's Health and Reproduction Group
Heidi Silven	University of Oulu, Oulu, Finland	heidi.silven@student.oulu.fi	Clinical Groups	Women's Health and Reproduction Group
Eeva Sliz	University of Oulu, Oulu, Finland	eeva.sliz@oulu.fi	Clinical Groups	Women's Health and Reproduction Group
Riikka Arffman	University of Oulu, Oulu, Finland	riikka.arffman@oulu.fi	Clinical Groups	Women's Health and Reproduction Group
Susanna Savukoski	University of Oulu, Oulu, Finland	susanna.savukoski@oulu.fi	Clinical Groups	Women's Health and Reproduction Group
Triin Laisk	Estonian biobank, Tartu, Estonia	triin.laisk@ut.ee	Clinical Groups	Women's Health and Reproduction Group
Natalia Pujol	Estonian biobank, Tartu, Estonia	natalia.pujolgualdo@oulu.fi	Clinical Groups	Women's Health and Reproduction Group
Mengzhen Liu	Abbvie, Chicago, IL, United States	mengzhen.liu@abbvie.com	Clinical Groups	Women's Health and Reproduction Group
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States	bridget.rileygillis@abbvie.com	Clinical Groups	Women's Health and Reproduction Group
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com	Clinical Groups	Women's Health and Reproduction Group
Janet Kumar	GlaxoSmithKline, Collegeville, PA, United States	janet.x.kumar@gsk.com	Clinical Groups	Women's Health and Reproduction Group
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com	Clinical Groups	Women's Health and Reproduction Group
liris Hovatta	University of Helsinki, Finland	iiris.hovatta@helsinki.fi	Clinical Groups	Depression group
Chia-Yen Chen	Biogen, Cambridge, MA, United States	chiayen.chen@biogen.com	Clinical Groups	Depression group
Erkki Isometsä	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	erkki.isometsa@hus.fi	Clinical Groups	Depression group
Kumar Veerapen	Broad Institute, Cambridge, MA, United States	veerapen@broadinstitute.org	Clinical Groups	Depression group
Hanna Ollila	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finl	and hanna.m.ollila@helsinki.fi	Clinical Groups	Depression group
Jaana Suvisaari	Finnish Institute for Health and Welfare (THL), Helsinki, Finland	jaana.suvisaari@thl.fi	Clinical Groups	Depression group
Thomas Damm Als	Aarhus University, Denmark	tda@biomed.au.dk	Clinical Groups	Depression group
Antti Mäkitie	Department of Otorhinolaryngology - Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland	antti.makitie@helsinki.fi	Clinical Groups	ENT (ear, nose and throath) Group
Argyro Bizaki-Vallaskan	ngas Pirkanmaa Hospital District, Tampere, Finland	argyro.bizaki-vallaskangas@tuni.fi	Clinical Groups	ENT (ear, nose and throath) Group
Sanna Toppila-Salmi	University of Helsinki, Finland	sanna.salmi@helsinki.fi	Clinical Groups	ENT (ear, nose and throath) Group
Tytti Willberg	Hospital District of Southwest Finland, Turku, Finland	tytti.willberg@tyks.fi	Clinical Groups	ENT (ear, nose and throath) Group
Elmo Saarentaus	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finl	and elmo.saarentaus@helsinki.fi	Clinical Groups	ENT (ear, nose and throath) Group
Antti Aarnisalo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	antti.aarnisalo@hus.fi	Clinical Groups	ENT (ear, nose and throath) Group
Eveliina Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	eveliina.e.salminen@hus.fi	Clinical Groups	ENT (ear, nose and throath) Group
Elisa Rahikkala	Northern Ostrobothnia Hospital District, Oulu, Finland	elisa.rahikkala@ppshp.fi	Clinical Groups	ENT (ear, nose and throath) Group
Johannes Kettunen	Northern Ostrobothnia Hospital District, Oulu, Finland	johannes.kettunen@oulu.fi	Clinical Groups	ENT (ear, nose and throath) Group
Kristiina Aittomäki	Department of Medical Genetics, Helsinki University Central Hospital, Helsinki, Finland	kristiina.aittomaki@helsinki.fi	Clinical Groups	POI (premature ovarian failure) Group
Fredrik Åberg	Transplantation and Liver Surgery Clinic, Helsinki University Hospital, Helsinki University, Helsinki, Finland	fredrik.aberg@helsinki.fi	Clinical Groups	LiverScore Group

Mitja Kurki	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, United States	mkurki@broadinstitute.org
Samuli Ripatti	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	l samuli ripatti@helsinki fi
Mark Daly	Institute for Molecular Medicine, Finland (FIMM), HiLIFE, University of Helsinki, Helsinki,	mark.daly@helsinki.fi
man baly	Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital	manage meleminin
Juha Karjalainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	l iuha karialainen@helsinki fi
Aki Hawlinna	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	
Juha Mehtonen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	
Priit Palta	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	•
Shabbeer Hassan	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	•
Pietro Della Briotta Parolo	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	
Wei Zhou	Broad Institute, Cambridge, MA, United States	wzhou@broadinstitute.org
Mutaamba Maasha	Broad Institute, Cambridge, MA, United States	mmaasha@broadinstitute.org
Kumar Veerapen	Broad Institute, Cambridge, MA, United States	veerapen@broadinstitute.org
Shabbeer Hassan	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	
Susanna Lemmelä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	
Manuel Rivas	University of Stanford, Stanford, CA, United States	mrivas@stanford.edu
Mari E. Niemi	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mari.e.niemi@helsinki.fi
Aarno Palotie	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	
Aoxing Liu	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	•
Arto Lehisto	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	9
Andrea Ganna	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	aganna@broadinstitute.org
Vincent Llorens	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	· ·
Hannele Laivuori	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	
Taru Tukiainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	l mary.reeve@helsinki.fi
Henrike Heyne	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hheyne@broadinstitute.org
Nina Mars	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	,
Joel Rämö	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	l joel.ramo@helsinki.fi
Elmo Saarentaus	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	l elmo.saarentaus@helsinki.fi
Hanna Ollila	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hanna.m.ollila@helsinki.fi
Rodos Rodosthenous	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	rodos.rodosthenous@helsinki.fi
Satu Strausz	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	satu.strausz@helsinki.fi
Tuula Palotie	University of Helsinki and Hospital District of Helsinki and Uusimaa, Helsinki, Finland	tuula.palotie@helsinki.fi
Kimmo Palin	University of Helsinki, Helsinki, Finland	kimmo.palin@helsinki.fi
		-

FinnGen Analysis working grou FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group

Javier Garcia-Tabuenca	University of Tampere, Tampere, Finland	javier.graciatabuenca@tuni.fi
Harri Siirtola	University of Tampere, Tampere, Finland	harri.siirtola@tuni.fi
Tuomo Kiiskinen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	tuomo.kiiskinen@helsinki.fi
Jiwoo Lee	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki,	jiwoo.lee@helsinki.fi
	Finland; Broad Institute, Cambridge, MA, United States	
Kristin Tsuo	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki,	kristintsuo@fas.harvard.edu
	Finland; Broad Institute, Cambridge, MA, United States	
Amanda Elliott	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki,	aelliott@broadinstitute.org
	Finland; Broad Institute, Cambridge, MA, USA and Massachusetts General Hospital, Boston,	
Kati Kristiansson	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	kati.kristiansson@thl.fi
Mikko Arvas	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki,	mikko.arvas@veripalvelu.fi
	Finland	
Kati Hyvärinen	Finnish Red Cross Blood Service, Helsinki, Finland	kati.hyvarinen@veripalvelu.fi
Jarmo Ritari	Finnish Red Cross Blood Service, Helsinki, Finland	jarmo.ritari@veripalvelu.fi
Olli Carpén	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	olli.carpen@helsinki.fi
Johannes Kettunen	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District,	johannes.kettunen@oulu.fi
	Oulu, Finland	
Katri Pylkäs	University of Oulu, Oulu, Finland	katri.pylkas@oulu.fi
Eeva Sliz	University of Oulu, Oulu, Finland	eeva.sliz@oulu.fi
Minna Karjalainen	University of Oulu, Oulu, Finland	minna.k.karjalainen@oulu.fi
Tuomo Mantere	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District,	tuomo.mantere@oulu.fi
	Oulu, Finland	
Eeva Kangasniemi	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,	eeva.kangasniemi@pshp.fi
	Tampere, Finland	
Sami Heikkinen	University of Eastern Finland, Kuopio, Finland	sami.heikkinen@uef.fi
Arto Mannermaa	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,	arto.mannermaa@uef.fi
	Kuopio, Finland	
Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland	eija.k.laakkonen@jyu.fi
Nina Pitkänen	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland	Niina.Pitkanen@tyks.fi
Samuel Lessard	Translational Sciences, Sanofi R&D, Framingham, MA, USA	samuel.lessard@sanofi.com
Clément Chatelain	Translational Sciences, Sanofi R&D, Framingham, MA, USA	clement.chatelain@sanofi.com
Perttu Terho	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland	perttu.terho@tyks.fi
Sirpa Soini	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	sirpa.soini@thl.fi
Jukka Partanen	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki,	jukka.partanen@veripalvelu.fi
	Finland	

FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working group

FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group FinnGen Analysis working grou FinnGen Analysis working group

Biobank directors
Biobank directors
Biobank directors
Biobank directors
Biobank directors

Eero Punkka	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	eero.punkka@hus.fi	Biobank directors	Biobank directors
Raisa Serpi	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District,	raisa.serpi@ppshp.fi	Biobank directors	Biobank directors
	Oulu, Finland			
Sanna Siltanen	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,	sanna.siltanen@pshp.fi	Biobank directors	Biobank directors
	Tampere, Finland			
Veli-Matti Kosma	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,	veli-matti.kosma@uef.fi	Biobank directors	Biobank directors
	Kuopio, Finland			
Teijo Kuopio		teijo.kuopio@ksshp.fi	Biobank directors	Biobank directors
	Jyväskylä, Finland			
Anu Jalanko	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	•	FinnGen Teams	Administration
Huei-Yi Shen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	•	FinnGen Teams	Administration
Risto Kajanne	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	•	FinnGen Teams	Administration
Mervi Aavikko	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mervi.aavikko@helsinki.fi	FinnGen Teams	Administration
Mitja Kurki	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki,	mkurki@broadinstitute.org	FinnGen Teams	Analysis
	Finland; Broad Institute, Cambridge, MA, United States			
Juha Karjalainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	juha.karjalainen@helsinki.fi	FinnGen Teams	Analysis
Pietro Della Briotta Parolo	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	pietro.dellabriottaparolo@helsinki.fi	FinnGen Teams	Analysis
Arto Lehisto	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	arto.lehisto@helsinki.fi	FinnGen Teams	Analysis
Juha Mehtonen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	juha.mehtonen@helsinki.fi	FinnGen Teams	Analysis
Wei Zhou	Broad Institute, Cambridge, MA, United States	wzhou@broadinstitute.org	FinnGen Teams	Analysis
Masahiro Kanai	Broad Institute, Cambridge, MA, United States	mkanai@broadinstitute.org	FinnGen Teams	Analysis
Mutaamba Maasha	Broad Institute, Cambridge, MA, United States	mmaasha@broadinstitute.org	FinnGen Teams	Analysis
Kumar Veerapen	Broad Institute, Cambridge, MA, United States	veerapen@broadinstitute.org	FinnGen Teams	Analysis
Hannele Laivuori	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hannele.laiwori@helsinki.fi	FinnGen Teams	Clinical Endpoint Development
Aki Hawlinna	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	aki.havulinna@helsinki.fi	FinnGen Teams	Clinical Endpoint Development
Susanna Lemmelä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	susanna.lemmela@helsinki.fi	FinnGen Teams	Clinical Endpoint Development
Tuomo Kiiskinen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	tuomo.kiiskinen@helsinki.fi	FinnGen Teams	Clinical Endpoint Development
L. Elisa Lahtela	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland		FinnGen Teams	Clinical Endpoint Development
Mari Kaunisto	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mari.kaunisto@helsinki.fi	FinnGen Teams	Communication
Elina Kilpeläinen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	elina.kilpelainen@helsinki.fi	FinnGen Teams	E-Science
Timo P. Sipilä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	timo.p.sipila@helsinki.fi	FinnGen Teams	E-Science
Oluwaseun Alexander Dad	ϵ Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	alexander.dada@helsinki.fi	FinnGen Teams	E-Science
Awaisa Ghazal	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	awaisa.ghazal@helsinki.fi	FinnGen Teams	E-Science
Anastasia Kytölä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland		FinnGen Teams	E-Science
Rigbe Weldatsadik	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	rigbe.weldatsadik@helsinki.fi	FinnGen Teams	E-Science

Kati Donner	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	kati.donner@helsinki.fi	FinnGen Teams	Genotyping
Timo P. Sipilä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	timo.p.sipila@helsinki.fi	FinnGen Teams	Genotyping
Anu Loukola	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	anu.loukola@hus.fi	FinnGen Teams	Sample Collection Coordination
Päivi Laiho	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	paivi.laiho@thl.fi	FinnGen Teams	Sample Logistics
Tuuli Sistonen	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	tuuli.sistonen@thl.fi	FinnGen Teams	Sample Logistics
Essi Kaiharju	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	essi.kaiharju@thl.fi	FinnGen Teams	Sample Logistics
Markku Laukkanen	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	markku.laukkanen@thl.fi	FinnGen Teams	Sample Logistics
Elina Järvensivu	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	elina.jarvensivu@thl.fi	FinnGen Teams	Sample Logistics
Sini Lähteenmäki	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	sini.lahteenmaki@thl.fi	FinnGen Teams	Sample Logistics
Lotta Männikkö	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	lotta.mannikko@thl.fi	FinnGen Teams	Sample Logistics
Regis Wong	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	regis.wong@thl.fi	FinnGen Teams	Sample Logistics
Auli Toivola	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	auli.toivola@thl.fi	FinnGen Teams	Sample Logistics
Minna Brunfeldt	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	minna.brunfeldt@thl.fi	FinnGen Teams	Registry Data Operations
Hannele Mattsson	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	hannele.mattsson@thl.fi	FinnGen Teams	Registry Data Operations
Kati Kristiansson	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	kati.kristiansson@thl.fi	FinnGen Teams	Registry Data Operations
Susanna Lemmelä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	l susanna.lemmela@helsinki.fi	FinnGen Teams	Registry Data Operations
Sami Koskelainen	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	sami.koskelainen@thl.fi	FinnGen Teams	Registry Data Operations
Tero Hiekkalinna	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	tero.hiekkalinna@helsinki.fi	FinnGen Teams	Registry Data Operations
Teemu Paajanen	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	teemu.paajanen@thl.fi	FinnGen Teams	Registry Data Operations
Priit Palta	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	priit.palta@helsinki.fi	FinnGen Teams	Sequencing Informatics
Kalle Pärn	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	kalle.parn@helsinki.fi	FinnGen Teams	Sequencing Informatics
Mart Kals	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mart.kals@helsinki.fi	FinnGen Teams	Sequencing Informatics
Shuang Luo	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	shuang.luo@helsinki.fi	FinnGen Teams	Sequencing Informatics
Vishal Sinha	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	l vishal.sinha@helsinki.fi	FinnGen Teams	Sequencing Informatics
Tarja Laitinen	Pirkanmaa Hospital District, Tampere, Finland	tarja.laitinen@pshp.fi	FinnGen Teams	Trajectory
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mary.reeve@helsinki.fi	FinnGen Teams	Trajectory
Marianna Niemi	University of Tampere, Tampere, Finland	marianna.niemi@tuni.fi	FinnGen Teams	Trajectory
Kumar Veerapen	Broad Institute, Cambridge, MA, United States	veerapen@broadinstitute.org	FinnGen Teams	Trajectory
Harri Siirtola	University of Tampere, Tampere, Finland	harri.siirtola@tuni.fi	FinnGen Teams	Trajectory
Javier Gracia-Tabuenca	University of Tampere, Tampere, Finland	javier.graciatabuenca@tuni.fi	FinnGen Teams	Trajectory
Mika Helminen	University of Tampere, Tampere, Finland	mika.helminen@tuni.fi	FinnGen Teams	Trajectory
Tiina Luukkaala	University of Tampere, Tampere, Finland	tiina.luukkaala@tuni.fi	FinnGen Teams	Trajectory
lida Vähätalo	University of Tampere, Tampere, Finland	iida.vahatalo@epshp.fi	FinnGen Teams	Trajectory
Jyrki Pitkänen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	l jyrki.pitkanen@helsinki.fi	FinnGen Teams	Data protection officer
Marco Hautalahti	Finnish Biobank Cooperative - FINBB	marco.hautalahti@finbb.fi	FinnGen Teams	FINBB - Finnish biobank cooperative

Johanna Mäkelä Finnish Biobank Cooperative - FINBB Sarah Smith Finnish Biobank Cooperative - FINBB Tom Southerington Finnish Biobank Cooperative - FINBB

johanna.makela@finbb.fi sarah.smith@finbb.fi tom.southerington@finbb.fi FinnGen Teams FINBB - FINBB - FINGEN Teams FINBB - FIN

FINBB - Finnish biobank cooperative FINBB - Finnish biobank cooperative FINBB - Finnish biobank cooperative